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Abstract
The stevor family is the third largest multigene family in the P. falciparum 3D7 genome 
(Gardner et al., 2002). With 30 copies estimated per genome, each encoding a predicted 
transmembrane spanning protein: a conserved N-terminal domain is followed by 
hydrophobic regions, a 100 amino acid ‘hyper-variable’ region (HVR), conserved 
transmembrane domain and short highly conserved cytoplasmic C-terminus.
In 3D7, stevor is transcribed in trophozoites and STEVOR protein was found in 
cytoplasmic membranous structures known as Maurer’s clefts (Kaviratne et al., 2002). 
The Maurer’s clefts are implicated in trafficking of proteins to the infected red blood cell 
(iRBC) surface, and pre-assembly of proteins destined for knob structures on the surface 
(Craig and Scherf., 2001). Stevors have also been detected in gametocyte stages and a 
STEVOR peptide found in sporozoite extracts (Sutherland, 2002 and Florens et al, 2002). 
The HVR of STEVOR may play a role in immune evasion. To investigate this further, we 
have started to characterise the genomic repertoire and expression profile of stevor genes 
in laboratory lines and field parasite isolates from Kenya, East Africa. Using stevor 
specific primers, we have identified 152 stevors in P. falciparum laboratory lines and 
Kenyan isolates. In addition, 27 stevors were identified in the genome of a Ghanaian field 
isolate (vwvw.plasmodb.org) and 17 in a second laboratory isolate IT.
Western blots identified a protein of approximately 30 kDa; expected STEVOR mean 
molecular mass is 36.75kDa. Immunofluorescence assays showed that in mature, 
segmented schizonts, STEVOR is redistributed from the Maurer’s clefts to throughout the 
iRBC cytosol. Interestingly, STEVOR was also observed in the apex of merozoites.
An extremely important observation for the application of in vitro cultured P. falciparum 
clones is the huge difference in STEVOR expression to that in the field parasite isolates. 
STEVOR protein is expressed in only 5% of P. falciparum 3D7 schizonts, whereas it is 
found in 50% of Kilifi field isolate schizonts.
We investigated field isolates further to see whether STEVOR is on the iRBC surface 
together with other multigene families, such as the var encoded PfEMPl and RIFINS, 
where STEVOR could play a role in antigenic variation which enables the P. falciparum 
parasite to evade the host immune response. Alternatively, STEVOR may have ligand 
binding functions/ RBC adherence properties during final schizont stage, rupture and 
merozoite reinvasion.
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Chapter 1_________________________________________________________ Introduction
Chapter 1) Introduction
1.1. Malaria: perspective
The discoveries that malaria is caused by the blood-borne protozoan parasite, 
Plasmodium falciparum, and transmitted by mosquitoes were made more than a century 
ago by Laveran and Ross, respectively. Despite these early discoveries and the 
subsequent decades of research into many aspects of malaria, we still do not have an 
effective control strategy, and there is evidence that the burden of malaria continues to 
rise. Recently, Snow et al estimated that there are 300 million to 660 million cases of 
clinical P. falciparum malaria every year (see figure 1.1) (Snow et a l , 2005). This burden 
is spread across a predicted 40% of the world’s population and over 90 countries.
Malaria is a devastating disease of unprecedented impact upon the lives and communities 
of the people it affects. Those at greatest risk are children below the age of 5, and 
pregnant women and their unborn babies. Almost all of these deaths are caused by P. 
falciparum, one of the four species of malaria parasites that infects humans (reviewed in 
(Snow et al., 2005). Three other species naturally infect humans including Plasmodium 
vivax, Plasmodium malariae, and Plasmodium ovale. However, P. falciparum produces 
the most severe manifestations of the malarial disease, usually due to destruction of 
normal and infected red blood cells (iRBCs), the disruption of blood circulation during 
the asexual-stage development of the parasite, and an exaggerated immune response to 
the parasite and its products. Cerebral malaria, severe-anaemia, and respiratory acidosis 
are the main clinical syndromes of severe life-threatening malaria. Severe malaria is most 
common in children below 5 years, who suffer a spectrum of symptoms ranging from low 
birth-weight to death, arising from malaria infections during pregnancy and in the early 
years of life.
Sadly, the prospect of a malaria-free world continues to fade as the currently available 
control methods are ineffective and are complicated by a number of factors. Firstly, there
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is the spread of insecticide-resistant mosquito populations, evolved through long-term
usage of inadequate levels of insecticides, combined with the creation of new breeding
sites for mosquitoes through road building, deforestation, mining, irrigation projects, and
new agricultural practices. The increased numbers and habitat range of mosquito
populations has lead to an increase in malaria transmission. Secondly, the rapid spread of
parasites resistant to the first-line anti-malarial drugs is thought to be the primary reason
for the dramatic increase in deaths from malaria in the last three decades (reviewed in
(Greenwood & Mutabingwa, 2002; Phillips, 2001). The few effective drugs available are
too expensive for many populations at risk, and development of new therapies is not a
commercial priority for the major pharmaceutical companies of the world. Thirdly,
despite the many initiatives to develop an effective anti-malaria vaccine, none have
succeeded to date. This is largely attributed to the complexity of the malaria parasites,
their life-cycle, interaction with the human host, and their sophisticated strategies for
evading the host immune responses. Drug cure is therefore the mainstay for malaria
control, although problems of resistance and cost render it at best a ‘holding strategy’.
This leaves malaria eradication as a distant memory of the ‘roll back malaria’ campaigns
of the last century, and malaria control under the jurisdiction of only those governments
with the money, resources, and long-term perspective required to attempt it.
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Figure 1.1: Geographical distribution o f malaria for the year 2002 (Snow et al., 2005)
P. falciparum endemicity distribution within the global limits o f risk. Endemicity classes: 
light green, areas in which the childhood infection prevalence is less than 10%; medium 
green, areas where infection prevalence is between 11% and 50%; dark green, areas with 
an infection prevalence o f greater than 50%. Unclassified areas (yellow) represent 6% o f  
total area at risk. All other areas are outside the transmission limits geographically or 
the population density is deemed below that required for transmission. Figure adapted 
from Snow et al, 2005.
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1.2. Malaria: the parasite
1.2.1. Phytogeny
Malaria parasites are classified into the genus Plasmodium, family Plasmodiidae, phylum 
Apicomplexa (Levine, 1988). In a more recent classification system Plasmodium is 
included in one of six major clusters, Chromalveolata. This cluster groups the alveolata 
(including ciliates, the dinoflagellates, and the Apicomplexa) with cryptophytes, 
haptophytes, and stramenopiles (including brown algae, the diatoms, many zoosporic 
fungi, and opalinids, amongst others) (Adi et al., 2005). This classification recognises the 
shared ancestry of Plasmodium with ancient photosynthetic organisms, accounting for the 
presence of the vestigial chloroplast known as the apicoplast/plastid.
The two most common human malaria species, P. vivax and P. falciparum, are thought to 
have diverged approximately 200,000 to 300,000 years ago, based on phylogenetic 
analysis of the cytochrome b protein from the mitochondrial genome (Escalante et al., 
1998). The authors concluded that the genus Plasmodium is polyphyletic, with P. 
falciparum  and P. reichenowi forming a separate lineage to other primate malarial 
parasites, and sharing a common ancestor with avian parasites e.g. P. gallinaceum (see 
figure 1.2 ).
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Figure 1.2: Phylogenetic relationship among the 17 Plasmodium species inferred from  
the gene encoding cytochrome b. The tree was estimated using the Neighbour-Joining 
(NJ) method. Bootstrap values are provided as percents over 1000 replications. The tree 
shows the location o f  the root f  as estimated by the DNAMLK algorithm from PHYLIP, 
which assumes a molecular clock. Figure taken from (Escalante et al., 1998).
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Figure 1.3: Life-cycle o f  P. falciparum (adaptedfrom a drawing by J. Langhorne).
The parasite undergoes sexual development, replication, and growth within the mosquito 
host, and asexual replication and growth within the human host. Green arrows indicate 
parasite protein exposure to human-host-immune elements.
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1.2.2. Life-cycle of P. falciparum
The malaria parasite has a complex life-cycle involving both an invertebrate mosquito 
vector and a vertebrate host (figure 1.3). Infection of the human host with P. falciparum 
begins with injection of motile sporozoites into the sub-cutaneous tissue and occasionally 
directly into the bloodstream via the bite of a female Anopheline mosquito.
1.2.2.1. Invasion of hepatocytes
Once in the bloodstream, the sporozoites are rapidly transported to the liver, where they 
invade hepatocytes. Sporozoites pass through several hepatocytes before invasion is 
followed by parasite development and replication (Mota et al., 2001). The asexual 
multiplication hepatoschizont-stage forms approximately 20,000— 40,000 haploid liver- 
stage merozoites, over seven days. After release from the hepatocytes, the merozoites are 
capable of invading red blood cells (RBCs), in the next stage of the life-cycle.
1.2.2.2. Erythrocytic (asexual) cycle
The asexual blood or erythrocytic-stage begins with the released merozoites invading
RBCs, in the case of P.falciparum both normocytes and reticulocytes. Each P. falciparum
or P. vivax merozoite undergoes a process of growth and asexual multiplication to
produce around 20 daughter merozoites per infected RBC over a period of 48 hours.
Parasite growth within the iRBC progresses through a series of distinct stages, the first of
which is the ring-stage at which the parasite begins to metabolise haemoglobin. As the
ring-stage parasite grows, it exports its own proteins beyond the confines of the parasite,
and the parasitophorous vacuole in which it develops, and into the cytosol and the surface
plasma membrane of the iRBC. The parasite continues to grow forming the trophozoite-
stage with its characteristic haemozoin pigment. Transcription of var starts as early as 9
hours into the cycle with Plasmodium falciparum erythrocyte membrane protein 1
(PfEMPl) reaching the iRBC surface at 16-20 hours post-invasion (Kriek et al., 2003).
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PfEMPl contains specific endothelial cell-binding domains, which enable the parasites to
withdraw from normal blood circulation in order to avoid splenic clearance. Once
sequestered, development into the fully mature schizont form occurs, where nuclear
divisions result in a species-dependent number of daughter merozoites. Identification of
the different human malaria species is also facilitated by the absence of mature forms of
P. falciparum in peripheral blood. The iRBC then bursts, dispersing the merozoites,
which are then competent to reinvade new RBCs.
I.2.2.3. Invasion of RBCs
The blood-stage merozoite on contact with a RBC re-orientates so that the apical end can 
make a close contact with the RBC surface (see figure 1.4). The apical tip contains the 
apical complex which consists of three sets of secretory structures: 1) the micronemes, 
which contain adhesins and molecules linking host cell-surface to the underlying motor 
complex; 2) the rhoptries, containing lipids and proteins, contributing to parasite vacuole 
formation, and also similar to micronemal proteins contributing to RBC surface binding, 
e.g. RhopH complex; and 3) the dense granules, containing proteins of the 
parasitophorous vacuole membrane (PVM) that enable traffic between the parasite, within 
the parasitophorous vacuole, and host cell (reviewed in (Rats et al., 2006)).
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Figure 1.4: Three-dimensional organisation o f  a P. falciparum merozoite, with the 
pellicle partly cut away to show the internal structure (image taken from L. Bannister et 
al (Bannister & Mitchell, 2003)). The apical complex organelles are shown including the 
micronemes, rhoptries, and dense granules. The surface location o f  MSP119 is indicated 
as merozoite coat.
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Proteins, such as merozoite surface protein 1 (MSP1) and apical membrane antigen 1
(AMA1), are released from these organelle structures. MSP 119 coats the merozoite
surface, whilst AMA1 is released from the micronemes and is involved in the apical end
reorientation (Bannister et al., 2003). It has been suggested that the location of these
important receptor-engaging molecules within organelles may protect the parasite from
antibody-mediated neutralisation, as the ordered release from apical organelles after
contact with the RBC may limit their exposure to antibody (Miller et al., 2002).
The parasite vacuole is formed primarily of host-cell plasma membrane, but sorting of
host membrane proteins occurs such that most transmembrane proteins are excluded but
detergent-resistant membranes remain {i.e., Duffy receptor, GPI-anchored proteins,
including parasite-derived proteins such as exported protein 1(EXP1)) (Lauer et al.,
2000).
This period of exponential asexual parasite growth and replication is responsible for all 
the symptoms of malaria and continues until the parasite is controlled (through drug 
intervention, the host’s innate and adaptive immune responses, unavailability of fresh 
RBCs, or death of the overwhelmed host). The synchronous nature of the parasite’s 
development and simultaneous rupture of the iRBCs, releasing large amounts of parasite 
material, is thought to result in induction of the host’s cytokine response and induction of 
cyclical fevers (every 48 hours for P. falciparum).
1.2.2.4. Sexual cycle
The parasite’s sexual development begins during the blood-stage with differentiation of 
male (micro-) and female (macro-) gametocytes from a small proportion of infecting 
merozoites; these are subsequently taken up in the mosquito’s blood meal. Environmental 
triggers such as the temperature drop within the invertebrate host, and specific chemicals 
such as xanthurenic acid (Billker et al., 1998), trigger the exflagellation of male gametes
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giving rise to 8 micro-gametocytes, each containing a haploid nucleus, which fuse with
the female haploid nucleus to form a zygote (diploid)-stage in the mosquito mid-gut. The
zygote is then able to invade the gut-wall epithelium, where it develops into an oocyst
between the epithelium and basal-membrane. Large numbers of sporozoites are formed,
which then mature during their migration to the mosquito salivary glands. The mature
sporozoites are then ideally placed for injecting into a new host when the mosquito takes
its next blood meal, thus completing the cycle.
1.3. Malaria -  the disease
Humans living within malaria endemic areas (see figure 1.1) will be intermittently re­
infected with P. falciparum. The course and outcome of the resultant disease will depend 
upon the age, genetics, and infection history of the patient. No disease symptoms are 
experienced during the initial (approximately 7 days) liver-stage infection, whereas a 
variety of clinical symptoms occur during the asexual blood-stages, ranging from mild, 
asymptomatic parasitaemia in immune adults, to acute disease with clinical symptoms 
including 48-hour cyclical fevers, muscle-aches, and head-aches to life-threatening severe 
malarial anaemia, metabolic acidosis, and coma that occurs in young children and non- 
immune adults. In addition to young children and non-immune adults, pregnant women 
are at increased risk from P. falciparum infection, where malaria infection of the placenta 
is associated with inter-uterine growth retardation and premature delivery leading to 
neonatal mortality (Steketee et al., 2001), maternal anaemia (reviewed by (Menendez et 
al., 2000)), and higher mortality for the primigravidae ((Brabin, 1983), reviewed by 
(Shulman & Dorman, 2003)).
The degree of clinical symptoms suffered is mainly dependent on the level of immunity 
acquired through previous infections. Older children and adults thus often suffer from 
asymptomatic or mild malaria, whereas young children suffer from severe malaria, the
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syndromes of which include cerebral malaria, severe anaemia, and respiratory distress
(Marsh et al., 1995). Severe malaria is now understood to be a multi-system disorder
similar to sepsis syndromes and affecting multiple organs of the body (reviewed by
(Mackintosh et a l,  2004)). The strongest indicator of death in severe malaria is metabolic
acidosis, which leads to the clinical symptoms of respiratory distress (English et al., 1995;
Marsh et al., 1995; Taylor et al., 1993). Cerebral malaria is characterised by impaired
consciousness, confusion, or un-arousable coma; the mortality levels resulting from this
syndrome vary (Kwiatkowski et al., 1993; Marsh et al., 1995; Molyneux, 1989; White et
a l, 1985) but are associated with the depth of the coma (Marsh et al., 1995; Molyneux,
1989; Taylor et al., 1988). Many studies have searched for specific linkage of parasite
molecules with typical disease patterns.
In addition, malaria is in part an immune-mediated disease. The initial systemic pro- 
inflammatory cytokine response leads to fever, nausea, headaches, and other clinical 
symptoms; therefore inflammatory mediators are also implicated in the pathogenesis of 
severe malaria.
1.3.1. The relationship between age and disease
Immunity to infection by P. falciparum is probably never complete: even adults who 
remain in areas of high-transmission throughout their lives may be parasitised (Trape & 
Rogier, 1996). This is in contrast with other, mainly viral, pathogens where a single 
infection or immunisation can result in long-lived sterile immunity.
Babies below the age of 6 months are protected from infection by a number of factors: 
maternal malaria-specific protective antibodies acquired initially through the placenta and 
later transmitted through breast milk (Kassim et al., 2000), foetal haemoglobin, and 
reduced contact with infective mosquitoes (Hogh et al., 1995; Sehgal et al., 1989; Snow 
eta l., 1998).
32
Chapter 1_________________________________________________________ Introduction
However, disease prevalence then rises to a peak in young children, before resistance to
severe life-threatening infections develops. In areas where malaria is endemic, resistance
to the severest forms of P. falciparum is nearly complete by the age of 5 years. In areas of
most intense transmission, risk from severe malaria is greatest between the ages of 1 and
2 years (Snow et a l, 1997). In contrast, clinical immunity to mild malaria is acquired
slowly, and is not usually effective until early adolescence.
In areas of low transmission, resistance to severe (non-cerebral) malaria requires a greater 
number of infections before becoming protective, thus immunity is acquired over a 
broader age range, and the peak prevalence occurs later in childhood (Reybum et a l, 
2005; Snow et a l, 1997; Snow & Marsh, 2002). Thus the prevalence of severe malaria, 
mild malaria, and parasite prevalence give characteristic age-dependent curves (figure 
1.5).
Cerebral malaria exhibits a different age-related profile to that of the other manifestations 
of severe malaria disease. Incidence of cerebral malaria peaks at a later age than for other 
main severe syndromes such as severe anaemia. The incidence of cerebral malaria peaks 
at a mean age of 45 months in the Gambia (Brewster et a l,  1990), and 40 months in 
coastal Kenya (Marsh & Snow, 1997).
In summary, this suggests that in regions of high transmission, immunity to severe 
disease is acquired earlier than in low-transmission regions. Cerebral malaria is therefore 
less common, and severe anaemia becomes a more important factor in severe life- 
threatening malaria.
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Figure 1.5: The theoretical relationship between parasitaemia, mild, and severe (non­
cerebral) malaria with age in endemic areas. The age-pattern o f asymptomatic parasite 
prevalence and the period prevalence o f both mild and severe clinical malaria are shown 
in relation to maximum prevalences recorded. Based upon a figure from Marsh and 
Kinyanjui (Marsh & Kinyanjui, 2006), which uses Kilifi population indices o f immunity to 
malaria data.
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1.4. Immunology of malaria
The observation that a semi-immune status to severe life-threatening malaria is induced 
during childhood in endemic areas suggests iRBC surface antigens are present to which 
naturally acquired immunity to malaria is induced and effective, so that by adulthood 
malarial disease is reduced to mild and often asymptomatic parasitaemia. However, the 
continuation of mild malaria infections into adulthood suggests this immunity is not 
sterile, possibly due to the presence of polymorphic immune targets. Indeed, it has been 
suggested that it is the additive effects of the gradual acquisition of immunity to these 
polymorphic targets that results in a repertoire of antibodies against the local parasite 
population. The age of acquisition of these antibodies inversely correlates with the 
transmission rates (Bull et al., 1998). Thus given an infinite number of polymorphic 
variants of immune targets, only a semi-immune status can ever be achieved.
In order to make effective use of information on these important immune targets, we need 
to know what they are, how they may vary, and their mechanism(s) of protection. To 
make a study of immune processes during malarial disease, it is necessary to make use of 
non-human malaria models, and to utilise prospective studies of human malaria infections 
from early last century. In addition, assessments of genetically inheritable traits that 
correlate with protection are important indicators of these mechanisms, and will be 
discussed first here.
1.4.1. Genetic resistance to malaria
P. falciparum has evoked huge selective pressure upon human populations for thousands 
of years. It is estimated that the divergence of the human P. falciparum parasite from P. 
reichenowi or a P. reichenowi-\ike parasite occurred between 4 and 4.75 million years 
ago, a time-frame consistent with the divergence of Homo and Pan, which is estimated 
between 4 and 5 million years ago (Horai et al., 1995). Therefore this highly virulent
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parasite has been exerting a positive selective force for various protective genetic traits by 
causing mortality in pre-reproductive age groups.
Two basic forms of genetically inheritable protection exist (table 1.1): firstly, those that 
affect the RBC’s ability to provide the parasite with a suitable ‘home’ (for instance, 
polymorphisms in genes encoding haemoglobins, specific RBC enzymes, or RBC 
proteins), and, secondly, those genetic traits which result in improved efficiency of the 
immune system for specifically targeting this intra-cellular obligate pathogen. This 
requires polymorphisms in the many immune-response genes.
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Table 1.1) Genetic traits that affect immunity to malaria
Components Trait Gene/
Allele
Effect/mechanism
Factors affecting 
RBCs
Thalassaemias a-thalassaemia
(3-thalassaemia
Protection is limited to the anaemic form of malarial disease (Wambua et 
al., 2006) Reduced CR1 expression therefore protective through reduced 
rosetting (Cockbum et al., 2004)
Partially due to early removal o f iRBC through an innate mechanism (Ayi
et a l ,  2004)
Haemoglobinopat Haemoglobin S HbS Partially due to early removal o f iRBC through an innate mechanism (Ayi
hies (sickle cell disease) et al., 2004) but the protective effect increases with age (Williams et al., 
2005), and may be also due to an accelerated acquisition o f immunity to 
PfEM Pl (Cabrera et al., 2005)
Haemoglobin C HbC (Mockenhaupt et al., 2004; Modiano et al., 2001) Possible inhibition of 
parasite growth (Fairhurst et al., 2003; Friedman et al., 1979; Pasvol et 
al., 1982; Rihet et al., 2004) May also protect through failure of HbC 
cells to display PfEMPl on iRBC surface
Haemoglobin E HbE Prevalence and severity o f complications reduced in adult carriers with 
malaria, admitted to hospital in Thailand (Hutagalung et al., 1999)
Cells surface 
molecules
CR1 (CD35)
Duffy blood-group 
negativity
CR1 SI (a-) RBCs are unable to form rosettes with P. falciparum  iRBCs (a 
virulence factor in P. falciparum  malaria) (Chen et al., 1998; Rowe et al.,
1997)
Duffy blood-group negativity is completely protective against disease 
caused by the P. vivax parasite (Arevalo-Herrera et al., 2005)
Gerbich-negative 
blood group
GYPCAex3 Confers protection against parasite invasion via P. falciparum  merozoite 
erythrocyte-binding antigen 140 (EBA-140) and glycophorin C (Maier et 
al., 2003; Thompson et al., 2001)
Ovalocytosis SLC4A1A2 Deletion in gene encoding RBC membrane protein band 3 is protective
(Southeast Asian) 7 against cerebral malaria (Allen et al., 1999; Genton et al., 1995) Possible 
protection against subset o f parasites causing severe disease, or enhanced 
CD36 binding reducing cerebral cytoadhesion (Cortes et al., 2005; 
Newbold et al., 1997; Turner et al., 1994)
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Factors affecting 
im m unity
Cells surface HLA HLA-Bw53 Associated with reduced risk of severe malaria (Hill et a l ,  1991)
molecules IFN-y receptor IFNGR1-
56
Heterozygous individuals protected from cerebral malaria (Koch et a l,
2002)
IFN -a receptor IFNAR1 17470-G/G and L168V-G/G genotypes associated with protection from 
cerebral malaria (Aucan et a l., 2003)
CD36 (scavenger 
receptor)
CD36 Promoter polymorphisms associated with protection from cerebral mal 
mutations leading to reduced expression associated with increased ri 
o f severe malaria; nonsense mutation associated with protection froi 
severe malaria (Aitman et al., 2000; Omi et al., 2003; Pain et al., 20C
CD40L CD40L
726C
X-linked; marked reduction in risk for severe malaria in homozygous 
males (Sabeti et al., 2002)
KIR KIR3DL2 Association with malaria specific IFN-y production by NK cells 
(Artavanis-Tsakonas et al., 2003)
CD31 CD31/PEC 
AM
The frequency o f the 125 V/V 563 N/N genotype was significantly high 
in cerebral malaria patients as compared with severe cases without 
cerebral malaria (Kikuchi et al., 2001)
Cytokines TNF TNF2 Promoter polymorphism that affects OCT1 binding increases 
susceptibility to cerebral malaria (Knight et al., 1999; McGuire et al.,
1994)
IL-4 IL-4-524T Increased malaria-specific antibody levels (Luoni et al., 2001)
IL-12p70 IL-12B Promoter polymorphism leading to decreased IL-12 production associated 
with increased mortality in Tanzanian but not Kenyan children (Morahan
et a l., 2002)
Serum factors Mannose-binding 
lectin deficiency
MBL Low serum Mannose-binding lectin levels associated with increased risk 
o f severe malaria (Luty et a l ,  1998)
Enzymes Inducible nitric NOS2 NOS2A-1659T associated with increased susceptibility to cerebral
oxide synthase (iNO) malaria.
NOS2A-954C and NOS2A-1173T associated with protection from 
clinical malaria and severe anaemia, respectively (Burgner et al., 2003; 
Hobbs et al., 2002; Kun et al., 2001)
Glucose-6-
phosphate
dehydrogenase
deficiency
G6PD Protective mechanism may work through early phagocytosis o f iRBC (at 
early ring-stage). Due to IgG and complement deposition possibly due to 
accelerated oxidative membrane damage as a result o f impaired anti­
oxidant defence in G6PD deficient cells (Cappadoro e ta l ,  1998)
Pyruvate kinase Pklr Protects mice against P. chabaudi chabaudi infection (Min-Oo et al.,
2003)
This table was modified from (Stevenson & Urban, 2006; Williams, 2006).
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1.4.2. Innate immune responses control acute asexual blood-stage parasitaemia
In the absence of an immune response, exponential growth of the parasite during the 
erythrocytic-stage would continue until all available RBCs were infected, and death 
follows as an inevitable consequence. However, this initial acute phase is controlled to a 
greater or lesser extent, depending on genetic traits, by innate immunity. Innate immune 
responses are normally sufficient to reduce the initial peak parasitaemia preventing death 
of the host, but are not sufficient for clearance of the parasite and hence a chronic 
infection follows. This works in the parasite’s favour, as the chronic stage of infection 
allows a prolonged period in which transmission to the mosquito vector can occur.
Innate responses are also key in the initiation and direction of the subsequent acquired 
immune response, and the malaria parasite (and other protozoa) have developed multiple 
strategies for subverting the innate defences of the host and redirecting the development 
of the acquired response (reviewed in (Sacks & Sher, 2002)).
1.4.3. Rodent immune responses to malaria infection
Rodent Plasmodium infections are used to model human Plasmodium infections, and 
although there are differences between human and mouse immune systems, different 
aspects of human malaria have been replicated, dependent upon the genetic strain of the 
rodent host and the infecting Plasmodium species. In particular, the immune response to 
blood-stage parasites has been extensively studied using P. chabaudi chabaudi AS, with 
either C57BL/6 or BALB/c mice. Here the immune response is divided into two stages, 
the first o f which being the acute phase with the first wave of parasitaemia, which is 
controlled, in resistant mice strains, by antibody-independent (innate) mechanisms. This 
first peak of parasitaemia is followed by the chronic infection stage, which requires CD4+ 
T cells and antibody-mediated (adaptive) mechanisms for complete clearance of the 
parasite.
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1.4.3.1. Innate immune responses
The innate immune system is crucial in malaria immunity. For instance, in the absence of 
natural killer (NK) cells, P. c. chabaudi AS infections show a higher peak parasitaemia 
during the acute phase than in wild type mice (Mohan et al., 1997). In addition, the early 
production of interferon-y (IFNy) from NK and also possibly yb T cells is essential to 
avoid a lethal infection in mice infected with various Plasmodium species (De Souza et 
a l, 1997; Mohan et al., 1997).
The innate immune system is linked with the adaptive system through the stimulation of 
toll-like receptors (TLR) on antigen-presenting cells (APCs) by pathogen antigen 
molecule patterns (PAMPs). TLRs are expressed on the surface or endosomes of NK 
cells, macrophages, and dendritic cells (DCs). APCs are then induced to produce 
cytokines, and, in the case of DCs, present antigen to T-cells. Upon infection of naive 
mice, APCs produce IL-12 thus initiating the adaptive immune response. IL-12 is an 
essential cytokine mediating effects through IFNy and tumour necrosis factor (TNF), 
leading to induction of IFNy, and ThI cell differentiation, and thus is essential for the 
development of acquired cell-mediated and antibody-mediated immunity to intracellular 
parasites.
1.4.3.2. Acquired immune responses
As briefly mentioned above, the control and clearance of a chronic malaria infection 
requires protective CD4+ T-cell-dependent mechanisms. Evidence from P. c. chabaudi 
AS infections indicates mice lacking or depleted of CD4+ T-cells during the acute phase 
of an infection are not able to control and clear the parasite (Langhome et al., 1990; Suss 
et al., 1988). In contrast, depletion of CD8+ or by T-cells before infection only leads to a 
slight parasitaemia increase and delay in parasite clearance (Seixas et al., 2002). The 
early pro-inflammatory response leads to induction of IgG2a, IgG2b, and IgG3 sub-
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classes of antibodies in mice (reviewed in (Okamura et al., 1998; Purkerson & Isakson,
1992)), and it is the antibody response that is responsible for final clearance of the
parasite.
Despite such overwhelming and/or longstanding evidence that antibody is protective we 
still do not know the mechanism of protection. Several mechanisms have been proposed 
and partially demonstrated:
1) Antibody-mediated phagocytosis by macrophages (Shear et al., 1979), although 
FcyRII receptor-deficient and wild type mice are equally capable of resolving a P. yoelii 
yoelii or P. c. chabaudi infection (Langhome et al., 2002; Rotman et al., 1998).
2) Complement-dependent antibody-mediated cytolysis of Plasmodium -infected 
mouse erythrocytes and merozoites (Gabriel & Berzins, 1983; Krettli et al., 1976).
3) Opsonising and neutralising antibodies inhibiting iRBC sequestration (Pleass & 
Holder, 2005).
4) Invasion-inhibiting antibodies through neutralisation of merozoites or inhibition of 
merozoite surface protein-1 (MSP-1) processing (Blackman et al., 1994; Guevara Patino 
etal., 1997).
All four mechanisms probably participate in the antibody-mediated parasite clearance to a 
variable degree, dependent on the Plasmodium spp. and the infected host.
1.4.4. Human immune responses to malaria infection
Data from the rodent models is complemented by data obtained in humans through 
retrospective analyses of data collected by the U.S. Public Health Service between 1940 
and 1963, when malaria-induced fevers were used to treat neurosyphilis. The treatment 
course with a primary P. falciparum, P. ovale, P. malariae, P. vivax infection and with/or 
without a secondary infection was followed in patients, and suppressive, but non-curative 
anti-malarial treatments were given where necessary.
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1.4.4.1. Innate immune responses
Analysis of the clinical records of repeated infections in non-immune neurosyphilis 
patients that were treated with malaria induced fevers showed that the density of 
parasitaemia at which parasite growth was controlled was highly predictable in an 
individual, and independent of the Plasmodium strain or species. The authors concluded 
that this data is best explained by the induction of innate immune mechanisms 
(Molineaux et al., 2002). Thus parasite growth can be modulated very early in the course 
of infection. The initiation of innate immune responses is crucial for the subsequent 
triggering of the adaptive responses, and pro-inflammatory cytokines including IFN, 1L- 
12p70, and IL-18 (normally made by innate cells) were increased in the serum at the first 
appearance of iRBCs in the blood of malaria naive individuals experimentally infected 
with P. falciparum (Hermsen et a l , 2003).
1.4.4.2. Acquired immune responses
Immunity to malaria is both stage- and species-specific: re-infection is the norm, and 
sterile immunity does not occur, unlike with viral pathogens. Clinically protective 
immune responses require repeated exposures to infection over an individual’s lifetime 
(see also section 1.3.1).
Evidence that humans develop naturally acquired immunity is derived from retrospective
examination of patient data, where, on re-inoculation with either a homologous or
heterologous strain, humans were susceptible but experienced fewer high-intensity fever
episodes and lower asexual and gametocyte parasite counts. This suggests the
development of acquired immunity within a single infection (Collins & Jeffery, 1999a;
Molineaux et al., 2002). Interestingly, only a primary infection of P. malariae, but not P.
ovale or P. vivax, was shown to protect against a secondary P. falciparum infection
(Collins & Jeffery, 1999b). It was suggested that P. malariae shares common antigens
that are able to induce protective immunity. However, this may also be a reflection of the
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greater role that the acquired immune response plays in the control of P. malariae
infection, which has a slower development and later peak parasitaemia than P. ovale or P.
vivax.
A crucial point is that although antibodies can be strain-specific, at some level it is 
possible to use antigens from one strain to induce immunity to heterologous strains, and 
therefore an anti-malaria vaccine is theoretically possible. The main target of antibodies 
has emerged as the parasite-encoded variant-surface antigens (VSA) found on the surface 
of the iRBC.
The protective effect of anti-malaria antibodies was first demonstrated in the 1960s. y- 
Globulin transferred from immune adults into non-immune children with severe clinical 
malaria in the Gambia brought about a reduction in parasitaemia and alleviation of 
disease symptoms (Cohen et al., 1961). Subsequent studies showed that this antibody 
immunity was strain-transcending, protecting children exposed to malaria parasites from 
different geographical locations (McGregor et al., 1966; Sabchareon et al., 1991). 
However, the persistence of parasite and length of time it takes to acquire protective 
immunity against mild malaria indicates that the parasite’s clonal VS A may prevent the 
development of a fully protective antibody response.
A study by Marsh and Howard in 1986 showed that sera obtained from 10 Gambian 
children during the acute phase of infection were unable to agglutinate iRBCs from the 
corresponding infection, but that convalescent sera, obtained 3—4 weeks later, contained 
antibodies recognising those same parasites but not recognising heterologous parasites 
(Marsh & Howard, 1986). In contrast, sera from adults living in the same area were able 
to agglutinate all or the majority of the 10 parasite isolates. Thus as people get older they 
accumulate a repertoire of strain-specific antibodies that recognise VS A on the surface of 
iRBCs. Subsequently, more extensive studies have evaluated these targets of the antibody 
response and identified the highly polymorphic VS A PfEMPl as key targets.
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Convalescent sera from children infected by P. falciparum agglutinate homologous
parasites, but frequently do not show reactivity to heterologous parasites (Bull et a l,
1998). Thus only those parasites expressing VS A corresponding with a gap in the host’s
antibody repertoire are able to maintain infection.
1.5. Molecular aspects of malaria disease
1.5.1. Parasite immune targets in the human host
As indicated by the green arrows in the life-cycle (figure 1.3), there are several points 
during the parasite’s life-cycle at which it may be vulnerable to immune antibody attack. 
Multigene families, an immune evasive mechanism, encode many of the exposed parasite 
proteins on the iRBC and merozoite surfaces. In the case of the iRBC-stage, PfEMPl 
(which is one of the important immune targets on the iRBC surface) can undergo clonal 
antigenic variation (reviewed by (Kyes et al., 2001). Clonal antigenic variation of 
PfEMPl is crucial to the parasite as a means of prolonging chronic infection, and evading 
the host antibody response. A brief discussion of the pre-erythrocytic-stage immune- 
targets will be followed by discussion of the merozoite and iRBC surface as targets of 
immunity.
1.5.1.1. Sporozoites and pre-erythrocytic-stages as a target for immunity
Briefly, immunity may be directed at the sporozoite from the point it is injected into the
skin and its migration through the blood to intra-hepatocytic schizont development. There 
is a very short window in which antibodies may potentially protect against the sporozoite, 
either by opsonisation of the sporozoite or prevention of hepatocyte invasion. Anti- 
sporozoite and liver-stage targets include the immunodominant circumsporozoite protein 
(CSP), liver-stage antigen-1 (LSA1), and thrombospondin-related adhesive protein 
(TRAP), among others (Calle et al., 1992; Esposito et a l, 1988; John et al., 2003; Kumar
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et a l,  2006). Interestingly, the best induction of protective immunity is through
immunisation with attenuated sporozoites (Nardin et al., 1999). However this is in
contrast to naturally induced anti-sporozoite immunity, which does not immediately
induce sterile protection.
1.5.1.2. Merozoites as a target for immunity
Invasion of RBCs is a key moment in the parasite’s life-cycle, requiring a complex 
cascade of events, starting with initial attachment, re-orientation, and invasion of the RBC 
(described in section 1.2.2.3). Proteins necessary for all these processes are exposed on 
the merozoite surface or secreted onto the merozoite’s surface upon contact with the 
RBC. However, the timing between merozoite release and re-invasion is short, and 
therefore antibodies are the main source of protective immunity against merozoites. 
Antibodies may protect through blocking invasion by opsonisation, inducing 
complement-mediated damage, preventing processing of merozoite invasion proteins, or 
blocking RBC-binding interactions.
A monoclonal antibody-screen of P. falciparum parasites isolated from different 
geographical locations has provided evidence for considerable antigenic diversity, and 
most of the strain-specific determinants were shown to be associated with merozoite 
surface proteins (McBride et a l,  1982). Therefore fine specificity of the antibody, in 
addition to the antigen in question, is relevant in determining whether antibodies correlate 
with protection from malaria (reviewed by (Jennings et al., 2006; Marsh & Kinyanjui, 
2006)).
Merozoite proteins vary using two basic mechanisms: 1) they may exist as different 
allelic forms of the same gene whereby a parasite has one copy of a gene which varies 
from parasite to parasite, resulting in polymorphic proteins found in different parasite 
clones (for example, MSP-1), (Anders et a l, 1993); or 2) merozoite proteins may be the
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products of multigene families, such as the two classes of ligand-binding invasion
proteins found in the merozoite apical organelles. These are the family of reticulocyte
binding protein homologues (RBPs) and the family of erythrocyte binding
proteins/ligands (EBLs). The RBP superfamily includes, the P. yoelii 235kDa rhoptry
proteins (Py235) (Holder & Freeman, 1981). P. vivax reticulocyte binding proteins
(PvRBP 1 and 2) (Galinski et al., 1992), and the P. falciparum rhoptry protein
homologues (PfRHl, PfRH2a, PfRH2b, PfRH3, PfRH4 and PfRH5) (Cowman & Crabb,
2006; Kaneko et al., 2002; Rayner et al., 2000; Rayner et al., 2001; Stubbs et a l, 2005;
Taylor et a l,  2001; Triglia et al., 2001a; Triglia et a l, 2005; Tsuboi et a l, 1994). EBL
homologues include the Duffy Binding Protein (DBP) of P. vivax and P. knowlesi, the P.
falciparum EBA175, BAEBL (EBA140), EBL-1, JESEBL (EBA181) and PEBL
(EBA165) (Camus & Hadley, 1985; Lobo et a l, 2003; Peterson & Wellems, 2000;
Triglia et a l, 2001b). Therefore merozoites have the potential to vary antigenically in
order to evade antibody opsonisation and other cellular immune mechanisms.
I.5.I.3. The surface of the iRBC as a target for immunity
As the parasite grows and matures within the iRBC, it inserts parasite-derived proteins, or 
alters host-cell proteins, which are then exposed on the iRBC plasma membrane. The 
iRBC surface proteins are here referred to as VS A and are, in the majority, the product of 
multigene families. There are three main multigene families in P. falciparum-, one of 
these is the prime target of anti-VS A antibodies, PfEMPl. However, the products of the 
other two extensive multigene families, r if  and stevor, may also be expressed on the iRBC 
surface. A fourth, much smaller, family encoding SURFINs is co-transported with 
PfEMPl and RIFINs to the iRBC surface (Winter et a l, 2005). In addition, a number of 
hypothetical proteins may also be expressed on the iRBC surface. The multigene families 
of P. falciparum are described later (see section 1.6).
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1.5.2. Identification of parasite proteins and novel immune targets
1.5.2.1. Genome projects
Significant progress in the field of comparative genomics has been made in recent years. 
This is due to the extensive sequencing and availability of several human and other 
malarial parasite genomes (www.sanger.ac.uk/Projects/Protozoa/). These include the P. 
falciparum 3D7 whole genome, lx  coverage of a second laboratory clone P. falciparum 
IT, and, most interestingly, substantial coverage (8x) of a Ghanaian field isolate parasite 
clone. The P. falciparum 23-megabase nuclear genome consists of 14 chromosomes, 
encodes about 5,300 genes, and is the most (A + T)-rich genome sequenced to date 
(Gardner et al., 2002).
Sequencing of several rodent malaria genomes (including Plasmodium berghei, 
Plasmodium chabaudi, Plasmodium yoelii) has allowed the identification of 
approximately 4500 orthologues shared between the rodent malarias and P. falciparum 
(Kooij et al., 2005). Conversely, 575 P. falciparum-specific genes and gene families were 
identified in the sub-telomeric regions, plus 168 other P. falciparum-specific genes, 
located at the boundaries of conserved (syntenic) regions (Kooij et al., 2005). Clustering 
of P. falciparum sub-telomeric genes revealed that nearly 50% of these genes belong in 
just 12 distinct gene families, including the var, r if  and stevor families, plus families with 
various or unknown functions Pf-fam-a through Pf-fam-i (Carlton et al., 2005). However 
the majority of these P. falciparum-specific genes were predicted to play a role in host- 
parasite interactions such as invasion, adhesion, and antigenic variation (Carlton & 
Carucci, 2002). Therefore comparative genomics has facilitated the identification of 
hypothetical and other parasite proteins that are potential therapeutic targets.
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1.6. Clonal antigenic variation and multigene families
Clonal antigenic variation is a mechanism employed by extra-cellular pathogens such as 
African trypanosomes to escape immune clearance, but is also used by the intracellular 
malaria parasite. In the case of malaria parasites, multigene families are generated by 
gene recombination during transmission through the mosquito vector. In turn, the 
variation with time of multigene-encoded antigens allows the parasite to replicate in an 
infected human host, utilising antigenic variation as a means of immune evasion. The 
resultant chronic infection then enables the parasite to increase its potential for mosquito 
transmission and further gene recombination.
Another mechanism for the generation of multigene families is gene duplication. This 
ensures retention of the gene’s original function, whilst allowing the potential for new 
functions. Recombination and duplications in sub-telomeric chromosomal regions are 
important in the generation and diversity of large multigene families in P. falciparum. 
Pseudogenes, with the potential for chromosome crossover events, may provide an 
additional store of diversity to be accessed through telomeric recombination.
1.6.1. Location of multigene families in chromosome ends
A clone of P. falciparum , 3D7 has been completely sequenced (Gardner et al., 2002). 
This has revealed a number of multigene families, the vast majority of which are located 
in sub-telomeric regions of the parasite’s 14 chromosomes. These include the var, rifin, 
stevor, Pf60, and P. falciparum Maurer’s cleft 2 transmembrane (PfMC-2TM) multicopy 
families (Baruch et a l , 1995; Carey et a l , 1994; Cheng et a l , 1998; Sam-Yellowe et a l , 
2004; Smith et a l , 1995; Su et a l, 1995). There are also several hundreds of hypothetical 
proteins within the sub-telomeric regions as yet not identified as belonging to particular 
gene families (Gardner et a l , 2002).
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Location in the sub-telomeric regions is significant as there is conservation of gene order
in these regions (Bowman et al., 1999; Gardner et al., 2002; Lavazec et al., 2006).
Multigene family genes are located sub-telomerically after 20— 40kb of non-coding
sequences, consisting of a mosaic of telomere-associated repetitive elements (TAREsl-6)
(figure 1.6) (de Bruin et al., 1994; Delves et al., 1989; Gardner, 1999). TAREs are
implicated in the formation of chromosome clusters in the nuclear periphery and hence
gene-transcriptional regulation. It has been shown recently that transcription of specific
var genes is dependent on the separation of a chromosome end away from its cluster, a
change in chromosome structure and telomere-associated proteins (PfSir2) (Duraisingh et
al., 2005; Freitas-Junior et al., 2005; Ralph et al., 2005). This is, however, a highly
localised change, as other genes located close-by on the same chromosome do not
necessarily become actively transcribed at the same time.
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Telomere
Noncoding region TAREs1-6 
~ 30-40kb
var
Coding region 
~ 20kb
rif
Figure 1.6: Detailed structure o f  P. falciparum chromosome ends
Showing typical ordering o f multigene family genes in the sub-telomeric coding regions.
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1.6.2. Antigenic variation and the discovery of parasite-derived proteins on the
surface of the P. falciparum  iRBC
The first evidence for parasite-derived proteins in schizonts as targets of acquired 
immunity was found by Eaton (Eaton, 1938), who used a parasite agglutination test to 
demonstrate the existence of the schizont-infected cell agglutination (SICA)-var proteins 
in the highly virulent monkey {Rhesus mulatto) malaria, Plasmodium knowlesi. Indirect 
evidence for antigenic variation came from work in rodent malarias. A study of relapse 
Plasmodium berghei infections suggested that during latency parasites undergo biologic 
variation that results in variants that can replicate freely in the previously immune host- 
mouse, resulting in relapses and parasitic recrudesences (Cox, 1958).
Using the parasite agglutination test (Eaton, 1938), antigenic variation of proteins at the 
schizont-stage of infection was later demonstrated to be the cause of chronic P. knowlesi 
infections in R. mulatto (Brown & Brown, 1965). These variant antigens were present on 
the surface of P. knowlesi iRBC from Rhesus-species monkeys, as detected by the SICA 
assay (Barnwell et al., 1982).
A study by Hommel et al in 1983 showed that new antigenic determinants were also 
detectable on the surface of iRBCs specifically infected with the trophozoite/schizont 
developmental stages of P. falciparum (Hommel et a l,  1983). These new antigenic 
determinants were sensitive to protease treatment suggesting that they were proteins. 
Importantly, this study showed that antigenic variation was also possible not only across 
strains but within a cloned population, and immune pressure, in the form of passive 
transfer of immune serum, could also induce antigenic variation in P. falciparum 
(Hommel et a l,  1983).
These strain-specific surface antigens were metabolically labelled with radioactive amino 
acids, indicating that they were of parasite origin rather than altered host components 
(Leech et a l, 1984). Importantly, the parasite iRBC surface proteins, present in knob-like
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structures, may be responsible for cytoadherence between iRBC and endothelium (Luse
& Miller, 1971; Schmidt et a l, 1982; Udeinya et al., 1981).
Expression of a single protein denoted PfEMPl (P. falciparum erythrocyte membrane 
protein 1) immunoprecipitated by immune sera was correlated with the ability of immune 
sera from Aotus monkeys, infected repeatedly with one of four strains of P. falciparum, to 
block in vitro cytoadherence of iRBCs and agglutinate iRBCs infected with homologous 
but not heterologous parasites (Howard et al., 1988).
The genes for the PfEMPl proteins were eventually cloned and the large and extremely 
diverse var multigene family described in P. falciparum (Baruch et al., 1995; Smith et al., 
1995; Su & Stevenson, 2002). To date, three large multigene families that are potentially 
on the iRBC surface have been described in P. falciparum. The PfEMPl and RIFIN 
families together with other iRBC surface proteins (including AEl/band 3, a RBC 
membrane anion transporter modified by P. falciparum infection, clags, PfMC-2TM, and 
SURFINs) are here briefly described. This is then followed by a detailed description of 
the final major gene family STEVOR, the main subject of this thesis.
1.6.3. P. falciparum  erythrocyte membrane protein 1 (PfEMPl)
var genes encode the PfEMPl proteins (Smith et al., 1995; Su et al., 1995). The 
sequenced P. falciparum 3D7 clone has 59 var gene copies found sub-telomerically (and 
occasionally centrally) in all 14 chromosomes (Gardner et al., 2002); however, var gene 
repertoires are thought to be strain-specific. PfEMPl variants are large proteins 
(approximately Mr -220-350kDa). PfEMPl are iRBC surface-membrane proteins as 
determined by lactoperoxidase-catalyzed radio iodination (125I) (Leech et al., 1984), 
trypsin treatment sensitivity (0.1pg/ml) (Hommel et al., 1983; Leech et al., 1984), and 
antibody immunoprecipitation of intact iRBC (Leech et al., 1984). They are anchored in 
the iRBC plasma membrane as determined by detergent solubility (Leech et al., 1984).
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PfEMPls are highly diverse but share similar organisation as single transmembrane-
spanning proteins. Each member consists of a large 5’ exon with high sequence- 
variability separated from a smaller highly conserved 3’ exon by a transmembrane 
domain. The 3’ exon encodes the acidic terminal segment (ATS), presumed to anchor 
PfEMPl to knob-like structures on the iRBC surface, while the N-terminal end is extra­
cellular, and contains 2 to 5 copies of a motif denoted DBL (Duffy-binding-ligand). The 
nomenclature of the DBL motifs is based on numbering them in the order from the gene’s 
5’ end, and to denote their sequence type by Greek letters a  - s, (x) (i.e. Common 
organisation of var results in DBL 1(a), DBL2 (P),.. .DBL5(e)).
A second motif common to all PfEMPls is the cysteine-rich inter-domain region (CIDR), 
of which there are one or two copies (termed a  and p or 1 and 2). The first CIDR, CIDR- 
1(a), is found immediately after DBL l a  in most var genes. The detailed domain structure 
of PfEMPl is illustrated in figure 1.7.
Specific domains of PfEMPl interact with specific host endothelial cell receptors e.g. 
CD36 or ICAM-1 (intercellular adhesion molecule 1), which endow the parasite with the 
ability to bind to endothelial cells (Baruch et al., 1995; Smith et al., 1995). Binding to 
endothelial receptors enables parasites to sequester out of peripheral circulation, thereby 
escaping splenic clearance of iRBC, and thus facilitates chronic infections that give 
gametocytes time to develop. This is especially important to P. falciparum parasites 
where the gametocytes have a particularly long developmental period before appearing in 
peripheral circulation (minimum 7 days) (Lensen et al., 1999; Sinden & Smalley, 1979). 
Early-stage gametocytes express PfEMPl and their sequestration is dependent on binding 
to the CD36 host endothelial receptor (Hayward et al., 1999; Piper et al., 1999b). 
Parasite-binding properties (such as to ICAM-1 in the brain micro vasculature) have been 
correlated with the variation in var repertoire between parasite strains, and could explain
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the serious disease morbidity and slow development of natural immunity to P.
falciparum .
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Exon 1 
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7 0 0 -  1500bp
Exon II 
I 1 ~1500bp
1------------------------------------------------------------------- l / v j --------------1
DBLIoc CIDRIcx D BLn CI°R  n 0 ATS
Exon 1 
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~350bp
Exon 1 
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Figure 1.7: Representative structures o f the var, rif, and stevor genes as well as the 
encoded PfEMPl, RIFIN, and STEVOR proteins, var genes are between 3.9 and 13 kb in 
size. The encoded PfEMPl 5 are composed o f different numbers (n) o f Duffy-binding-like 
(DBL) and cysteine-rich interdomain region (CIDR) domains. All var genes have an 
intron relatively close to the 3' end, and all PfEMPls have a transmembrane region (dark 
blue) followed by an intracellular acidic terminal segment (ATS) (pink). 
rif and stevor genes as well as their encoded RIFIN and STEVOR proteins are similar in 
structure. Exon I  o f both genes only encode a hydrophobic signal peptide sequence 
(green). Their introns are different lengths, and are relatively close to the 5' end. Two 
predicted transmembrane sequences (dark blue) are located in the middle as well as close 
to the C-terminus o f RIFIN and STEVOR, and a region o f extreme polymorphism is 
enclosed (orange). Figure is adaptedfrom a review by Rasti et al., (Rasti et al., 2004).
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1.6.4. Cytoadherence-linked asexual genes (RhopHl)
P. falciparum has five clag genes, of which clag9 has the highest homology across 
parasite isolates (Gardner, 1999; Gardner et a l, 2002; Manski-Nankervis et al., 2000). 
The clags have putative signal peptides and clag9 has four predicted transmembrane 
domains. Clag9 was originally described as a mature-stage 220kDa iRBC surface-protein 
(distinct from PfEMPl) (Trenholme et al., 2000).
Deletion of clag9 from chromosome 9 has been associated with the loss of ability to 
cytoadhere to CD36 receptors in certain P. falciparum lines maintained in vitro (Day et 
a l,  1993; Trenholme et a l, 2000). Artificial disruption of the clag9 gene also abolished 
this adherence (Holt et a l, 1999).
However, clag genes have since been shown to encode the 150kDa RhopHl protein, 
which is a part of the high-molecular-mass rhoptry protein complex (RhopH) found in the 
merozoite rhoptry organelles (Kaneko et a l, 2001; Kaneko et a l, 2005; Ling et a l, 
2004). Thus the clag-variant proteins may provide the RhopH complex with multiple 
functions, potentially including a cytoadhesive role, dependent on the exact clag protein 
combination in its composition (Ling et al., 2004).
1.6.5. Surface-associated interspersed genes (SURFINs)
In P. falciparum, SURFINs encoded by 10 surf genes are located in “an amorphous cap at 
the parasite apex” during the merozoite-stage (Winter et al., 2005). These proteins are 
also expressed on the iRBC surface of mature parasites: A SURFIN was cleaved by 
trypsin off the surface of P. falciparum 3D7 live iRBC (Winter et al., 2005).
1.6.6. P. falciparum Maurer’s cleft two transmembrane proteins (PfMC-2TMs)
PfMC-2TMs are transcribed during the trophozoite-stage of the erythrocytic cycle (Sam- 
Yellowe et a l, 2004). Genes are located sub-telomerically, and PfMC-2TM proteins were
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located in the Maurer’s clefts. This family has a signal peptide and Pexel/VTS motifs
characteristic of parasite proteins within the iRBC cytosol. 13 members of the PfMC-
2TM family share amino acid conservation throughout with the exception of a 17 amino
acid HVR between the two predicted transmembrane domains.
1.6.7. Human anion-exchange protein 1 (AE1 or band 3)
Unlike the other proteins associated with the iRBC membrane, AE1 (otherwise known as 
band 3) is not of parasite origin, but it is included here as it constitutes a major 
modification of the iRBC membrane. Modified AE1 enables the parasite iRBC to interact 
with other host cells in a similar fashion to parasite-derived iRBC surface proteins. 
Normal AE1 is a major membrane protein of RBCs, with two main functions: 
maintenance of RBC structure, and transport of carbon dioxide from the intra-cellular to 
the extra-cellular space. Parasite growth modifies the AE1 protein, so that normally 
unexposed parts are exposed on the iRBC surface. By the late parasite-stages, these 
exposed regions result in an increase in iRBC adhesiveness (Crandall & Sherman, 
1994b).
Peptides designed on human-band 3 epitopes were able to block iRBC adhesion to C32 
amelanotic melanoma cells in a dose-dependent manner, as did antibodies to these 
sequences. These cytoadherence blocking band 3 peptides were termed Pfalhesin 
(Crandall & Sherman, 1994a). When Pfalhesin peptides were infused into Aotus or 
Saimiri monkeys infected with P. falciparum , large numbers of trophozoites and 
schizonts were observed in peripheral blood 24 hours post-infusion, suggesting that these 
peptides delayed or reversed sequestration (Crandall et al., 1993). The endothelial cell 
receptors for Pfalhesin have been identified as thrombospondin (TSP) and CD36 
(Crandall et a l , 1994; Eda et a l, 1999).
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Interestingly, parasite merozoite-binding ligands MSP 142 and MSP 119 have been shown
to recognise and bind to extra-cellular regions of normal AE1 in a sialic acid-independent
parasite-host interaction (Goel et al., 2003).
Both normal and modified AE1 forms therefore function as a major point of interaction 
between the parasite and host, as a binding ligand on RBCs at the merozoite invasion- 
stage, and a sequestration ligand in post-24hours trophozoite /schizont-stages, where 
modification of this major RBC protein by the parasite growth leads to increased iRBC 
cytoadherence to CD36 receptors and TSP resulting in iRBC sequestration. In addition to 
its other normal functions, this ubiquitous membrane transport protein also provides 
signals marking up senescent cells for removal by the immune system in mammals, thus 
the parasite has the potential to interfere with the regulation, aging processes and removal 
of iRBCs (Kay et al., 1990; Low et a l, 1985).
1.6.8. Repetitive interspersed family of genes (RIFINs)
The r if  gene family was identified as an interspersed repetitive gene sequence (rif), with 
149 copies in the 3D7 genome (Gardner et al., 2002). RIFINs encode variable size (27- 
45kDa) proteins transcribed and expressed in the trophozoite-stage (figure 1.7). The 
proteins have an N-terminal semi-conserved domain with the majority of cysteines, while 
the C-terminal contains two predicted transmembrane domains and a highly polymorphic 
region (Cheng et al., 1998; Kyes et al., 2001). RIFINs were initially linked to rosetting 
although this is a role now fulfilled by the complement receptor 1 (CR1) binding domain 
to PfEMPl (Fernandez et al., 1999; Helmby et al., 1993; Stanley & Reese, 1986). The 
two transmembrane domains are thought to create a polymorphic loop present on the 
iRBC surface consistent with a role in antigenic variation (Fernandez et al., 1999; Kyes et 
al., 1999). However recent work by Khattab and Klinkert used green fluorescent protein 
(GFP)-chimeric molecules to track a RIFIN through the iRBC, and found the RIFIN
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localised to the Maurer’s clefts (MC), with the polymorphic region exposed to the iRBC
cytosol (Khattab & Klinkert, 2006). Maurer’s clefts are flattened vesicular structures
localised beneath the iRBC surface membrane (Bannister & Mitchell, 2003).
Antibodies in hyper-immune sera from adults recognise RIFIN proteins, indicating that,
like PfEMPl, they are immunogenic, exposed, and induce malaria-specific IgG
antibodies. The concentration of anti-RIFIN antibodies has been correlated with time
taken for parasite clearance suggesting they confer some protection against malaria
(Abdel-Latif et al., 2002; Abdel-Latif et al., 2003; Abdel-Latif et al., 2004).
1.6.9. Sub-telomeric variable open reading frame (STEVORs)
The sub-telomeric variable open reading frame {stevor) multigene family is the third 
largest family in P. falciparum and is the subject of this study. Genomic sequencing of 
laboratory lines predicted the stevor family to consist of 33 copies in P. falciparum 3D7, 
30 copies in P. falciparum W2 and 34 copies in P. falciparum Dd2 parasites (Cheng et 
al., 1998). Originally identified and used as a DNA probe, to distinguish between P. 
falciparum isolates, stevors have similarities to the rifs, however they are two clearly 
distinguishable gene families. Stevors are smaller lkb genes compared with r if  genes 
which are 1.3kb on average (Limpaiboon et al., 1990). Like the r if genes, stevors are 
found on all 14 chromosomes, however unlike the vars, none is located centrally on the 
chromosomes (Gardner et al., 2002).
Stevor proved a sensitive target for PCR, and has been used for clinical purposes 
(detecting 0.01 parasites in lp l of blood) (Filisetti et a l,  2002), giving distinctive multiple 
banding patterns in Southern blots capable of distinguishing P. falciparum parasite clones 
(Limpaiboon et al., 1990; Prescott et al., 1994).
The two-exon structure of stevor and r if  was confirmed by Cheng et al, 1998 (figure 1.7) 
(Cheng et al., 1998). The first short exon, approximately 50— 75bp in length, encodes a
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start codon and predicted canonical signal sequence. Analysis showed the AT-rich intron
starts with a GT and ends in a poly-T sequence before a consensus TAG splice site. The
second exon, shorter in stevor than rif, encodes several conserved regions and a highly
polymorphic region flanked by two predicted transmembrane domains. This region is
predicted by Kyes et al to be an external ‘hyper-variable loop’ and is considerably longer
in RIFIN (170 amino acids) than STEVOR (70 amino acids) (Cheng et al., 1998; Kyes et
al., 2001).
STEVOR is a transmembrane, integral-membrane protein, which has been located in 
Maurer’s clefts in the iRBC cytosol (Cheng et al., 1998; Kaviratne et al., 2002; Kyes et 
al., 1999; Przyborski & Lanzer, 2005). STEVOR is located in the Maurer’s clefts during 
the trophozoite-stage of a laboratory P. falciparum line (3D7), which is grown 
continuously in in vitro cultures (Kaviratne et al., 2002). Polyclonal mouse and rabbit 
antibodies against conserved STEVOR N- and C-terminal peptide sequences were used to 
demonstrate STEVOR expression in blood-stage parasites. An approximately 37kDa 
protein was recognized in Western blots of asexual 3D7 parasite lysate. These same 
antibodies were used in immunofluorescence assays, and in the 3D7 strain co-localised 
the STEVOR proteins in the Maurer’s clefts with P. falciparum Skeletal Binding Protein- 
1 (PfSBPl) and truncated P. falciparum Erythrocyte Membrane Protein-3 (PfEMP3) 
antibodies (Blisnick et al., 2000; Kaviratne et al., 2002; Waterkeyn et al., 2000). Like 
other Maurer’s cleft structural components, STEVOR reportedly remains associated with 
the iRBC ghost after schizont rupture and merozoite release, indicating stable STEVOR- 
Maurer’s clefts associations (Kaviratne et al., 2002). This is in contrast to the iRBC 
surface location of the other multigene families: PfEMPl and RIFINS.
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1.6.9.1. STEVOR in gametocyte-stages
STEVOR has also been shown to be present in gametocyte-stages (McRobert et al., 
2004). In late-stage gametocytes STEVOR appears to be associated with the iRBC 
membrane. However, this is via a Maurer’s cleft-independent pathway as gametocytes 
lack Maurer’s clefts. Identical STEVOR proteins are transcribed and expressed in P. 
falciparum 3D7 asexual and gametocyte parasites (McRobert et a l , 2004; Sharp et al., 
2006). In addition, truncated STEVORs are found in gametocytes (Sutherland, 2001). The 
population of truncated STEVORs may be important as they lack the second predicted 
transmembrane domain and therefore would be arranged differently within the membrane 
(Sutherland, 2001). They could also be redundant transcripts. However, a smaller protein 
band with sizes corresponding to the truncated transcript was detected by Western blot 
only in gametocyte parasite lysates (McRobert et al., 2004).
As mentioned previously, early-stage gametocytes express PfEMPl and sequestration is 
dependent on binding to the CD36 host endothelial receptor (Day et al., 1998; Hayward et 
al., 1999; Piper et al., 1999a). However gametocyte-stages II-IV, which also adhere to 
endothelium, use a CD36-independent adhesion mechanism (Rogers et al., 2000). 
STEVOR is suggested as one potential candidate for this adhesion mechanism.
1.6.9.2. STEVOR in sporozoite-stages
There is also evidence for the presence of STEVOR in sporozoite-stages. Proteomic
analysis of total sporozoite extracts indicated the presence of a single STEVOR protein
(Florens et al., 2002). In addition, the presence of STEVOR in sporozoites has been
demonstrated by immunofluorescence within cytoplasmic vesicles (McRobert et al.,
2004). However, presence in sporozoites is not unique to the STEVOR multigene family,
as PfEMPl and RIFIN peptides were also found within the sporozoite-stage (Florens et
al., 2002), and transcriptome data detected twenty-five rifin genes, four stevor genes, and
a single common var detected in sporozoites (Le Roch et al., 2003).
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1.7. Proteins targeted by P. falciparum  to the host iRBC cytosol and surface
All the protein families described above belong with a catalogue of proteins that are
predicted to be trafficked into the iRBC cytosol. They are grouped according to criteria
describing architecture, for example size (-300 amino acids) and a 2-transmembrane
topology.
Recent work suggests that combinations of signals are important for the transport of 
parasite-proteins into the iRBC cytosol, to the Maurer’s clefts and iRBC surface:
1) Canonical (Burghaus & Lingelbach, 2001; Waller et a l , 2000) or 
unconventional hydrophobic N-terminal signal sequences target the 
protein to the parasite endoplasmic reticulum (Lopez-Estrano et al., 2003; 
Wickham et a l, 2001).
2) An eleven-amino acid-vacuolar transit sequence/ pentameric sequence- 
protein export element (VTS/PEXEL) motif: RxLxE/Q, identified in the 
N-terminal domain of exported proteins, is required for transport across 
the PVM (Hiller et a l, 2004; Marti et a l, 2004). PfEMPl lacks this exact 
motif, but an N-terminal conserved motif with similar features is thought 
to function as its translocation motif: AKHLLDRLG (Marti etal., 2004) or 
FFRWFSEWSE (Hiller et a l, 2004).
3) Only one transmembrane domain is required for STEVOR, an integral- 
membrane protein (Przyborski et a l, 2005), and for PfEMPl, which, 
despite the transmembrane domain, traffics as a soluble protein within a 
chaperoned complex, to associate with the Maurer’s clefts (Knuepfer et 
a l , 2005b; Papakrivos et a l , 2005). These signals are present in many of 
the proteins exported into the iRBC cytoplasm defined as the “secretome” 
(Hiller et a l, 2004; Marti et a l, 2004).
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Proteins move via the Maurer’s clefts to the iRBC surface. PfEMPl, the best
characterised of the parasite-derived proteins that are expected on the iRBC surface, is
known to be exported via Maurer’s clefts (Haeggstrom et a l,  2004). Another parasite-
derived protein associated with the iRBC surface and Maurer’s clefts, PfEMP3, is thought
to be important for the modification of the iRBC surface by insertion of PfEMPl into
knobs on the iRBC surface (Knuepfer et a l, 2005a; Waterkeyn et a l,  2000). Knob-
associated histidine-rich protein (KAHRP), which contains the conserved P. falciparum
PEXEL/VTS motifs (Hiller et a l , 2004; Marti et a l , 2004), is also transiently associated
with the Maurer’s clefts before being redistributed to knobs on the cytoplasmic face of the
iRBC (Lopez-Estrano et a l, 2003; Wickham et a l, 2001).
Several parasite proteins reside in the Maurer’s clefts: these include PfSBPl (an 
established Maurer’s-cleft marker (Blisnick et a l, 2000)), the Maurer’s cleft two- 
transmembrane domain proteins (Pf MC 2-tm) (Sam-Yellowe et a l,  2004), the 
membrane-associated histidine-rich protein 1 (MAHRP1) (Spycher et a l, 2003), and a 
number of novel proteins identified through proteomics analysis (Vincensini et a l, 2005). 
In addition STEVOR is exported and remains integral to these membranous structures 
(Kaviratne et a l , 2002).
1.7.1. Maurer’s clefts as a protein transport organelle
Evidence exists for classical secretory transport of proteins in the iRBC. Interestingly, 
several Maurer’s-cleft-associated proteins (including PfEMP3, REX1, PfSec31p, and 
PfSarlp) show structural similarity to vesicle-tethering proteins (Hawthorne et a l, 2004; 
Waterkeyn et a l, 2000). In addition, the Maurer’s-cleft proteins PfSec31p and PfSarlp 
are P. falciparum homologues of COPII proteins, which mediate vesicle transport, and 
are evidence that the parasite exports proteins for vesicle-mediated protein transport into 
the iRBC cytosol (Adisa et a l, 2001; Albano et a l, 1999), suggesting that Maurer’s clefts
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are probably the parasite’s answer to the protein-trafficking and -sorting problem posed
by living within a de-nucleated cell lacking a protein-transport system. In this case,
Maurer’s clefts would provide the parasite with a location within which protein
complexes are assembled before being transported to the iRBC surface. Indeed targeted
gene disruption of PfSBPl, (an integral Maurer’s-cleft protein with a cytoplasmic C-
terminal, and Maurer’s cleft lumen N-terminal), prevented iRBC adhesion due to loss of
PfEMPl expression on the iRBC surface (Cooke et al., 2006). Functional
complementation of the PfSBPl-deleted parasites with a chimeric SBP1 gene restored the
wild-type phenotype, and thus PfSBPl crucially functions in the transfer of PfEMPl from
the Maurer’s clefts to the iRBC surface.
Crucially, parasite proteins use Maurer’s clefts to get to the iRBC surface. STEVOR co- 
localises along with the surface-expressed multigene families, RIFINs and PfEMPl, to 
these structures. This raises the question of whether STEVOR also goes to the surface of 
the iRBC as its final destination within the blood-stage cycle. Therefore the key is to 
locate STEVOR more specifically in iRBCs.
1.8 Justification and objectives
Analysis of data obtained from the treatment of neurosyphilis with malaria fevers 
suggested that although the immunity generated by infection was protective for 
homologous parasites, an important component of protective immunity is ‘strain’ specific. 
Parasite heterogeneity and specificity of the resulting immune response is a plausible 
explanation of the need for prolonged exposure to multiple parasites, in order to achieve 
both anti-parasite and clinical immunity to malaria. Parasites vary through 
polymorphisms in the putative target antigens for protective immune responses, either 
through the existence of alternative allelic forms in the case of many key merozoite 
antigens, or through the existence of multiple homologous genes and the mechanism of
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clonal antigenic variation, in the case of important iRBC surface proteins. The emerging
evidence of protective responses being directed against such polymorphic and variant
epitopes implies that it is unlikely that immune status will ever be defined by any single
response. This has serious implications for the future planning of vaccine components and
current trials have generally not accounted for this variation. Therefore a fuller
knowledge of the potential parasite genotypic and phenotypic variation is necessary
before an effective vaccination strategy can be attained.
A substantial body of information has been gathered on the iRBC surface protein 
PfEMPl, which has revealed certain common var genes, which the parasites use initially 
unless prevented by a specific protective immune response. The stevor multigene family 
is the third next largest gene family in the P. falciparum genome, and as such, it is of 
interest to determine whether a similar hierarchy of common variants exists between 
different parasite genomes. Initially it will be necessary to determine if the stevor family 
is a common feature of P. falciparum parasites, as current knowledge only extends to the 
laboratory line 3D7. Field parasite isolates are of particular interest given the expectation 
that multigene families are positively driven by immune responses.
Currently, it is not known whether STEVOR proteins are exported to the surface of the 
iRBC, which would make them key immune targets. In addition, it is likely that STEVOR 
proteins may play important roles in the biology of the parasite and pathogenesis of 
malaria. Therefore a more extensive study of the localisation of these proteins, 
particularly in field-isolate parasites, is necessary. As has already been discussed, 
evidence exists for expression of STEVOR in several different-stages of the life-cycle, 
which may suggest that STEVOR has multiple functions. However, it also suggests that 
similar antigenic surfaces will be presented to the immune system enabling a multi-stage 
targeting immune response. These studies aim to gain a more intimate knowledge of the
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biology of the parasite and its interactions with the human host with specific regard to
STEVOR.
1.8.1. Specific objectives
1) To assess the newly available genomic sequence data for stevor to identify the 
global STEVOR repertoires in available parasite genomes.
2) To determine if stevor is transcribed and expressed in all parasites (different
parasite isolates from laboratory and field).
3) To compare the expression profiles of STEVOR across different laboratory
parasite isolates and field parasites.
4) To make a detailed assessment of the location of STEVOR within the
erythrocytic-stage parasites, including gametocytes.
5) To determine if STEVOR is expressed on the iRBC surface.
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Chapter 2) Materials and Methods 
2.1. Media, solutions and buffers
All chemicals and reagents were of analytical grade and purchased from BDH chemicals 
Ltd, UK, or Sigma, UK, unless otherwise stated. Compositions of media solutions and 
buffers are given in the text.
2.1.1. Parasite media
RPMI 1640 complete medium (with 10% Albumax) (Gibco) for laboratory parasite lines 
RPMI 1640 with 10% AB serum supplemented (see below) for Kilifi parasite isolates 
RPMI 1640 complete medium (without Albumax) (Gibco) for washes etc
2.2. Parasites
The parasites used in this study were well-characterised laboratory strains or were blood 
samples isolated from in Africa. See table 2.1 for list of all parasite clones used for in 
vitro culture and their origin.
The African study parasites were acquired at Kilifi district hospital, situated 60km north 
of Mombasa on the Kenyan coast. More than 10% of the children under the age of 5 years 
who reside within the Kilifi district are admitted into hospital each year. The area has 
prolonged seasonal P. falciparum transmission following the long and short rains, 
transmitted by the Anopheles gambiae s. I. complex (Mbogo et al., 1993).
Parasites were obtained from the KEMRI-Wellcome Trust, Kilifi, Kenya. Blood was 
taken from patients in the Kilifi general district. Lymphocytes were removed from blood 
samples prior to preservation in liquid nitrogen.
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2.2.1. Parasite culture of P. falciparum  laboratory lines
All media used for parasite culture were first warmed to 37 °C. All centrifugation steps 
were carried out at 25 °C.
Laboratory parasite lines were cultured in fresh human RBC (supplied by National UK 
Blood Donation Service) in RPMI 1640 complete medium (with Albumax) 
(supplemented with 2mM glutamine (NIMR media service)) (Trager & Jensen, 1976). 
The flasks were maintained in a low oxygen environment (88% Nitrogen with 5% 
Oxygen and 7% Carbon dioxide). Medium and gas were changed daily, and cultures 
maintained at below 30% parasitaemia in approximately 2% haematocrit.
Parasitaemia was monitored by microscopy; thin blood films were fixed in methanol onto 
glass slides, and stained with Giemsa stain (diluted in water). The slides were examined at 
100X with an oil objective on a light microscope.
Table 2.1) The origins of P. falciparum clones used for in vitro culture
Clone Parent isolate Geographical origin Reference
3D7 NF54 Amsterdam airport - 
Netherlands (unknown origin)
(Walliker et a l, 1987)
A4 IT04 Brazil (Roberts et a l, 1992)
CIO 1776 Malaysia (Ang et al., 1996)
DIO FCQ-27 Papua New Guinea (Chen et a l, 1980)
Dd2 W2-MEF Indochina (Oduola et al., 1988)
FcBl Colombia (Schrevel et al., 1994)
T9/96 T9 Thailand (Thaithong et al., 1984)
2.2.2. Induction of gametocytes during P. falciparum  3D7 culture
In order to induce gametocyte production, P. falciparum 3D7 stock culture was increased 
to 4-6% haematocrit with fresh RBC (personal communication Muni Grainger). The 
culture was monitored by thin blood smears over approximately 18 days for the
68
Chapter 2________________________________________________Materials and Methods
development of gametocytes. During this period, no new RBCs were added to the flask
but medium and gas were changed daily.
2.2.3. Recovery of P. falciparum Kilifi parasite isolates from frozen stock
Cryovials of between 500pi and 1ml infected-blood were removed from liquid nitrogen 
and thawed rapidly at 37°C (by enclosing the cryovial in a fist). Samples were gradually 
returned to isotonicity, using a three-step process. First, 200pl sodium chloride (12% 
solution) was added drop-wise with agitation over 2 minutes, (to a 1:5 saline to sample 
volume ratio). This was followed by 5mls (5 volumes) sodium chloride (1.8% solution) 
added with agitation over 5 minutes, finally 5mls sodium chloride (0.9% solution) was 
added likewise. The blood was centrifuged at 561xg, 5 minutes at 24°C and the 
supernatant removed.
2.2.4. In vitro culture of P. falciparum isolates from Kilifi
The parasites (iRBCs) were cultured in RPMI 1640 media supplemented with 10% AB 
human serum (Kilifi General Hospital, Kenya), 2mM L-glutamine (Gibco), 37.5mM 
HEPES (Gibco), 20mM Glucose, 2pg/ml Gentamycin (Gibco), pH 7.2 in a reduced 
oxygen environment (see above for exact gas mixture). No fresh RBCs were added to the 
cultures, and the parasites were maintained in culture for approximately 30 hours, or 
allowing for delayed growth, until they reached late trophozoite/schizont-stages. Parasite 
samples were divided into two for later processing for gDNA and RNA (see below).
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2.2.5. Schizont purification and synchronisation
Parasites were first washed in RPMI 1640 medium (without Albumax), and resuspended 
at 20% haematocrit. The parasites were layered gently on top of 5mls 70% isotonic 
Percoll (in PBS pH7.2) (Amersham Biosciences) in RPMI 1640 (without Albumax), in 
20ml universal tubes. The gradient was spun at lOOOxg, for 10 minutes, without brake. 
The resultant schizont layer was removed and resuspended 1:1 in RPMI 1640 (without 
Albumax). The schizonts were washed by centrifugation at 815xg, 3 minutes and the 
supernatant containing residual Percoll was removed.
The schizont pellet could then be used for snap freezing etc, or the parasites added back 
into culture with fresh RBC for reinvasion and synchronisation of the culture.
To synchronise the culture, approximately 2 hours after reinvasion of merozoites into 
RBC, or once ring-stages were visible by thin blood film, 5% sorbitol (NIMR media 
service) was added 1:1 for twelve minutes in a 37°C water bath, to remove stages older 
than 24 hours post-invasion (Hoppe et al., 1991). The culture was then washed in RPMI 
1640 (without Albumax) to remove contaminating sorbitol, centrifuged at 815xg, for 
three minutes, and the supernatant removed. The remaining sorbitol-treated iRBCs were 
replaced back in culture with fresh RBCs and RPMI 1640 (with Albumax).
2.2.6. Parasite purification on a MACS column (miltenyibiotec)
Synchronised parasites were purified on a MACS column (20ml) placed in a magnetic 
field to remove all uninfected RBC and ensure parasites for protein extraction were high 
purity (Taylor et a l, 2002). Haemozoin within the iRBCs is bound by the magnet 
allowing all other cells to be washed off the column. The column was washed with 
distilled water to remove all traces of ethanol and equilibrated with RPMI 1640 (without 
Albumax) before the parasite culture was applied to the column. The column was washed 
with a further 2 column volumes of RPMI 1640 (without Albumax), before the column
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was removed from the magnetic field and the bound parasites eluted into a new tube.
Parasites for protein extraction were then centrifuged (815xg, 3 minutes) and aliquots of
the pellet snap frozen in an ethanol/ dry ice bath prior to storage at -80°C.
2.2.7. Purification of P. falciparum 3D7 gametocytes on a Percoll gradient
A discontinuous Percoll gradient was used to purify the gametocytes from culture. 
Solutions of 90% (2ml), 60% (2ml), 54% (4ml), 45% (2ml), 30% (2ml) Percoll were 
layered carefully in 15ml Falcon tubes, before adding the gametocyte enriched cultures at 
20% haematocrit on top. The gradients were then centrifuged at 815xg, 6 minutes without 
brake. The top layer containing parasite debris was removed, and the gametocyte- 
containing fraction, between the 54 and 45% gradient layers, was collected.
The purity of the gametocytes was approximately 6-16%.
2.3. Preparation and manipulation of parasite DNA and RNA
2.3.1. Preparation of parasite genomic DNA (gDNA)
P. falciparum iRBC, which had been cultured for more than 30 hours (to late trophozoite 
stage of development) were centrifuged 560xg 5 minutes. The pellets were stored at - 
80°C in screw top cryovials. A Phenol /Chloroform extraction method was used for larger 
(greater than 500pl) iRBC pellets (Beck, 2002). The DNeasy® kit (Qiagen) protocols 1 
and 2 (see manufacturer’s handbook) were used for small (less than 500pl) blood 
samples. DNA was resuspended in nuclease-free water (50pi).
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2.3.2. Preparation of parasite RNA
Corresponding P. falciparum iRBC, at late trophozoite developmental stage (positive for 
expected r i f  stevor transcription, which had been cultured for more than 30 hours were 
centrifuged 560xg for 5 minutes, then iRBC pellets (approximately lOOpl) for RNA 
extraction were stored at -80°C in 1ml (10 pellet volumes) pre-warmed (37°C) Trizol® LS 
reagent (Gibco Invitrogen) in screw top cryovials. Kyes et al developed the extraction 
method, used for analysis of the var and r if  multigene family expression patterns (Kyes et 
al., 2000). RNA was resuspended in nuclease-free water (20pl).
2.3.3. Primer design for stevor specific PCR/RT-PCR
The primers were assessed using multiple sequence alignments to ensure that the chosen 
sequences were in regions conserved within the stevor gene family, but not in other genes 
(for example the r if  gene family). A combination of two sets of primers in a nested PCR 
was used. Cheng designed the RepFl, RepF2 and RepR intemal-PCR primers (table 2.2) 
(Cheng et al., 1998). The RepFl/2 primers were redesigned to remove an opal stopcodon 
(TGA) replacing it with (TGC). The smfl/smrl external primers were from (Kaviratne et 
al., 2002). All primers were synthesised by Eurogentic/Oswel (Southampton, UK) or 
Research Biolabs (Singapore). The use of a nested-PCR protocol for RT-PCR was 
problematic, due to amplification of contaminating gDNA, therefore a stevor-specific 
single step amplification was designed, facilitated by the complete genome sequence 
(Gardner et a l, 2002), using the primers JBSTEVORF1 and JBSTEVORR1 (table 2.2).
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Figure 2.1: Schematic o f stevor showing primer location
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Table 2.2) Primer sequences
Materials and Methods
Primer name Direction Primer Sequence (5' -3') Tm
(°C)
smfl sense GAY SCAGAACTCAARGAAATWATTG 46.42
smrl anti sense GCAGMACCAAAGYWGYAATACC 47.9
JBSTEVORF1 sense AGATGTACCCGTGGTATATGTTCTTGCA 54.96
JBSTEVORR1 antisense GCTAAT AT AAGT AGAACC AAAGCTGC AAT AC 54.44
RepFl sense AGATGAATTCGTGGTATATRTTYTTGYTC 55.84
RepF2 sense AG AT G A ATTCGGGGTTT AGTT GT GTGTGC 63.86
RepR antisense TTTAGGATCCAGAACCAAARYTGCAATACC 62.21
TARepFl sense AG AT GC ATTCGT GGT AT ATRTT YTT GYT C 53.13
TARepF2 sense AGATGCATTCGGGGTTTAGTTGTGTGTGC 61.42
TARepR antisense TTTAGGATCCAGAACCAAARYTGCAATACC 56.9
pET24RepF 1 sense GG AATT C CAT AT GGG ATCC AG AT GC ATTCGT GGT AT ATRTT YTT G YTC 62.5
pET24RepF2 sense GG AATTCC AT AT GGG ATCC AG AT GC ATTCGGGGTTT AGTT GTGTGT GC 65.5
pET24RepR anti sense GGAATTCTTTAGGATCCAGAACCAAARYTGCAATACC 58.3
TOPORepF 1 Jane sense C ACC AG AT GC ATT CGGGGTTT AGTT GTGTGT GC 60.6
TOPORepF2Jane sense CACCAGATGCATTCGTGGTATATRTTYTTGYTC 56.2
RepRTOPO antisense TTTAGGATCCAGAAGGAAARYTGCAATACC 53.8
M13 Forward sense T GT AAAACGACGGCCAGT 42.9
M l3 Reverse antisense CAGGAAACAGCTATGACC 42.9
T7 promoter sense TAATACGACTCACTATAGG 39.5
T7 terminator antisense GCTAGTT ATT GCTC AGCGG 46
M13 Forward sense GTAAAACGACGGCCAG 50
M13 Reverse anti sense CAGGAAACAGCTATGAC 50
TrxFus forward sense TTCCTCGACGCTAACCTG 56
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2.3.4. Polymerase chain reaction (PCR) amplification of stevor genes’ hyper-variable
region
The target region of stevor genes was amplified from gDNA using PCR. PCR reactions 
were carried out in both Eppendorf Mastercycler gradient, and standard machines 
(Eppendorf, Hamburg, FRG). A combination of heated lid, plate sealers (Eppendorf), 
and/or 50pl mineral oil was used to prevent sample evaporation. See table 2.2 for primer 
sequences.
Separate primer sets were designed for 3 vector systems used for product sequencing 
(Figure 2.2): A) pCR2.1 B) pCRII C) pET-24a (+) and D) pET102/D-TOPO vectors. The 
pCR2.1/pCRII system utilises a one-step cloning strategy that does not require addition of 
restriction sites to the primers. The pET-24a (+) and pET102/D-TOPO systems were each 
designed to include a restriction or ligation site at the end of the resultant product. The 
Magnesium chloride concentration (2mM-4mM), and primer annealing temperatures 
were optimised for the different reactions.
The production of PCR products for sequencing was further optimised by the use of a 
proof reading polymerase Pfu enzyme (Stratagene). The 5’ to 3’ -DNA polymerase and 
3’- to 5’ -exonuclease activity results in a six-fold increase in fidelity of DNA synthesis 
compared to Taq DNA polymerase (Stratagene product information). A brief incubation 
step with Taq polymerase for 10 minutes at 72°C following PCR with the proof reading 
enzyme added the 3’ A-overhang necessary for cloning into the pCR2.1/pCRII systems.
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Figure 2.2: Plasmid vector maps
A) pCR2.1 (invitrogen)
B) pCRII (invitrogen)
C) pET-24a (+) (Novagen)
D) pET102/D-TOPO (invitrogen)
E) pET-24a (+) SI insert (Novagen)
F) pET-24a (+) S2 insert (Novagen)
Vector maps obtained from manufacturer’s product protocols.
Materials and Methods
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A)
lacZa ATG 
M13 Reverse Primer I HimJill Kpn I Sac I SamHI I I Spe I
CAG GAA ACA GCT M S  AC C ATG ATT ACG CCA AGC TTG GTA CCG AGC TOG GAT CCA CTA 
GTC CTT TGT CGA TAC TG G TAC TAA TOC GCT TCG AAC CAT GGC TCG AGC CTA GOT GAT
BsfX I EcoRII I
GTA ACG GCC GCC ACT CTG CTG GAA TTC GGC TT 
CAT TGC CGG CGG TCA CAC GAC CTT AAG CCG
EcoRV
Ava I 
Paaffl I 
Xho I Nsi I Xba I
EcoR I I
GCC GAA TTC TGC 
TT CGG CTT AAG ACG
Apa IBsfX I Not I
AGA TAT OCA TCA CAC TGG CGG CCG CTC GAG CAT OCA TCT AGA GOG CCC AAT TCG 
TCT ATA GCT ACT CTG ACC GCC GGC GAG CTC CTA CCT AGA TCT CCC GOG TTA AGC
CCC TAT 
GGG ATA
T7 Promoter
ACT GAG TCG TAT TA C AAT TCA 
TCA CTC AGC ATA AT GTTA ACT
M13 Forward (-20) Primer 
CTG GCC CTC CTT TTA dAA CGT CCT GAC TGG GAA AAC 
GAC CGG CAG GAA AAT G TT GCA GCA CTG ACC CTT TTG
pCR
Comments for pCR®2.1 
3929 nucleotides
LacZa gene: bases 1-545
M13 Reverse priming site: bases 205-221
T7 promoter: bases 362-381
M13 (-20) Forward priming site: bases 389-404
f1 origin: bases 546-983
Kanamycin resistance ORF: bases 1317-2111
Ampicillin resistance ORF: bases 2129-2989
pUC origin: bases 3134-3807
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B)
/acZaATG 
M13 Reverse Primer I
CAG GAA ACA GCT A IS AC C ATG ATT ACG CCA AGC T AT TTA GCT GAC ACT ATA G AA 
CTC CTT TCT OGA TAC TG GTAC TAA TGC GCT TCG A TA AAT CCA CTG TGA TAT CTT
Sp6 Promoter
A/s# I Hind III Kpni Sac I fiamHI Spe Il i  l l i  i
TAC TCA AGC TAT GCA TCA AGC TTG CTA CCG AGC TCG GAT CCA CTA CTA ACG GCC 
ATG ACT TCG ATA CCT ACT TCG AAC CAT GGC TCG AGC CTA GCT GAT CAT TGC CGG
BsfX. I EcoRI
GCC ACT CTG1 CTG GAA TTC GGC TT 
CGG TCA CAC GAC CTT AAG CCG
EcoRI EcoRVI I
GCC GAA TTC TGC AGA TAT 
T T CGG CTT AAG ACG TCT ATA
BsfX I Hof | Xho I Nsi I Xba I Apali l l  l i  I
CCA TCA CAC TGG CGG CCG CTC GAG CAT GCA TCT AGA GGG CCC AAT TCG 
GCT ACT CTG ACC GCC GGC GAG CTC CTA CCT AGA TCT CCC GGG TTA AGC
T7 Promoter
ACT GAG TCG TAT TA 
TCA CTC AGC ATA AT
M13 Forward (-20) Primer
CCC TAT 
GGG ATA
~ r ~
CTG GCC CTC CTT TTA C AA CGT CCT GAC TGG GAA AAC 
GAC CGG CAG CAA AAT G TT GCA GCA CTG ACC CTT TTG
Comments for pCR®1l 
3971 nucleotides
LacZa gene: bases 1-587 
M13 Reverse priming site: bases 205-221 
Sp6 promoter: bases 239-256 
Multiple Cloning Site: bases 269-381 
T7 promoter bases 404-423 
M13 (-20) Forward priming site: bases 431-446 
f1 origin: bases 588-1025 
Kanamyein resistance ORF: bases 1359-2153 
Ampidllin resistance ORF: bases 2171-3031 
pUC origin: bases 3176-3849
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C)
f E M 4 « « H _________
T7 promoter 
T7 transcription start 
T7«Tag coding sequence 
Multiple cloning sites 
(AunHI-Xtol)
Hls»Tag coding sequence
T7 terminator
iac/coding sequence
pBR322 origin
Kan coding sequence
f l  origin
311-327
310
207-239
158-203
MO-157
26-72
714-1793
3227
3936-4748
4844-5299
The maps for pET-24b(+). pET-24c(+) and 
pET-24d(+) are the same as pET-24a(+) 
(shown) with the following exceptions: 
pET-24b(+) is a 5309bp plasmid: subtract 
lbp from each site beyond SamH I at 198. 
pET-24c(+) is a 5308bp plasmid: subtract 
2bp from each site beyond BamH I at 198. 
pET-24d(+) is a 5307bp plasmid; the BamH I 
site is in the same reading frame as in pET- 
24c(+). An Ate I site is substituted for the 
Nde I site with a net lbp deletion at position 
238 of pET-24c(+). As a result Nco I cuts 
pET24d(+) at 234. and Nbe I cuts at 229. For 
the rest of the sites, subtract 3bp from each 
site beyond position 239 in pET-24a(+). Ndt 
I does not cut pET-24d(+). Note also that 
Sty I is not unique In pET-24d(+).
Dra IIKsoee)
PVU 1(43*7) 
S(|f 1(4367)
X hoqise)
MndM(iTS) 
SatlriTS) 
S ac  ittaoi EmRqiKQSty 1(57)
Bpu11Q2l<ao)
Nhe l(23i) 
NdaK23S)
Xba K276)
B 0  11(342)
SgrA ipes)
Sph 1(538)»8A6-5299)
Mki K1064) 
Bd 1(1078)Sma i(424i) J l l
BstE 11(1345) 
Apa 1(1275)
Ctal(40S8)
Nm l(4024) pET-24a(+)
(5310bp)
f/B esH  11(1475)
ECOR V(1514)
Hpa 1(1570)EC057 1(3713) 
AlwN 1(3661)
B sss  1(3338)
BSpUJII 1(3165)
Sap 1(3046)
Bstl 1071(2636) 
T ttlll 1 K2910)
PshA 1(1906)
Bgl 1(2126) 
FSp 1(2146) 
PSp6 11(2171)
T7 pramoUr primar 466346-3
amwat
AGATCTCCATCCCGCGAAATTAATACGACTCACTATACGGGAATTGTGAGCGGATAACAATTCCCCTCTAGAAATAATTTTGTTTAACTTTAAGAAGGAGA 
p € T - 2 4 o ___    < = ? ?!B m H ia » B i  Sac I Swi h w i  Mot I Hte-TAg
p E I - 2 4 d
Ateol
. . TACCATGGCTAGC._____ MetAJoSer.
fljpt/11021 __________________________
C A T C C C 6tTC C TA A C A A A S C C C 6A A A G C A A SC T6A C TTS 6C T6C TS C C A C ^C T C A G C A A T A A C T A 6C A TA A C C €C TTC C C C C C TC TA A A C C 6fiTC TT6A S C G C TTTfTTG
T7 terminMor primtr *60337-3
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D)
T7 term6xHisl a c O l  R B S
pETl 02/D-TOPO 
6315 bp
Comments for pETl 02/D-TOPO*
6315 nucleotides
T7 promoter bases 209-225 
T7 promoter priming site: bases 209-228 
lac operator (lacO): bases 228-252 
Ribosome binding site (RBS): bases 282-288 
His-patch (HP) thioredoxin ORF: bases 298-627 
TrxFus forward priming site: bases 607-624 
EK recognition site: bases 643-657 
TOPO* recognition site 1: bases 670-674 
Overhang: bases 675-678 
TOPO* recognition site 2: bases 679-683 
V5 epitope: bases 700-741 
Polyhistidine (6xHis) region: bases 751-768 
T7 reverse priming site: bases 822-841 
T7 transcription termination region: bases 783-911 
bla promoter bases 1407-1505 
Ampicfllin (bla) resistance gene (ORF): bases 1506-2366 
pBR322 origin: bases 2511-3184 
ROP ORF: bases 3552-3743 (complementary strand) 
lad  ORF: bases 5055-6146 (complementary strand)
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E)
Dra IIKSOM)
Xno KIM)
Sty K67)
Bpui 1021(8(0 Nne 1(231)Nde K2sn
Xbe 1(278)
Bgl 0(342) 
SgrAlpes) 
Sph 1(536)*64^5299)
PvumaeT)
Sma l(424i)
CtalMose)
NlU 1(4024) pET-24a(+)(531 Obp)
E0057K3M3) 
AKvN 1(3681)
Nde1 / Xho 1 
Insert P. falciparum 
PF10 0395
MUK1064)
Bdl(i<>78)
BsC 0(1245)Apa 1(1275)
f/BssH 0(1475) EooR V(1514) Hpa 1(1570)
PahAkisoe)
B sss 1(3338)
BapLUII 1(3165)
Sap 1(3048) 
86(11071(2836) 
TV llll 1(2910)
Bgl 1(2126) Fsp 1(2146) Pap5 0(2171)
>PF10_0395
TATGCAAAATAAGCATTATAACATAAGCCTCATACAAAACAACACGCAAG
GAACAACGATAAAATCAAGATTATTAGCACAAACCCAAAATCATAATCCA
CATTATCATAATGATCCAGAACTCAAAGAAATAATTGATAAATTAAACGA
TGAAGCAATAAAAAAATACCAAAAAACCCATGATCCATATAAACAATTG
AAAGAAGT AGT AGAAAAAAACGG AACC AAAATTAGAGGCGGA AATTCTG
CAGAACCTATGTCAACGATAGAAAAAGATTTATTGGAAAAATATGAAGAC
GTGTTTGGTGACAAAAATCATGCTATGTTAAAATCAGGTAGGTACCCAAA
TGATGATGACGAATCGGATGATTCATCTTCATGTGGATGTACTGATATTAA
TAATGCAGAATTAGAAAAAACAAAAGGAAGAGATAAGTATTTAAAACAC
TTA AAA GGG AG AT GTAC C C TCGA
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F)
Xho ki5«) Not 1(168)
SbJCSL
•Sty K87)
,Bpu11021(80)
Dra 111(5088)
Pvu 1(4387) 
Sflf 1(4367).
MkJ 1(1084) 
-B d  1(1078)
BstE 11(1245) 
'A pa 1(1275)
CtB 1(4058) 
NlU 1(4024) pET-24a(+)
(531 Obp)
F / b SSH 11(1475) 
AECOR V(1514)
A Hpa 1(1570)
PshA 1(1908)
A  Bgl 1(2128) 
\  Fsp 1(2146) 
PSp5 11(2171)
Nhe1 / Xho 1 
boncm? insert Pfalciparum
^  SgrA 1(383) PFF0850C 
Sph 1(538)
Sm a K424i)
EC067 1(3713)
AlwN 1(3681)
BSSS 1(3338)
BspLim 1(3165)
Sap 1(3048)
BS(1107 1(2936) 
T#1111 1(2910)
>PFF0850c
CTAGCATG C AT AATG A AAATTGTC A AAATAAC C AATAT AATATAAG 
CCTC AT.AAAAAAC AAC AC AC AAAGAAC AACGATAAAACC AAG ACTCTTA 
GC AC AAACC AAAAACC AT AATCC AC ATTATC ATAATGATC C AGAACTC AA 
AGA A ATG ATTG AC A AATTG AAC A A AG AAGC AAT AAA AAAAT AC C A A A A A 
ATTC ATGAACCATATGAAC AATTGC AAGAATTAGTAGAAAAAAAAGGAA 
C AAAAC CTGT AGGT GAAC AT GGT AC AGAACCT ATGTC AACG AT AGAAAA 
AGAATTATTGGAAACATATGAAAAAATGTTTGGTGACAAAAAGGATATTA 
TGTTAAAATCGGGTATGCCCCCAAATGATGATGACAGATCAGACAAGTCA 
ATAACATGTGAATGCACTGATATTAATAATCCAGACTTAACAAAAGCAAA 
AAGCAAGGATAAGTATTTAAAACGC’TTAAAAGAGTCGAG
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2.3.5. PCR using external primers
Reactions were performed in 50pl volumes, or divisions thereof (25pi/12.5pi) containing 
approximately lOOng gDNA template, 10 pmoles of each primer: Smfl/Smrl 
(Eurogentic), 5 pi 10X PCR buffer without MgC^ (lOOmM Tris-HCl, 500mM KC1) 
(Applied Biosystems Roche), 2mM Magnesium chloride (Roche), 200pM each of dATP, 
dCTP, dTTP and dGTP (Amersham Biosciences), and 5 units AmpliTaq™ polymerase 
(Applied Biosystems Roche).
The PCR programme consisted of:
Step 1 94°C 3 minutes Initial denaturation
Step 2 93°C 1 minute Denaturation
Step 3 62.5°C 1 minute Annealing
Step 4 72°C 1 minute Extension, to step 2 for 35 cycles
Step 5 72°C 10 minutes Final Extension 4°C.
2.3.6. Nested PCR using internal primers for TA cloning® system
Internal RepFl/2, RepR primers were used to amplify the HVR from the external PCR 
products. Reaction volumes were 25 pi or divisions there of, containing 2pl external PCR 
product, 5 pmoles RepFl and RepF2, 10 pmoles RepR, 2.5pl 10X PCR buffer, 3mM 
MgCh, 200pM each of dATP, dCTP, dTTP and dGTP and 2.5 units AmpliTaq™ 
polymerase.
The PCR programme consisted of:
Step 1 94°C 3 minutes Initial denaturation
Step 2 93°C 30 seconds Denaturation
Step 3 45°C 50 seconds Annealing
Step 4 70°C 30 seconds Extension, to step 2 for 40 cycles
Step 5 72°C 10 minutes Final Extension 4°C.
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2.3.7. PCR using pET-24a (+) vector primers for sequencing STEVOR HVR
Nested PCR conditions using pET-24a (+) specific primers were as above. PCR products 
were digested with BamHl and EcoRI restriction enzymes as per the manufacturer’s 
protocols (New England Biolabs) (see restriction digests below).
2.3.8. PCR using pET102/D-TOPO vector primers for sequencing STEVOR hyper­
variable regions
Forward primers RepFlTOPO and RepF2TOPO, and reverse primer RepRTOPO were 
used to amplify the same HVR but were designed for the pET102/D-TOPO vector. 
Optimum PCR conditions were assessed and found to be as follows: Reactions were 
performed in 50pl volumes containing lpl external PCR product. Each reaction contained 
25 pmoles of each forward primer and 50 pmoles of reverse primer, 5 pi 10X PCR buffer 
without MgS04  (Fermentas), 3mM MgSCU, 200pM each of dATP, dCTP, dTTP and 
dGTP, and 1.25units Pfu DNA polymerase (Fermentas).
PCR conditions were adjusted for the new enzyme as follows:
Step 1 95°C 4 minutes Initial denaturation
Step 2 94°C 30 seconds Denaturation
Step 3 45°C 50 seconds Annealing
Step 4 70°C 1.5 minutes Extension, to step 2 for 40 cycles
Step 5 72°C 10 minutes Final Extension 4°C.
Blunt-ended PCR products were suitable for cloning directly into the pET102/D-TOPO 
vector.
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2.3.9. Preparation of RNA for Reverse Transcriptase (RT)-PCR
2.3.9.I. DNase digestion of contaminating DNA
2 pi RNA (500-1000ng/pl) in water were incubated with lunit Deoxyribonuclease I 
(DNase I) (amplification grade, Invitrogen), 1.5 pi 10X DNase I Reaction buffer, 40 units 
Recombinant RNasin Ribonuclease inhibitor (Promega, Madison, USA) plus water up to 
15pl.
The Eppendorf mastercycler was programmed as follows:
15 minutes at 37°C Incubation
15 minutes at 55°C Followed by addition of a further 1 unit DNase I
15 minutes at 37°C Incubation
10 minutes at 65°C Enzyme inactivation
Hold at 4°C Addition of 1 pi EGTA 20mM pH8.0
(RQ1 stop solution, Dnase digestion kit, ProMega)
5 minutes at 65°C Enzyme inactivation
Hold at 4°C
2.3.9.2. cDNA (First strand) synthesis
Two tubes containing 5 pi DNase digested RNA (see above), 3pg random primers 
(Invitrogen), lOmM dNTPs (Amersham), up to 8pl in water were incubated 5 minutes at 
65°C then kept on ice. A total of 11 pi reaction mixture (4pl of 5X First-Strand-Buffer 
(250mM Tris-HCl, pH8.3, 375mM KC1, 15mM MgCl2) (Invitrogen), 4pl of 25mM 
MgCl2 (Roche), 2pl 0.1M DTT (Invitrogen), and lp l (40units) RNasin (Promega) were 
added to each tube. The contents were mixed and spun briefly before incubating 2 
minutes at 25°C and returning onto ice.
lp l (200units) superscript™ II Reverse Transcriptase (RT) (Invitrogen) was added to the 
RT positive tube, whilst 1 pi water was added to the RT negative control tube.
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The reactions were then incubated as follows:
Materials and Methods
10 minutes at 25°C 
50 minutes at 42°C 
15 minutes at 70 ° C 
Hold at 4°C
After a brief (30 second) centrifugation at lOOOOxg, the reactions were then amplified 
using stevor-specific primers in a nested PCR (see above). Presence of a product in the 
RT negative control tube was indicative of contaminating DNA and the RT-PCR, or RNA 
extraction and RT-PCR, repeated until this was clean.
2.4. Separation of DNA, RNA, and PCR products by agarose gel electrophoresis
DNA and RNA were separated by electrophoresis in 1% multi purpose agarose (Roche) 
in IX Tris (0.089 M), Boric acid (0.089 M), 2mM EDTA (TBE) buffer. Smaller PCR 
products (<lkb) were separated by electrophoresis in 2.5% Metaphor agarose (Cambrex 
Biosciences, Rockland, USA) in IX TBE. Gels contained 0.25 pg /ml Ethidium bromide 
to enable UV visualization. RNA gels also contained 5mM Guanidine thiocyanate. All 
gels were run in IX TBE buffer.
2.4.1. Nucleic acid quantification and fragment size comparison
Nucleic acid concentration was estimated by comparison with molecular markers run 
adjacently on an Ethidium bromide-stained agarose gel. A XHind III molecular mass 
marker (Biorad) or the Hyperladder 1 (Bioline) bands of known concentration and size 
were used for comparison. Biorad 1 kb/100 bp, or Amplisize 50 -2000bp molecular rulers 
were used to determine DNA fragment size.
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2.5. Restriction digests
Purified DNA vector and PCR products were prepared for ligation by restriction 
digestion. Plasmids extracted from transformed bacteria were screened by restriction 
enzyme digestion to verify the presence of the insert. Table 2.3 shows the enzymes used 
and their respective buffers as recommended by manufacturers.
Table 2.3) Enzymes for restriction digests and their buffers
Enzyme Buffer
Eco R1 (Promega, UK) Multicore (Promega, UK)
Eco RJ (Roche Diagnostics, UK) H (Roche Diagnostics, UK)
Eco R1 (NE Biolabs) Unique (NE Biolabs)
Bam H I (Promega, UK) Multicore (Promega, UK)
Bam HI (Roche Diagnostics, UK) B (Roche Diagnostics, UK)
Bam H I (NE Biolabs) Unique (NE Biolabs)
pET-24a (+) vector DNA was digested for 4 hours, whilst PCR products were incubated 
from 4-12 hours with the required number of enzyme units at 37°C. If a change of 
restriction enzyme buffer was required, a buffer exchange was facilitated through G50 
microspin columns (Amersham). pET-24a (+) plasmid was digested sequentially with 
EcoRI and BamHl restriction enzymes according to manufacturer’s instructions (NE 
Biolabs). The double digested plasmid was then treated with calf intestinal alkaline 
phosphatase (Promega) before ethanol precipitation using 7.5M ammonium acetate.
2.5.1. Cleaning of PCR and RT-PCR products
The QIAquick PCR purification kit (Qiagen, Hilden, Netherlands) was used according to 
manufacturer’s directions to remove primer dimers. The reactions were eluted into 50pl
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(IH2O. Amersham Microspin G-50 columns were used as per manufacturer’s instructions,
to remove small DNA fragments following restriction enzyme digestions.
2.6. Ligation
Purified PCR products for sequencing were cloned into the pCR®2.1 or pCR® II vectors 
(Invitrogen) according to manufacturer’s protocols. Ligation occurs via a 3’ single 
deoxyadenosine on the end of the PCR product combining with the linearised vector’s 
single 3’ deoxythymidine residue. Approximately 13ng of PCR product was ligated with 
50ng TA vector, (typically 2pl nested PCR product).
The pET102/D-TOPO plasmid required blunt-ended PCR product inserts generated using 
Pfu DNA polymerase (Fermentas). Plasmid specific primers were used to generate 
translatable PCR products and cloning carried out according to Novagen’s pET system 
manual.
2.7. Transformation of DNA constructs
Ligation reactions were transformed into One Shot™ competent cells {Escherichia coli 
IN V aF’ or TOPI OF’) (Invitrogen) provided with the relevant vector kits using 
manufacturer’s protocols. Colonies from LB agar Ampicillin or Kanamycin plates were 
picked into 3ml LB broth containing 50pg/ml Ampicillin or 30pg/ml Kanamycin, and 
grown at 37°C with agitation.
2.8. Small-scale preparation of plasmid DNA (minipreps)
Plasmid DNA was isolated using either the QIAprep spin SNAP Miniprep® Kit 
(Invitrogen), or the Wizard ® Plus Miniprep kit in combination with the Vac-Man® 
vacuum manifold (Promega) according to the manufacturer’s protocols (The Wizard ® 
Plus Miniprep kit was later identified as unsuitable for further sequencing procedures).
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The QIAgen Maxiprep® kit was used according to manufacturer’s protocol to isolate
larger quantities of pET-24a (+) vector.
2.9. Automated DNA Sequencing
Following DNA expansion, purification, and confirmation a stevor insert was present, the 
DNA was then, quantified by spectrophotometry, pelleted and dried before sequencing. 
Three systems have been used for sequencing reactions:
a) The BigDye® Terminator Cycle Sequencing Ready Reaction kit (Perkin-Elmer, 
Applied Biosystems, Warrington, USA) was used according to manufacturer instructions. 
The reaction is carried out using approximately 600ng of pCR®2.1 or pCR® II DNA 
(vector plus insert) per sample with either Ml 3 forward or reverse primers in the 
Eppendorf Mastercycler. Unincorporated dye terminators are removed by ethanol 
precipitation. Samples were resuspended in 3 pi loading dye 16.5% v/v Blue Dextran/ 
EDTA (Applied Biosystems) in formamide (Amresco, Solon USA), followed by 
electrophoresis and data collection on the ABI PRISM™ 377 DNA sequencer (Perkin - 
Elmer).
b) The BigDye® reactions were also used with T7 primers and pET-24a (+) DNA, or 
TrxFus forward or T7 reverse primers with pET102/D-TOPO DNA. Sequencing was 
performed at the National Neuroscience Institute, Singapore (commercial service).
c) The MegaBACE system (Amersham Biosciences) was used. The ABI PRISM® 
BigDye® Terminator v l.l  Cycle Sequencing kit (Applied Biosystems) cycle sequencing 
mix was used according to the manufacturer’s protocols. Samples were ethanol 
precipitated before addition of MegaBACE™ loading solution (Amersham Biosciences) 
and loading onto a MegaBACE 96-capillary machine.
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2.10. Bioinformatics
2.10.1 Sequence alignment analysis (hyper-variable loop)
A fragment of approximately 280 base pairs (bp) was successfully isolated through PCR 
and RT-PCR amplification; however due to the variant nature of the hyper-variable loop, 
sequences varied in length, coding for a maximum of 82 amino acids. Clones have been 
obtained from multiple PCR reactions to reduce PCR bias, and were sequenced in 
forward and reverse directions; differences in the degenerate primer regions were 
disregarded. P. falciparum  3D7, IT and Ghanaian isolates, and P. reichenowi stevor 
sequences were obtained from BLAST and Tools-oligo searches within the 
http://www.plasmodb.org site.
Editing of nucleotide and amino acid (translated) sequences was carried out using the 
Autoassembler®, Chromas®, DNAstar (2001) freeware programmes. The sequences 
from different parasite sources and different amplification reactions were aligned by 
using ClustalX® (Higgins & Sharp, 1988), and Bioedit7.0.1® softwares (Hall, 1998). 
Multiple alignments and their corresponding chromatograms were edited manually for 
discrepancies in mistaken nucleotide assignment by automated sequencing method. 
BLAST analysis, version 4.4 from www.plasmodb.org was used in order to confirm that 
DNA sequences were the result of the amplification of stevor exon-2 hyper-variable loop 
locus (now accessible at http://v4-4.plasmodb.org/plasmodb/servlet/sv?page=blast).
2.10.2 Phylogenetic analysis
Phylogenetic trees showing genetic distance were constructed using the following 
programmes: Molecular Evolutionary Genetics Analysis (MEGA) 2.1 or 3.0®, PAUP 
version 4.0 (Kumar et al., 2004; Swofford, 2003), and Tree view® (Page, 1996). These 
programmes enable the construction of trees using tree-building models: neighbour- 
joining, maximum parsimony and maximum likelihood, taking into account the observed
90
Chapter 2_________________________________________________Materials and Methods
nucleotide frequency, substitution rate and transition/transversion ratio, based on Nei
genetic distance estimates (Kumar et al., 2004). The bootstrap analysis (Felsenstein,
1988) was used in order to statistically assign support to hypotheses of phylogenetic
relationship among sequences estimated by the methods mentioned above.
Further protein structural prediction analysis was done using PIX multi-programme
analysis web tool. This was available from the human genome mapping project site
(www.hgmp.mrc.ac.uk/Registered/Webapp/pix). Protein structure predictions based upon
protein alignments were made using the web-based tool from
http://www.predictprotein.org.
2.11. Source of protein expression constructs
The pET-24a (+) vector constructs (figure 2.2E and F) containing the N-terminal semi­
conserved fragments (amino acids 26-182) of PF10 0395 (SI) and PFF0850c (S2) were 
kind gifts from Peter Preiser (Nanyang Technological University, Singapore).
2.11.1. Transformation of competent E. coli bacterial cells for plasmid maintenance
In each case, a 50pl aliquot of E. coli DH5a cells (sub-cloning efficiency) was thawed on 
ice. 0.1 pi of DNA was added to the cells and mixed gently. The mixture was incubated on 
ice for 30 minutes. The mixture was then incubated for 20 seconds in a 42° C water bath 
and then quickly placed back on ice for a further 2 minutes. 950pl of pre-warmed LB 
medium containing 30pg/ml Kanamycin was added and the mixture shaken at 225rpm for 
1 hour in a 37°C incubator. The cells were centrifuged at full speed (13000 x g) in a 
bench top centrifuge for 30 seconds and 800pl media removed. The remainder (50pl and 
lOOpl) was plated out on two pre-warmed Kanamycin plates to ensure well-spaced 
colonies on at least one plate. The plates were then incubated overnight at 37°C.
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2.11.2. Transformation of competent E. coli bacterial cells for protein expression
Initial protein expression protocols (performed in Singapore) using standard BL21 E. coli 
had resulted in insoluble protein only. Therefore, two different E. coli cell lines were 
tested in order to maximise the possibility of obtaining soluble proteins, BL21- 
CodonPlus® (DE3)-RIL (Stratagene), and Rosetta-gami 2 (DE3) pLysS (Novagen). The 
BL21-CodonPlus® (DE3)-RIL competent cells have functional expression of the rare 
tRNA genes and this rare codon usage makes these cells more suitable for enhanced 
expression of eukaryotic proteins that contain codons rarely used in E. coli. The Rosetta- 
gami 2 (DE3) pLysS cells combine this feature with additional enhanced disulphide bond 
formation. 25pi and lOOpl aliquots, respectively, were thawed on ice and lp l DNA gently 
stirred in. Cells were incubated 5 minutes on ice, before heat-shock for 30 seconds at 
42°C, followed by 2 minutes on ice. 200pl of pre-warmed SOC medium was then added 
and the mixture was shaken at 225rpm in a 37°C incubator for 1 hour. 50pl or 150pl of 
the transformation reaction was then plated out on pre-warmed Kanamycin (50pg/ml) LB 
or Kanamycin (50pg/ml) plus Chloramphenicol (34pg/ml) agar plates. The plates were 
incubated overnight at 37°C.
2.11.3. Storage of transformed bacterial cells
For immediate use, single colonies of bacteria were picked and grown overnight in 5ml 
LB media containing 50pg/ml Kanamycin. Longer-term cultures were stored at -80°C 
after the addition of Glycerol, to 15% (V/V), to overnight culture medium.
2.12. Expression of recombinant proteins
The His-tag® expression system allows the target protein to be detected on Western blots
using commercially available specific and sensitive reagents. In addition, fusion to the
His-tag enables the protein product to be affinity purified on nickel-nitrilotriacetic acid
(Ni-NTA) agarose (Qiagen) columns, where the His-tag is bound with high affinity to 2
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ligand-binding sites of the nickel ion immobilised and coupled to sepharose® CL-6B. See
Figure 2.2C vector map pET24-a (+) illustrating the main features of this expression
system, and E and F showing insert details.
Initially, small-scale experiments were done in order to optimise conditions for the two 
proteins. After optimisation of the procedure, 8 hour BL21-CodonPlus® (DE3)-RIL 
bacterial cultures were diluted 1:50 with fresh LB media containing Kanamycin 30pg/ml, 
and grown overnight in a shaking (225rpm) incubator at 37°C. A 20L culture was then 
inoculated 1:40 with the overnight culture, and cultures incubated in a fermenter (Bioflo 
4000500, New Brunswick) until an OD600 reached 0.6. A sample of material was taken (0 
hours), before IPTG was then added to a final concentration of 0.5mM. The cells were 
cultured for a further 2 (SI) or 3 (S2) hours, before the cells were pelleted by 
centrifugation (20000 x g) in a Powerfuge (Carr) at 4°C. The cell pellet (approximately 
60g) was then resuspended thoroughly in 150ml cold lysis buffer (50mM NaHfePC^; 
300mM NaCl; lOmM imidazole; 5mM p-mercaptoethanol; pH8.0) plus complete 
protease inhibitor tablets (EDTA-free) (Roche); lysozyme lOOOU/ml; IGEPAL CA630 
0.2%; and DNase 1 (Roche). The mixture was then subjected to mechanical breakage 
using pressure (20-24000 psi) in a cell disrupter (constant systems) at 4°C. The lysed cell 
suspension was pelleted by centrifugation at 13000rpm (Beckman J2-MC) at 4°C for 20 
minutes. Supernatants were collected on ice, and pellets were frozen at -80°C. All 
following steps were maintained at 4°C. 3.5ml of 50% Ni-NTA agarose slurry was used 
per column (Econo-pac disposable chromatography columns, Biorad), and drained 
through gravity flow, before being equilibrated with cold lysis buffer. The supernatants 
were passed over the columns and the flow-through collected. The columns were then 
washed sequentially with 3 different buffers: Wash 1-lysis buffer (as above); Wash 2-high 
salt buffer (1M NaCl; 50mM NaFEPC^; lOmM imidazole; 5mM p-mercaptoethanol; 
pH8.0); Wash 3-increased imidazole buffer (50mM NaFLPC^; 300mM NaCl; 30mM
Chapter 2_________________________________________________Materials and Methods
imidazole; 5mM p-mercaptoethanol; pH8.0). Each wash was tested for protein content by
the Bradford test, lOpl wash sample was added to 1ml Bradford reagent (Biorad) and the
colour change (brown-blue) observed. The wash volume was dependent on the Bradford
test showing proteins were no longer present in the wash flow through. Each wash was
carefully collected into a clean tube and a small sample from the final stage of each wash
kept separately for later analysis. Finally the proteins were eluted off the column in
elution buffer (50mM NaFhPCU; 300mM NaCl; 300mM imidazole; 5mM |3-
mercaptoethanol; pH8.0). Again, the volume of elution buffer used was dependent on the
result from the Bradford assay, typically 6-8mls. Protein samples needed to be
concentrated before further purification steps. The fractions were concentrated to <5ml
using vivaspin 20ml spin columns with a MW cutoff of 5000kDa (Sartorius, UK). These
were pre-rinsed with water to remove trace Sodium azide, and centrifuged at 4000xg at
4°C.
2.13. Purification of recombinant proteins by gel filtration
The proteins were further purified by low-pressure chromatography on the Fast Protein 
Liquid Chromatography (FPLC) (Amersham’s AKTAPrime system, UK) over a 16/60 
superdex 75 prep grade column with 1XPBS tissue culture grade (pH7.2) as the mobile 
phase. The fractions corresponding to the peaks of interest in the FPLC elution profile 
were pooled and concentrated as described previously. The peak containing the protein of 
interest and its purity were assessed by SDS-PAGE, Coomassie blue staining and anti-His 
tag Western blot detection. Protein concentrations were assessed by spectrophotometry 
(absorbance over the range 240.1 -360nm).
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2.14. Peptide design
Peptides were designed against conserved regions of STEVOR based on translated and 
aligned P. falciparum  3D7 stevor genes. Three peptides were synthesised using the NIMR 
peptide synthesis service. Peptide 1 sequence: CNPHYHNDPELKEII corresponds to 
amino acids 57-71 of the alignment. Peptide 2 sequence: CEPMSTLEKELLETYE 
corresponds to amino acids 110-124. Peptide 3 corresponds to the C-terminal tail of the 
protein, sequence: RRRKNSWKHECKKHLC corresponds to amino acids 296-312 of the 
alignment. All peptides have an N or C-terminal cysteine to facilitate conjugation to a 
carrier protein.
A control peptide (A20/B) sequence: CTEEQLRSSQRRDVPRT was used as a rabbit 
anti-sera control. This peptide sequence was blasted against the plasmodb EST databases 
(www.plasmodb.org), but no sequence match identified.
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2.15. Production of specific anti-sera
2.15.1. Peptides
Peptide immunogenicity was increased by combining with a carrier protein: Reduced 
peptides were conjugated to Imject® Maleimide Activated Mariculture Keyhole Limpet 
Hemocyanin (KLH) (Pierce, Illnois, USA) according to manufacturer’s instructions. 
Solutions were transferred to Tube O Dialyzer™ vials (GenoTech). The solutions were 
dialysed twice in PBS (500ml) for 2 hours at room temperature, followed by overnight at 
4°C (1L PBS).
2.15.2. Immunisation protocols
2.15.2.1. Immunisation of mice with peptides
BALB/c mice were immunised intra-peritoneally with 50pg peptide-KLH conjugate in 
100pi of PBS and an equal volume of Freund’s complete adjuvant (Sigma). The 3 
identical boosts were administered in combination with Freund’s incomplete adjuvant and 
administered at a minimum interval of 30 days (maximum 176 days). Normal mouse 
serum was taken from each mouse before the start of the immunisation schedule. Post­
immunisation bleed 1 was taken approximately 1 week following the second boost, post 
immunisation bleed 2 , 1 week following the third boost, and the terminal bleed taken 
approximately 1 week after the last boost.
2.15.2.2. Immunisation of mice with soluble recombinant proteins
BALB/c mice were immunised intra-peritoneally with 50pg recombinant protein in 200pl
(100pl in each of 2 sites) PBS plus MPL + TDM adjuvant system (Sigma) followed by 3 
boosts, at intervals of between 2 and 5 weeks. The final bleed was taken 2.5 weeks after 
the final boost, and blood from 2 mice was pooled per heparin tube for extraction of
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serum. Blood was allowed to clot slowly at room temperature, before overnight
incubation at 4°C and serum separation.
2.15.2.3. Immunisation of rabbits with peptides
2 New Zealand White rabbits (female or male) were immunised per peptide; All work 
was carried out by Harlan Sera-Lab., Loughborough, UK. 200pg of peptide-KLH 
conjugate was given sub-cutaneously using Freund’s complete adjuvant for immunisation 
and incomplete Freund’s adjuvant for 3 boosts. Pre-immunisation bleeds were taken at 
day 0 followed by the initial immunisation. Boosts were at 14 day intervals followed by 
post-immunisation bleed 1 one week after the second boost (day35). A third boost at day 
42 was followed one week later by the terminal bleed. An additional test bleed 2 (rabbits 
8606 and 8607 only) was required, and taken after the third boost and prior to the 
terminal bleed.
2.15.2.4. Source of rabbit serum immunised with insoluble recombinant proteins
2 rabbits were immunised per STEVOR SI and S2 proteins; all work was carried out by
ProSci incorporated, CA, USA.
2.16. Testing for peptide/recombinant protein specific antibodies by enzyme-linked 
immunosorbent assay (ELISA)
Anti-sera were tested for the presence of peptide, or recombinant protein-specific 
antibodies. Rabbit sera were also tested for reactivity with the A20/B negative control 
peptide, and KLH or His-tagged positive control proteins (Calbiochem-Behring). Briefly, 
5//g peptide/ protein in 50//1 PBS per well was coated in 96-well, flat bottom Polysorb 
plates (NUNC, Roskilde, Denmark) and incubated overnight at 4°C in 100% humidity.
98
Chapter 2 Materials and Methods
Antigen was then removed by ‘flicking’/inverting plates, and 200pl blocking buffer (PBS 
plus 1% (w/v) Bovine Serum Albumin Fraction V (Sigma), 0.3% Tween 20 (BDH), 
0.05% NaNs) was incubated for 1 hour (minimum) at 37°C, to block non-specific binding. 
Wells were then washed 8 times in ELISA wash buffer (0.9% NaCl, 5mM K2HPO4, 5mM 
KH2 PO4, 0.025% (v/v) Tween 20, pH 7.0-7.2). Serial dilutions of the anti-sera in 
blocking buffer (50pl per micro well) were incubated at 37°C for 1 hour, before discarding 
well contents and washing as described previously. The bound antibodies were detected 
using a secondary antibody step of alkaline phosphatase conjugated anti-mouse or rabbit 
IgG (Sigma) 50pl per well, diluted 1:10000 in PBS. Secondary antibodies (table 2.4) 
were incubated at 37°C for 1 hour before discarding and washing as before. The substrate 
p-nitrophenylphosphate-sodium (PNPP) salt (Sigma) 1 mg/ml in diethanolamine buffer 
(4.85% (v/v) diethanolamine pH9.8, 0.2M MgCL 6H2O, 0.1% NaN3) was added 50pl per 
well. The reaction was developed in the dark at room temperature. Readings were taken 
using a MRX microplate reader (Dynex Technologies, Billingshurst, UK) at OD 405 
(reference filter 492) with Revelation 3.04 software (1997).
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Table 2.4) Secondary antibodies used to detect rabbit and mouse immunoglobulins
H ost Specificity C onjugate Dilution M anufac tu re r C atalogue
num ber
Goat Rabbit IgG
(whole
molecule)
Alkaline
phosphatase
1 in 10000 Sigma A-3687
Goat Mouse IgG 
(H+L)
Alkaline
phosphatase
1 in 1000 Southern Biotech 1031-04
Goat Mouse IgG (y- 
chain specific)
Alkaline
phosphatase
1 in 1000 Southern Biotech 1030-04
Goat Rabbit IgG Alkaline
phosphatase
1 in 2000 Dako D0487
Goat Mouse IgG (y- 
chain specific)
FITC 1 in 200 Sigma F-8264
Goat Rabbit IgG
(whole
molecule)
FITC 1 in 200 Sigma F-0382
Goat Mouse IgG ( y -  
chain specific)
FITC 1 in 200 Southern Biotech 1030-02
Swine Rabbit IgG FITC 1 in 200 Dako F0205
Goat Mouse IgG
(whole
molecule)
TRITC 1 in 200 Sigma T-5393
Goat Rabbit IgG
(whole
molecule)
TRITC 1 in 200 Sigma T-6778
Goat Mouse IgG ( y -  
chain specific)
TRITC 1 in 200 Southern Biotech 1030-03
Goat Mouse IgG 
(H+L)
Horse radish 
peroxidase
1 in 2000 Biorad 170-6516
Goat Rabbit IgG 
(H+L)
Horse radish 
peroxidase
1 in 2000 Biorad 170-6515
Goat Mouse IgG Horse radish 
peroxidase
1 in 1000 Dako P0447
Swine
(Human
absorbed)
Rabbit Ig Horse radish 
peroxidase
1 in 1000 Dako P0399
Goat Rabbit Ig Horse radish 
peroxidase
1 in 1000 Dako P0448
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2.17. Affinity purification of peptide-specific rabbit antibodies
Antibodies were affinity purified on peptides, which had been coupled to 1ml NHS-
activated Sepharose columns (Amersham Bioscience), according to the manufacturer’s
instructions. The column was washed with 6 ml of a cold HC1 solution (ImM HC1, ice
cold) at a flow rate of half a drop per second. Two to five milligram of reduced peptide
were dissolved in 1 ml coupling buffer (0.2M NaHC03, 0.5M NaCl, pH 7-9) and slowly
administered to the column. The peptide was coupled for 30 min at room temperature.
The column was deactivated with three repeats of 5 ml solution A (0.5M Ethanolamine,
0.5M NaCl, pH 8.3) and 5 ml solution B (0.1M Acetate, 0.5M NaCl, pH 4) and finally
washed with 5 ml phosphate buffer and stored in storage buffer (50mM NaH2P0 4 , 0.1%
NaN3, pH7).
Anti-serum was centrifuged for 10 min at 12,000g to remove precipitates. The 
serum was diluted 1/5 in PBS and administered to the column repetitively four times at a 
flow rate of half a drop per second. Non-specific antibodies and contaminants were 
washed off with 5-10 volumes of PBS. Bound antibodies were eluted with 5 times 1 ml 
elution buffer (0.2M Glycine, 0.15M NaCl, pH 2.7) and captured in 1.5 ml tubes 
containing 200 ml of neutralizing buffer (1M TrisHCl, pH 8.2). Antibody-containing 
elutions were pooled, concentrated with Vivaspin 20000 (MWCO 10,000, Vivascience) 
and dialyzed against PBS. Purified antibodies were stored at -20°C. The affinity 
purifications were tested and controlled on ELISA.
2.17.1. Measuring protein concentration
Protein concentrations were measured with the BCA protein assay (#23223, Pierce, 
Rockford, IL) according to the manufacturer’s instructions. Components A and B were 
mixed in a ratio of 50:1. The reaction was carried out in flat-bottomed 96-well plates 
where each well contained 200 pi of the pre-mixed BCA reagents and 25 pi of the
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protein. Concentrations of BSA (diluted in the same buffer as the protein samples)
ranging from 0-1 mg / ml were in included as a standard. The plates were covered and
incubated at 37° C for 30 min. The optical density at 565 nm was measured on the ELISA
reader, and the protein concentration calculated by comparison with BSA as standard
curve.
2.18. Separation of parasite extracts into soluble and membrane-bound protein 
fractions
2.18.1. Method 1: Hypotonic lysis (personal communication Irene Ling)
Parasitised RBC or RBC pellets ( lx l0 7cells) were lysed in 4 volumes of hypotonic lysis 
buffer at 4°C (lOmM Tris pH8 , 5mM EDTA, 5mM EGTA, complete protease inhibitors 
(Boehringer)). The samples were then sonicated 30 seconds and centrifuged at 100 OOOxg, 
for 1 hour. Supernatants were removed from the pellet. Soluble non-membrane proteins 
including haemoglobin remained in the soluble fraction (S), whereas non-soluble, 
membrane-bound proteins remain in the pellet (P) with membrane fragments.
Both fractions were resuspended in Nupage™ LDS loading buffer (4X) (Invitrogen), with 
10% 1M DTT, vortexed and centrifuged 14000xg, 6 minutes at 4°C. The supernatants 
were aspirated off, divided into aliquots and stored at -70°C.
Before finally loading onto protein gels, the supernatants were heated at 90°C for 3 
minutes.
2.18.2. Method 2: Hypotonic lysis and carbonate extraction of proteins
(figure 2.4) (Papakrivos et al., 2005)
Schizont parasitised or RBC 50pi pellets were lysed in 1 ml hypotonic lysis buffer (as 
above), incubated on ice 30 minutes, and mixed with a syringe and needle. The samples 
were centrifuged 100, OOOxg for 30 minutes, and separated into supernatant and pellet
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fractions. The pellet was processed in 1ml carbonate buffer (0.1M sodium carbonate 
pH 11.0 plus complete protease inhibitors), resuspended using a syringe and needle, then 
both pellet and soluble protein fractions were centrifuged again. The final pellet was 
resuspended in PBS (pH7.2), whilst the carbonate soluble fraction needed to be dialysed 
(Vivaspin mini spin columns, Sartorius) to decrease pH prior to SDS-PAGE. The 3 
fractions are referred to as soluble (S), carbonate (C) and pellet (P).
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Flowchart for sequential extraction of proteins
Schizonts iRBC/ RBC 
e.g. 50ul
I
Hypotonic lysis (10mM Tris pH8 + protease inhibitors) 
20 volumes (e.g.lml)
30 minutes on ice
I
Mix with syringe
Centrifuge 100000xg 30 minutes— ^ -S o lu b le  proteins (S) (spin again) 
30 minutes on ice
Carbonate buffer extraction (0.1 M sodium carbonate pH11+ protease inhibitors) 
20 volumes (e.g. 1 ml)
I
Mix with syringe
Centrifuge 100000xg 30 minutes — > » Peripheral membrane proteins (C)
■ (spin again/
X  buffer exchange)
Resuspend pellet in PBS — ^  Integral membrane bound proteins (P)
Figure 2.4: Flowchart showing sequential separation o f  iRBC proteins
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2.19. Protein separation by SDS-PAGE
Samples (prepared as above) were loaded onto a NuPAGE™ 10 or 12% Bis-Tris Gel
(1.0mm X 10/15 well) (Invitrogen). Proteins were run alongside 7pi IX SeeBlue Plus2®
pre-stained standard (Invitrogen).
Marker sizes (kDa):_
98 orange
62 
49 
38 
28
17 red
14 
6 
3
Gels were run in NuPAGE® IX MES SDS buffer (Invitrogen) plus NuPAGE® 
antioxidant as per manufacturer’s directions. Proteins were stained first by Coomassie 
brilliant blue R-250 staining solution (Biorad), before destaining in Coomassie R-250 IX 
solution (Biorad), as per manufacturer’s instructions, until proteins became visible.
2.20. Detection of STEVOR by Western blot analysis
Proteins were electrophoretically transferred (1 hour at 30 Volts constant) from the gel 
onto Hybond C membrane (Amersham Biosciences) in NuPAGE ™ lx  transfer buffer 
(Invitrogen) containing 10% methanol and NuPAGE ™ antioxidant (Invitrogen). The 
membrane and bound proteins were incubated overnight at 4°C with agitation, in blocking 
buffer (PBS plus 5 % (w/v) skimmed milk powder (Marvel, Wirral, UK) and 0.05%
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Tween 20). The membrane was washed three times for 10 minutes (all subsequent steps
were at room temperature with agitation) in PBS with 0.05% Tween 20.
Primary antibodies/anti-STEVOR sera were diluted in PBS plus 1% BSA, 0.05% Tween
20, and strips of membrane were incubated with antibodies for 1 hour. The strips were
then washed separately, 7 times for 5 minutes in PBS plus 0.05% Tween 20.
Secondary horse radish peroxidase-conjugated antibodies specific for either mouse or
rabbit IgG (table 2.4), were used at 1 in 1000-2000 in PBS plus 0.05% Tween 20. After
incubation for 1 hour, membrane strips were washed thoroughly 6 times, for 10 minutes
in PBS/ Tween, followed by a 30-minute wash in PBS only.
The peroxidase was detected using Pierce ‘Supersignal® west pico chemiluminescent 
substrate according to manufacturer’s protocol. The membrane was exposed (various 
exposure lengths) to Kodak® Biomax MR single emulsion film and the film developed.
2.21. Localisation of STEVOR using indirect immunofluorescent assay (IFA)
Thin blood smears were made following late trophozoite/schizont development in 
cultures. Slides were fixed in 4°C acetone for 2 to 5 minutes, wrapped in foil and kept in 
sealed bags at -20°C with silica gel. Slides were allowed to reach room temperature 
before unwrapping. Wells were marked (on topside) using immunopen™ (Calbiochem), 
and permanent marker (underside).
A blocking step of 30 minutes with 20pl per well PBS, 3% BSA, and 0.05% NaN3 was 
carried out prior to binding with anti-sera.
Primary antibodies (table 2.5) were diluted in PBS plus 1% BSA, and 0.05% NaN3, (lOpl 
per well), were added to the slides and incubated in a humid chamber for 1 hour at 37°C. 
The slides were washed in PBS three times for 5 minutes. After blotting off excess PBS, 
the appropriate secondary antibody (lOpl per well) was added and incubated 30 minutes-1 
hour at 37°C. All antibodies were added at separate incubation steps. The above
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incubation and wash steps were repeated for subsequent primary antibody or secondary
conjugated-antibody combinations. Slides were then dipped for 5 seconds in 4, 6-
diamindino-2-phenylindole (DAPI) 2pg/ml in PBS to stain the parasite DNA. Finally, the
slides were washed three times each for 5 minutes in PBS, before thoroughly air-drying.
The wells were covered with a drop of Citifluor AF1 (Citifluor, London, UK) and
coverslip. The edges were sealed with nail polish and slides stored in dark at 4°C. Slides
were viewed on a fluorescence microscope: (100X oil objective) Deltavision (Applied
Precision Inc) and camera (Roper Scientific) using SoftWoRx Explorer 1.0 software; or
LSM 510 Confocal microscope (63X or 100 X oil objectives) (Zeiss) using LSM510
META software.
2.21.1. Percentage measurement from IFA slides of STEVOR expressing iRBC
Total parasites determined by DAPI staining to be mature schizont-stages were counted in 
the relevant wells, before switching the microscope to FITC staining in order to count the 
number of schizonts expressing STEVOR. The percentage of parasites expressing 
STEVOR was calculated as follows:
Number of STEVOR positive parasites X 100%
Total number of schizonts
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Table 2.5) Primary antibodies used for STEVOR (co-) localisation studies
Host species Antibody
specificity
Dilution Source
Mouse (B28) PfSBPl 1 in 200 (IF A) C. Braun-Breton, 
France
Rabbit W49/W50 Human RBC ghosts 1 in 1000 (FACS) A.A. Holder NIMR, 
UK
Rabbit (Al) 3085 M SPI19 1 in 1000 
(IFA/FACS)
I. Ling NIMR, UK
Rabbit 1E1 MSP 119 1 in 500 (IFA) I. Ling NIMR, UK
Mouse 4E10 (mAb) RhopH2 Use neat culture 
supernatant (IFA)
I. Ling NIMR, UK
Mouse STEVOR peptide 1 1 in 2000 (Western) NIMR, UK
Mouse STEVOR peptide 2 N/a NIMR, UK
Mouse STEVOR peptide 3 N/a NIMR, UK
Rabbit (8225/8226) STEVOR peptide 1 1 in 20-80 (IFA) Harlan Seralab, UK
Rabbit (8606/8607) STEVOR peptide 2 1 in 20 (FACS) Harlan Seralab, UK
Rabbit (8432/8433) STEVOR peptide 3 1 in 20 (FACS) Harlan Seralab, UK
Mouse STEVOR 
P F 100395(S I)
1 in 100 (IFA) NIMR, UK
Mouse STEVOR PFF0850c 
(S2)
1 in 100 (IFA) NIMR, UK
Rabbit (5003/5004) STEVOR 1 in 500 (Western) P.R. Preiser,
P F 100395(S I) 1 in 200 (IFA) Singapore
Rabbit (5005/5006) STEVOR PFF0850c 
(S2)
n/a P.R. Preiser, 
Singapore
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2.22. Localisation of STEVOR using Flow cytometry (FACS)
Cells (lxlO 7) were first washed in sterile PBS (containing 0.5% BSA, 5 mM EDTA 
pH8.0 and 0.01% NaNs) and pelleted by centrifugation at 800xg for 2 minutes. The cells 
were then incubated for 45 minutes with anti-sera (table 2.5), washed 3 times as described 
above, and incubated with the appropriate secondary FITC conjugated anti-IgG antibody 
(table 2.4), for 45 minutes. Unbound antibody was removed by washing 3 times as above, 
and the parasite DNA was labelled with Hoechst 33342 dye (50 pi at lOpg/ml in PBS) for 
20  minutes.
After final 3 washes (as above), the cells were fixed in 1% paraformaldehyde in PBS. All 
antibody labelling was carried out in FACS tubes or 96-well microtitre plates (V- 
bottomed).
Flow cytometry was carried out on BD™ LSR (BD Biosciences) using Cell Quest 
software (Becton Dickinson, San Jose, CA, USA). Subsequent analysis was done using 
FlowJo version 6.2.1 software (Tree Star Inc, USA).
2.22.1. Live FACS and immunofluorescence studies of the iRBC surface
To make a thorough study of the localisation of STEVOR, it was necessary to study the 
surface of unfixed iRBC.
Two visualisation methods were used following identical staining protocols:
Parasite isolates were studied when the majority of parasites were ideally in late schizont- 
stage. The iRBCs were pelleted from culture by centrifugation at 800xg for 3 minutes the 
pellet was washed thrice with PBS plus 0.1% BSA wash buffer. Parasitaemia was then 
diluted with uninfected RBC to 5%, and the pellet resuspended at 5% haematocrit. 
lOpl of the iRBC/RBC suspension was placed per well in a round-bottomed 96-well 
plate, and 2 .5pi of test serum (various dilutions) added to give a final test serum dilution 
of 1:5. Anti-sera to internal iRBC proteins were included in the assay to control for the
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possibility of leakiness of the iRBC surface membrane. The reaction mixture was
incubated for 1 hour at room temperature following which the cells were washed thrice
with wash buffer, centrifuging between each wash to remove the wash medium. After
washing, the cells were re-suspended in 50pl of secondary anti-mouse or rabbit IgG
antibody, diluted in 0.1 %BSA/PBS and containing lOpg/ml Ethidium bromide. After
incubation for 30 minutes at room temperature, the cells were washed as previously.
Cells (100000) were collected on a FACscalibur™ using Cell Quest software (Becton
Dickinson, San Jose, CA, USA) and analysed as above, or were examined by
fluorescence microscopy by placing a drop of cells on a glass slide mixed with 50pl
Citifluor AF1. Fluorescence staining of the cell surface was visualised with a
fluorescence microscope: (100X oil objective) Deltavision (Applied Precision Inc) and
camera (Roper Scientific) using SoftWoRx Explorer 1.0 software.
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Chapter 3) Introduction: Bioinformatic analysis
The stevor multigene family was originally identified using a DNA probe, 7H8/6, 
containing a single full-length open reading frame originating from the P. falciparum 
Malayan Camp strain (Limpaiboon et al., 1990). This probe hybridised downstream of 
the telomeric rep20 repetitive sequences on most of the 14 chromosomes (Oquendo et al., 
1986), as seen by multiple bands on Southern blots of gDNA. This hybridisation pattern 
varied between P. falciparum clones, suggesting the existence of variable stevor 
repertoires between parasites. This was later confirmed by the amplification of variable 
numbers of stevor genes in different parasite clones as detailed in chapter 1 (Cheng et al., 
1998).
The work of Cheng et al., 1998 defined the sub-telomeric location, two-exon structure 
and multi-copy nature of the stevor gene family prior to publication of the complete P. 
falciparum genome and its annotation (Gardner et al., 2002). When the sequence of the 
complete P. falciparum 3D7 genome was available, 28 stevors were identified, along with 
a number of pseudogenes and gene truncations (Gardner et al., 2002). Two larger 
multigene families were also annotated, including 59 var and 149 rifs. These three 
multigene families are arranged in two basic arrangements, on 24 of the chromosome 
ends, each gene cluster starting with a var gene (see table 3.1 and figure 1.6).
Table 3.1) Telomeric multigene family arrangements (Gardner et aL, 2002)
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Importantly, r if  and var are found in centrally located clusters, whilst stevor genes are
exclusively found at telomeric ends.
The first exon is 66bp in length, encodes a secretory signal sequence and is conserved 
between gene family members. Stevor's second exon is approximately lkb in length and 
includes the most variable region. This HVR allows the differentiation of unique stevor 
genes whereas the N- and C-terminal regions are conserved or semi-conserved between 
stevors. Stevors and rifs (along with other variant antigen families) share architectural 
similarities, in particular, being characterised by the presence of two transmembrane 
domains. However stevors and rifs differ in that the HVR of r if  is up to 300bp longer than 
the equivalent region in stevor. In both protein families, predicted transmembraner 
spanning regions flank the HVR. Kyes et al., 2001 predicted the HVR formed a loop on 
the iRBC surface, exposing it to the immune system and placing the remainder of the N- 
terminal and C-terminal within the iRBC cytoplasm (Kyes et a l, 2001). Immunologically 
distinct variant proteins exposed to the immune system on the iRBC surface are driven to 
diversify by cross-reactive immune responses (Recker et al., 2004). Thus, the host 
positive pressure drives gene diversification of these protein-domain surface-targets. 
However nothing is known about the natural immune response to STEVOR, and indeed 
given the presence of a N-terminal signal sequence and two transmembrane domains, the 
classic protein secretion pathway would place the loop on the intracellular side of the 
iRBC membrane (Bock et al., 2001).
Recent studies using microsatellite markers and extensive sequencing of P. falciparum 
isolates from different regions worldwide have identified single nucleotide 
polymorphisms (SNPs) and insertion-deletion (indels) polymorphisms. These are the 
main mechanisms generating polymorphism in P. falciparum , with indels providing at 
least as much polymorphism as SNPs (Volkman et al., 2007a). SNPs were estimated to 
occur at a frequency of one every 446 bases across the genome (Volkman et a l,  2007b),
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with an overall pairwise nucleotide diversity (jt) =1.16 x 10'3. However, most of the
variation (nucleotide diversity) occurs in small regions of high diversity corresponding
with the genes in the gene ontology categories containing surface molecules involved in
cytoadherence and antigenic variation (Ashbumer et al., 2000). In this regard, the
individual genes with the greatest diversity were var, rif, and stevor genes (from j t  =1 x
10'3to at =6.1 x 10‘2).
African parasites are suggested to be the common ancestors of P. falciparum parasites 
worldwide in part because of their higher diversity (Wootton et al., 2002). However there 
are important differences between the parasite genomes worldwide: Linkage 
disequilibrium was found to extend over much shorter distances in African parasite 
genomes, than Asian (Volkman et al., 2007b). In addition, there is evidence, based on 137 
genotyped SNPs, for different clades with substantial parasite population differentiation, 
between the African, Asian or American continental groups.
A study of var gene sequences in 12 Kilifi parasite-isolates, showed these African 
parasites had a comparable number of var genes to the fully sequenced P. falciparum 3D7 
clone (Bull et al., 2005). The 3D7 var genes were grouped into six types based on 
specific sequence features, and the Kilifi vars had a similar type distribution. A total of 
878 non-identical var sequences were identified from these 12 parasite isolates with 
virtually no overlap between sequences from different isolates reported. A second study 
of var sequences from Amazonian parasite isolates indicated the expected repertoire size 
was again similar to the fully sequenced P. falciparum 3D7 genomic repertoire, and that 
the Amazonian var genes were most similar to vars isolated from other American isolates 
(Albrecht et al., 2006). This study also estimated significant repertoire overlaps between 
the r if  and stevor repertoires of the Amazonian isolates with the P falciparum  3D7 
genome. However, it is not known if field isolates will contain a similar number of stevor
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to the P. falciparum 3D7 clone. Additionally a more extensive study of stevor from
isolates worldwide is required in order to estimate global repertoire size.
Comparisons of long-term laboratory-adapted parasite cultures with recent isolates
showed laboratory-adapted parasites are not significantly more or less divergent than
recent isolates (Volkman et a l,  2007b). However, the P. falciparum isolate 3D7 was
shown to have accumulated DNA in culture through insertions at a rate of
+1 nucleotide/kb (Jeffares et al. ,2007).
Nucleotide substitutions can either be synonymous, where no change occurs to the amino 
acid sequence of the protein, or non-synonymous, when the amino acid changes. Thus 
rapidly evolving proteins can be predicted using the ratio of non-synonymous (dN) versus 
synonymous (ds) nucleotide substitutions, where pressure to evolve results in a high / 
ds value. This ratio was used in an analysis o f the P. reichenowi genome with P. 
falciparum 3D7 genome. Those genes, which had evolved furthest, as judged by 
significant excess of non-synonymous polymorphisms (amino acid changes), were those 
whose function is grouped in merozoite invasion or early ring formation (Jeffares et al., 
2007). In particular, predicted membrane-spanning proteins and exported proteins were 
also found to have evolved significantly more rapidly. This finding corresponds with a 
different study, which found that membrane-associated proteins accounted for more than 
85% of all polymorphisms (Volkman et al., 2002). In addition, rapidly evolving genes are 
characterised by their low expression levels and high expression duration i.e. expressed in 
multiple stages of the lifecycle (Jeffares et a l,  2007).
Var, rif, and stevor genes all meet the criteria for rapidly evolving proteins (as 
demonstrated by the high rate of amino acid evolution). This evolution is predicted to be 
as a result of strong immune-mediated diversifying selection (Mu et al., 2005; Trimnell et 
a l,  2006).
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Extensive sequencing of other P. falciparum parasites including a Ghanaian clinical
isolate (8x coverage), the IT isolate (current sequencing and lx  coverage), and the
closely-related parasite P. reichenowi (partial genome shotgun sequencing), now facilitate
the further exploration of the stevor multigene family in these parasites
(www. sanger. ac. uk/Proj ects/Protozoa/).
Objectives
1) Characterisation of stevor through comparison with rifs
2) Stevor expression, a comparison of laboratory and field parasite isolates
3) Characterisation of stevor sequence diversity, and comparison of laboratory 
and field parasite isolates
4) Predicting protein function using RIFIN based studies as a model
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Results
3.1. Characterisation of stevor through comparison with rifs
The rifs and stevors have recently been classified as a super family, due to structural 
similarities between the two gene families (Cheng et a l, 1998). Before comparing the 
genomic structure of these two gene families, it was important to identify the distinct and 
conserved regions. This was carried out using an alignment of STEVOR and RIFIN 
amino acid sequences taken from the annotated P. falciparum 3D7 plasmodb database 
(Bahl et a l, 2003; Gardner et a l, 2002).
Bootstrap consensus trees were generated at bootstrap values of 99% and STEVOR and 
RIFIN families were classified as two distinct sub-groups (figure 3.1a). In addition, when 
the two families are aligned before performing a profile alignment at 84% consensus, the 
RIFINs form two sub-groups (figure 3.1b, purple and green) defined by the presence of a 
consensus peptide sequence, KEL (X15) IPTCVCR approximately 100 amino acids from 
the N-terminus in one of the RIFIN sub-groups.
Interestingly, this additional 25 amino acid insert results in the addition of two cysteines 
in the RIFIN proteins, which are also present in STEVORs (figure 3.2 arrows 1 and 2). A 
total of 6 cysteines are conserved between the STEVORs and RIFINs (black arrows 1-6). 
RIFINs usually contain 10 cysteines in total, whereas STEVORs contain 8 cysteines.
Both STEVOR and RIFIN have the highest number of cysteines within the N-terminal 
region of the protein, and despite the HVR size difference both HVRs contain between 2 
and 4 cysteines in this region. The major difference in cysteine distribution lies in 
STEVORs having two cysteines in the extreme C-terminal domain not present in RIFINs. 
This may be indicative of differences in orientation and/or function between the two 
groups of proteins, as cysteines can facilitate di-sulphide bonds, which are important for 
tertiary structure.
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Figure 3.1: 26 STEVOR and 114 RIFIN amino acid sequences were aligned in Clustal 
X®  and bootstrapped. Bootstrapping is a test o f  reliability o f  the phylogenetic analysis; 
multiple random sampling (500 sets) from the original dataset creates pseudo-datasets o f  
an identical size to the input dataset. New trees are then generated from the pseudo­
datasets, and the frequency with which a branch remains in an identical position gives 
the bootstrapping value for that particular branch. Consensus neighbour joining un­
rooted phylogenetic trees were constructed in MEG A3, and bootstrapped to evaluate the 
validity o f  the phytogeny.
A) 99% consensus B) Radiation-format tree showing all branches. Groupings were 
identified manually STEVOR pink squares, RIFIN purple squares (sub-type 1) and green 
squares (sub-type 2).
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Figure 3.2: Schematic o f  conserved features in STEVOR and RIFIN proteins 
N-terminal signal sequences are shown in grey including a canonical signal sequence 
(encoded by exon 1) and Plasmodium exported element/vacuolar transport signal 
(PEXEL/VTS) sites. Predicted transmembrane domains are shown in black (TM1/2). 
Putative apical organelle targeting motifs (YLIL/YIWL) are identified in the C-terminal 
region following the TM2. Percentage similarity data are taken from a review from (Kyes 
et al., 2001).
Cysteines are marked (C): Black arrows indicate those cysteines that are conserved in at 
least 75% o f  proteins. Dark grey arrows indicate cysteines conserved in at least 50% o f  
proteins. Light grey arrows indicate cysteines conserved in less than 25% o f  proteins. 
Cysteines 1-6 are highly conserved at a structurally equivalent site in both STEVORs and 
the majority o f  RIFINs. Proteins are shown to scale (lcm equals 16 amino acids). Amino 
acid position is based on an alignment o f  the complete P. falciparum 3D7 STEVOR and 
RIFIN repertoires (www.plasmodb. org).
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3.2. DNA analysis of the P. falciparum stevor multigene family comparing laboratory
strains and Kilifi isolates
A detailed study of stevor in the P. falciparum clone 3D7 was possible using data from 
the sequencing project (Gardner et al., 2002). Two sets of s/evor-specific nested primers 
were designed on conserved regions, and spanned the predicted hyper-variable loop 
region.
To determine if the stevor multigene family is a common feature of P. falciparum 
parasites, gDNA was extracted from 5 different laboratory lines of various geographical 
origins: A4; FcBl; CIO; T9/96; and 3D7 (figure 3.3A, materials and methods table 2.1). 
In addition, gDNA was extracted from 70 blood samples taken from patients in the Kilifi 
region of Kenya. All were positive for stevor, indicating stevor genes are also present in 
the genomes of Kilifi isolates, and that the nested primers were designed to sufficiently 
conserved regions of stevor to detect stevor from Kilifi isolates (figure 3.3B). Multiple 
bands were observed after electrophoresis, and similar to P. falciparum 3D7 more than 
one PCR product was generated in the expected size range, by both the external primers 
(approximately 550-700bp), and the internal primers (approximately 250-350bp) (figure 
2 . 1).
Stevor genes were identified in all lines and isolates and the successfully amplified PCR 
amplicons were sequenced and used for comparative analysis to the P. falciparum 3D7 
clone, which was isolated in The Netherlands, but comes from an unknown origin 
(Walliker et al., 1987).
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Figure 3.3: Agarose gel showing PCR products obtained from laboratory parasite and 
from Kilifi parasite isolates ’ gDNA
Gel electrophoresis o f nested stevor PCR products from genomic (g)DNA extracted from
A) 5 representative P. falciparum laboratory clones: A4; FcBl: CIO; T9/96; and 3D7 or
B) 10 representative parasite isolates from Kilifi. 5p i o f each product was loaded onto a 
2.5% agarose gel. Results show two amplicons in the expected size ranges, products 
carried over in the nested PCR-step from the external PCR (approximately 600bp) with 
primers smfl and smrl, and internal PCR products (approximately 300bp) from primers 
RepFl/2 and RepR. lOObp marker (Fermentas). dH20 = negative control containing 
sterile water instead o f template DNA.
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3.3. RNA analysis of the P. falciparum stevor multigene family comparing laboratory
strains and Kilifi isolates
RT-PCR for measuring transcription of P. falciparum multigene families is difficult 
because of contamination by gDNA. Here, nested PCR often resulted in the amplification 
of gDNA (see sample K5 figure 3.4), which required improvement for RT-PCR. 
Therefore an additional single step primer set was designed facilitated by the publication 
of the complete P. falciparum 3D7 genome (Gardner et al., 2002). This modification 
greatly improved the efficiency of the RT-PCR.
Following confirmation that stevor was present in the genomes of the Kilifi isolates, I 
wanted to confirm that these parasites transcribed stevor. Transcription of stevor has been 
shown to occur from 22 hours onwards in the asexual lifecycle (Kaviratne et al., 2002); 
therefore parasites from the Kilifi isolates were grown in culture until they reached late 
trophozoite/schizont-stages, before RNA isolation, RT-PCR and the resulting cDNA was 
sequenced. As observed following amplification of gDNA, and in concordance with 
previous observations in P. falciparum 3D7 (Kaviratne et al., 2002), several RT-PCR 
products were observed after electrophoresis (figure 3.4), indicating that more than one 
stevor transcript is present in both P. falciparum laboratory and Kilifi parasite populations 
at one time.
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Figure 3.4: Agarose gel showing RT-PCR products from RNA extracted from laboratory 
and Kilifi parasite-isolates
Gel electrophoresis o f  nested stevor RT-PCR products from RNA extracted from A) 4 P. 
falciparum laboratory clones 3D7, T9/96, FcBl and DIO, or B) 12 representative P. 
falciparum Kilifi isolates. 5pl o f  each product was loaded onto a 3% Metaphor agarose 
gel. Results show two amplicons, products carried over from the external PCR 
(approximately 600bp) with primers smfl and smrl, and internal PCR products 
(approximately 300bp) from primers RepFl/2 and RepR. (+) Sample contained reverse 
transcriptase. Negative control (-) contained sterile water in place o f  enzyme. lOObp 
marker (Fermentas). dH20 = negative control containing sterile water instead o f  
template RNA +/- reverse transcriptase.
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3.4. Characterisation of stevor sequence diversity, and comparison of laboratory and
field parasite isolates
In order to make a comparison of stevor genomic and transcribed sequences from the 
genomes of laboratory strains and Kilifi isolates, as many stevor products as possible 
from both PCR and RT-PCR were ligated into plasmids and sequenced in both forward 
and reverse directions.
A total of 213 products from gDNA and RNA were successfully sequenced, and of these, 
133 were unique DNA sequences (alleles), coding for 108 unique STEVOR proteins. The 
number of times each allele was sequenced per isolate is shown in figure 3.5. The 3D7 
stevor repertoire has been included for comparison. Also 6 different stevor sequences 
were identified in the P. falciparum 3D7 isolate from the NIMR that were different from 
those in the stevor repertoire of the published 3D7 genome (3D7 1-3 41202 and 3D 71- 
3_181202).
3.4.1. Identification of common stevors
Evidence was sought for common stevors indicative of an already expanded stevor 
multigene family in the P. falciparum ancestral parasite. 8 of the 133 stevor sequences 
were found in more than one parasite isolate, 4 of these paralogues were identified in 3 or 
more parasite isolates. 1) The laboratory strains A4; CIO; FcBl and DIO share a common 
stevor gene (FcB 1 2 41202), which was also detected by RT-PCR and transcribed in 
FcBl and DIO. 2) The second common stevor gene (A4 1 41202) was shared by A4, 
CIO and FcBl, and again was transcribed in the FcBl clone. 3) The third common stevor 
(A4 4 41202) was identified in A4; CIO and T9/96 but no transcripts were detected by 
RT-PCR. 4) The fourth common stevor (A4 4 41202) was identified in A4; CIO and 
T9/96 isolates. Interestingly, although these four genes were found in multiple clones 
from the laboratory parasites, they were not detected in any of the Kilifi isolates.
126
Chapter 3 Results
The four other paralogues were each shared by just two isolates, two were shared only by 
laboratory lines: T9/96 or A4, with 3D7: 1) T9/96+14 190903 identical to 3D7 2 41202, 
or 2) A4 1 170105 identical to 3D7 1 181202. 3) A Kilifi isolate sequence, 
K1640 1 BD141105 is identical to PFL2610w from the P. falciparum 3D7 genome and 
is the only stevor shared between a laboratory line and a Kilifi isolate. A large number of 
stevor sequences were found in the Kilifi isolates, but only one stevor sequence was 
found present in more than one isolate. This particular sequence was transcribed in both 
the parasites K11 and K14: 4) sequences K11+1111104 and K14+ 2 1 11104.
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Figure 3.5: Number o f  times each stevor allele was identified per parasite isolate.
The stevor HVRs were amplified, cloned and sequenced from parasite DNA and RNA.
Graphs A and B) Clones derived from DNA have solid coloured bars those from RNA are
indicated by hatched coloured bars (Graph C shows transcribed (+) sequences only).
Parasite isolates are shown in different colours below the graph. The sequence name is
denoted along the x-axis, each sequence has a unique identifier consisting o f the parasite
isolate (+ i f  amplified from RNA), clone number and date. The number o f  clones per
sequence is shown on the y-axis. P. falciparum 3D7 genomic stevor sequences are
included for comparison (solid black).
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3.4.2. Repertoire of transcribed stevor genes
Interestingly, stevor was transcribed in all P. falciparum strains shown, with the 
exception of the parasite clone A4, which did not transcribe stevor, as no RT-PCR 
products were detectable, however, the A4 genome contains at least 15 different stevor 
genes (figure 3.5). The absence of A4 stevor transcription has also been observed by Sue 
Kyes (personal communication). Using RT-PCR it was identified that several P. 
falciparum laboratory lines including 3D7; T9/96; FcBl; DIO and 16 Kilifi isolates 
transcribed multiple stevors within the cultured populations, with up to 10 stevor genes 
from one Kilifi isolate: K5(+). Out of the 8 common sequences (present in two or more 
parasite isolates), 5 of the 8 were also transcribed (detected by RT-PCR).
3.4.3. Bootstrapped consensus phylogenetic tree analysis
Phylogenetic trees constructed from 152 HVR DNA sequences revealed overall, one large 
sub-group containing approximately one-third of the stevor sequences, with all isolates 
represented with the exceptions of DIO, K14, K11 and K6 (figure 3.6A).
In addition, there was evidence of sub-grouping based on geographical regions, 
significant grouping of stevors from different isolates, in particular T9/96 stevors formed 
three sub-groups containing three or more sequences (blue circles). Sequences from A4, 
CIO, FcBl and DIO clustered together, the majority of sequences falling within just four 
sub-groups (green circles). Whilst the majority of Kilifi isolate stevor sequences were 
contained within 7 sub-groups (yellow circles). These sub-groupings are present using 
two different methods of tree construction: Neighbour joining and minimum evolution, 
and are conserved at 95% significance bootstrap values. The complete P. falciparum 3D7 
stevor repertoire is included in the tree for comparison, and these are distributed 
throughout the entire trees (pink).
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Figure 3.6: Unrooted A) neighbour-joining and B) minimum evolution 95% consensus
phylogenetic trees o f  152 HVR stevor alleles
Trees are based upon a nucleotide alignment o f  the HVRs and condensed to show only 
those branches with a bootstrap value o f  95% significance and above. Sequences are 
colour coded according to originating isolate: Kilifi-yellow; T9/96-dark blue; 3D7-pink; 
A4 and CIO-green; FcBl-light blue; DIO-light green.
Orange open-circle around a branch point indicates the major stevor sub-grouping, blue 
open-circles highlight T9/96 sub-groups, green open-circles highlight sub-groupings 
including FcBl, CIO and A4 sequences, yellow open-circles highlight Kilifi sequence 
sub-groupings.
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Phylogenetic trees of 108 unique STEVOR amino acid sequences reveal firstly a trend for
sequences of the same geographical region to be more closely related, seen most clearly 
in figure 3.7a. These trees were then condensed to show only those branches with a 
bootstrap value of 85% or higher (figure 3.7b). The significant sub-groupings seen within 
the trees inferred from the nucleotide sequences (figure 3.6) are also maintained at the 
amino acid level. Again, a single major sub-group is observed (highlighted by an orange 
circle). Three sub-groups contain the majority of T9/96 sequences, laboratory clones A4, 
CIO, FcBl and the single DIO sequences are contained mostly within three other sub­
groups, and finally four sub-groups contain at least three Kilifi sequences. These sub­
groups are consistent using either of two methods for generating the trees.
This analysis was extended to include all STEVOR sequences including those from 
published databases (IT and Ghanaian isolates) and 75 South American region sequences 
obtained from Albrecht et al., 2006 (Albrecht et a l, 2006). In total 226 HVR amino acid 
sequences were used for the analysis (figure 3.7c). However, no significant sub-groups 
were present, although a number of non-significant groups were present when the tree 
was condensed at 50% bootstrap values.
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Figure 3.7: Unrooted phylogenetic trees using neighbour-joining and minimum evolution
methods A) showing all branches and B) 85% condensed trees using 108 amino acid
sequences C) 50% condensed tree using 226 amino acid sequences.
Trees are based upon an alignment o f  the HVRs then condensed to show only those
branches with a bootstrap value o f  85% or 50% significance and above. Sequences are
colour coded according to originating isolate: Kilifi field  isolates-yellow; T9/96-dark
blue; 3D7-pink; A4 and ClO-green; FcBl-light blue; DIO-light green, IT-black,
Ghanaian fie ld  isolate-red.
Orange open-circle indicates a major stevor sub-group, blue open-circles highlight T9/96 
sub-groups, green open-circles highlight sub-groupings including FcBl, CIO and A4 
sequences, yellow open-circles highlight Kilifi sequence sub-groupings.
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To determine the size of the stevor multigene family in isolates other than P. falciparum
3D7, data for stevor genes have been gathered from the genomes of 3 sequenced P.
falciparum isolates: 3D7, Ghanaian, and IT (table 3.2). Stevor sequence data was derived
from the P. falciparum genome project (www.plasmodb.org) and Wellcome Trust Sanger
Institute protozoan sequencing effort (www.sanger.ac.uk/Projects/Protozoa/).
A BLAST analysis was performed on the sequences of the IT and Ghanaian isolates using
the P. falciparum 3D7 stevor (PF07 0130) conserved N-terminal (first 36bp), and C-
terminal (last 38bp) sequences. These BLAST searches returned only stevor sequences
and the number of hits was recorded (table 3.2). Due to the incomplete status of coverage
of the two genomes, (lx  for IT compared with 8x for Ghanaian respectively), the BLAST
hit sequences recovered required editing. Sequences were recovered manually from the
contigs using 3D7 stevor sequence information to identify the full-length genes, where
possible. DNA sequences were then aligned in Clustal X®, and translated and edited in
BioEdit. Pseudogenes, short sequences, and duplicates were removed. The IT sequences
contained many duplications and incomplete open reading frames (possibly due to gene
location at the end of contigs), which was reflected by the high number of BLAST hits
(41 using the 5’ and 52 using the 3’ end sequences). The incomplete nature of the lx IT
coverage means that many smaller unassembled contigs are in the database. Increased
coverage would allow these to be assembled into fewer (larger) contigs, directly reducing
the number of incomplete open reading frames.
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Table 3.2) Stevor identification in genomic databases
Results
Database
searched
BLAST 
hits 
5’ (36bp)
BLAST 
hits 
3’ (38bp)
STEVOR
minus
short
/edited
STEVOR
minus
pseudogenes
STEVOR
minus
duplicates
Ghanaian 13 38 26 25
(full-length)
25
IT 54 107 99 41 (5’) 
52 (3’)
17
26 stevor sequences were identified in the Ghanaian isolate genome, two of these 
nucleotide sequences resulted in the same amino acid sequence STEVOR. 26 genes are 
comparable with the 28-stevor genes in the P. falciparum 3D7 genome. A total of 17 
unique stevor sequences were identified in the IT genome, none of which gave the same 
amino acid sequence. Therefore a total of 25 Ghanaian, and 17 IT-isolate STEVOR- 
sequences were used in the analysis.
3.5. Other malaria genomic data: P. reichenowi and P. gallinaceum
A simian malaria P. reichenowi, the most closely related parasite species to P. 
falciparum , had a total of 8 stevor sequences, all of which were found in the P. 
reichenowi database following BLAST searching using the degenerate internal primer 
sequences (RepFl/2 and RepR, table 2.2). All sequences were translatable and between 
651-672bp in length and therefore on average 300 nucleotides shorter than P. falciparum 
3D7 stevor.
In a tree based on the exon 2 sequences only, P. reichenowi stevor genes cluster together 
in two groups (orange circles) and were distributed throughout the tree (figure 3.8). This 
suggests P. reichenowi stevors are more similar to each other than to P. falciparum 
stevors. They are shorter missing the most N-terminal end of exon 2, indicating the N-
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terminal region is not functionally conserved between P. falciparum and P. reichenowi. 
This could also be due to the genome coverage of the P. reichenowi clone and greater 
coverage may reveal full-length stevors±
Although the P. falciparum origin has been suggested along with P. reichenowi to share a 
common ancestor with avian parasites (Escalante et al., 1998), no stevors were detected 
in the P. gallinaceum genome using the same BLAST search methods.
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Figure 3.8: 95% Consensus neighbour joining and minimum evolution un-rooted 
phylogenetic trees o f  stevor exon 2 were constructed using all available stevor sequences, 
and bootstrapped to evaluate the validity o f  the phylogeny. An alignment was made using 
P. reichenowi (black) and P. falciparum (3D7-pink; Dd2-grey; DIO-green) stevor 
sequences, which have dissimilar N-terminal sequences.
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3.6. Secondary structure and motif prediction
Secondary structure predictions were made based on an alignment of 24 STEVORs and 
89 RIFINs using ‘The PredictProtein Server’. Nucleic Acids Research 32 (Web Server 
issue): W321-W326. (Rost & Liu, 2003). Predicted gene structure was consistent 
regardless of the origin. All STEVOR and RIFINs were predicted as globular proteins 
with ‘all-alpha’ secondary structure composition, classified as greater than 45% a-helices, 
and less than 5% (3-sheets. However, despite having very similar percentages of 
hydrophobic amino acids in their composition (STEVOR=39.9% RIFIN =41.2%) 
STEVOR has more than double the amount of predicted helical transmembrane 29.4% 
compared with 13.8% in RIFINs. It is therefore possible that STEVOR proteins, but not 
RIFINs, have a third transmembrane-spanning region within the hyper-variable loop. 
Diversity of the majority of stevor sequences studied from all isolates was confined 
almost exclusively to the approximately 70 amino acid HVR (between the two predicted 
transmembrane domains). This HVR is punctuated with conserved residues such as 
cysteines, however the N-terminal by contrast, has extensive conserved stretches of 
amino acids, in particular the regions: NPHYHNDPELKEIIDK-M/L-NEE, EPMST-I/L- 
EKELLETYEE and KGRDKYLKHLK-E/H/G-R/G-C which are STEVOR specific. 
Attempts to align STEVOR-specific motifs against the RIFIN amino acid sequence 
alignment failed, indicating these proteins have not arisen through transfer of domains 
between these families.
A single highly conserved C-terminal motif was identified in both STEVORs (YWLY) 
and RIFINs (YLIL). This well-characterised type of C-terminal consensus motif consists 
of YXX<j) (X, any amino acid; <j), an amino acid with a bulky hydrophobic side chain) and 
acts as a sorting signal (Marks et al., 1996). It is located in both protein families at the C- 
terminal end of the most C-terminal transmembrane domain (TM2) (figure 3.2).
145
Chapter 3_______________________________________________________ Results
Although not included in the regions used for the phylogenetic analysis, the C-terminal of
STEVOR also includes a highly conserved motif consisting of HECKKHLC, this
contrasts with the RIFIN C-terminus, which does not contain cysteines. However, overall
both the RIFIN and STEVOR C-termini are positively charged consisting in the majority
of highly conserved lysines and arginines. In T.gondii, transmembrane micronemal
proteins use a tyrosine-based sorting motif and an acidic patch of residues in the C-
terminal tail (Di Christina et al., 2000). These features are also found on several P.
falciparum  micronemal proteins. However, in the case of the micronemal protein
erythrocyte binding antigen 175 (EBA-175) neither the tyrosine signal nor the acidic
patch are necessary for micronemal targeting. Instead, an unknown signal within the
cysteine-rich region directs EBA-175 to the micronemes and then unknown features
located within the cytoplasmic tail enable EBA-175 to function as an invasion ligand
(Gilberger et al., 2003).
Rhoptry protein targeting is Brefeldin-A sensitive indicating that proteins pass through 
the ER and Golgi (Howard and Schimdt., 1995 and Noe et al., 2000). Rhoptry protein 
targeting in T. gondii relies on a tyrosine-based motif, as described above, YXX<j), many 
P. falciparum  rhoptry proteins do contain a C-terminal tyrosine-based motif, although 
nothing is known of the requirements for rhoptry targeting. Rhoptry targeting in T. gondii 
also relies on the packaging of transmembrane proteins into clathrin-coated vesicles by an 
interacting of the C-terminal tyrosine motif with the p,l subunit of the adaptor protein 
complex-1 (AP-1) clathrin-coat complex (Ngo et al., 2003). All homologous components 
that are necessary for this targeting mechanism are present in P. falciparum , but whether 
they function in rhoptry targeting is unknown (Gardner et al., 2002).
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Discussion
In order to characterise stevor gene diversity and to form a framework for studies of 
parasite isolates from endemic areas, a phylogenetic analysis was performed on all 
available stevor sequences. I sought to establish whether stevor was indeed present in the 
genomes of all P. falciparum parasites, and whether stevor was transcribed in these same 
parasites. PCR and RT-PCR methods were used followed by extensive sequencing from 
the HVR of stevors from multiple laboratory lines and Kilifi isolates. Evidence was 
sought for the presence of globally conserved stevor genes, consistent with the hypothesis 
of an ancestral parasite with an already expanded stevor multigene family.
The stevor multigene family was found in all P. falciparum isolate genomes. The copy- 
number per genome for the Ghanaian isolate (26) is consistent with that of the P. 
falciparum 3D7 isolate, which has 28 copies. The 17 stevors in the IT genome, on the 
other hand, was considerably lower. However, it is likely that there are more stevor 
sequences, which have been missed due to the incomplete status of the sequencing of this 
genome.
It was interesting to note that the P. falciparum 3D7 clone from the NIMR is not identical 
to the 3D7 clone sequenced and published (Gardner et a l , 2002). Due to the multi-copy 
nature of the gene family and potential for recombination in the sub-telomeric 
chromosomal regions, this would not be surprising. When a similar sequencing study of 
the yir multigene family was made, sequences were found to be different to those 
published by Carlton 2002 (Carlton et al., 2002) (Sandra Koemig personal 
communication). However the P. yoelii 17XNL rodent parasite used for the published 
genome is different from the P. yoelii clone held at the NIMR.
STEVOR and RIFIN are distinct proteins despite sharing architectural similarities. The 
RIFINs form, in addition, two further sub-groups (Gardner et al., 2002), which are 
defined by a consensus 25 amino acid sequence present in only one of the RIFIN sub-
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groups. The phylogenetic analysis performed in this thesis supports this suggested sub­
grouping.
The HVR of STEVOR is highly divergent and there is no evidence of sub-groups from 
phylogenetic analysis based on this region from 226 amino acid sequences worldwide. In 
addition, although analysis from a smaller sample of STEVORs suggested sequences 
from the same isolate cluster together, when this analysis was extended this clustering 
was no longer evident. Overall, the Kilifi isolates appear to be more closely related to 
each other than any of the other laboratory parasites, and no common stevors were found 
between Kilifi isolates and for example A4 or FcBl. The only exception was a single 
stevor shared between a Kilifi isolate and the 3D7 isolate. The stevor found in two Kilifi 
isolates (Kll  and K14) may either be due to an overlap in stevor repertoire of the two 
infecting parasites, or homologous parasites infecting both patients. The most highly 
conserved stevor is in fact a pseudogene fragment also present in the P. falciparum 3D7 
genome (PFA0105w), and several other isolates including the Ghanaian isolate.
There are conserved genes (paralogues) identified in different P. falciparum isolates from 
different global locations for example: A4, CIO and FcBl in particular, contain several 
closely related stevors. These data are evidence therefore that the ancestral P. falciparum 
parasite genome already had multiple stevor genes. That may subsequently have 
diversified further within the different P. falciparum isolates. Since I identified 8 stevors 
in P. reichenowi this suggests that the ancestral multigene stevor family existed before the 
split of P. reichenowi from P. falciparum. It is likely that more than 8 stevors are present 
within the P. reichenowi genome (Chris Janssen, personal communication) however it has 
not been possible to obtain P. reichenowi DNA or RNA for further analysis.
Stevors were not detected in P. gallinaceum: Therefore the stevor multigene family has 
arisen in this particular branch of the primate malarias (figure 1.2), and is unlikely to be 
shared by other human malarias or the rodent malarias, such as in the Plasmodium
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interspersed repeats (pir) super-family, as suggested by Janssen 2004 (Janssen et al.,
2004).
Similar to the var genes, each parasite also has an extensive repertoire of stevor genes. 
Transcription of particular stevor genes is not up-regulated at a the gametocyte stage of 
the lifecycle (Sharp et al., 2006). By contrast, a defined subset of var genes (type Ups C), 
are specifically transcribed in the gametocyte-stages, and independently of the var type 
transcribed by the asexual-stage parasite-population (Sharp et al., 2006).
The RT-PCR data suggest that multiple stevors are transcribed in a parasite population. 
However, the presence of multiple transcripts does not necessarily imply more than one 
stevor is translated and expressed at a time in a single parasite, or rule out the possibility 
that different stevors may be expressed in different life cycle-stages. Therefore stevors 
may also be subject to clonal phenotypic variation.
As it has been suggested that particular regions of stevor may be exposed to the host 
immune system, we analysed the HVR. The diversity observed is almost exclusively 
specific to the region between the two predicted transmembrane domains. Data on the 
hyper-variable loop regions from other two-transmembrane-protein families e.g. 
SURFINs, give evidence that the loops are exposed on the surface of the iRBC, thus it is 
likely that this region of STEVOR is also exposed on the iRBC surface. However it has 
not been determined whether STEVOR is expressed on the iRBC surface, which would 
imply that the diversity observed in the loop region is driven by positive selection, and 
amplification of stevor genes is a direct result of the parasites’ need to avoid antibodies. 
However, the hydrophobic nature of this region and higher percentage of helical trans­
membrane predicted in STEVOR compared with RIFINs may also be more consistent 
with three transmembrane domains. This would potentially result in surface-exposure of 
both the HVR and N-terminal regions. It is possible that the N-terminus is functionally 
constrained, for example, due to coding for a specific binding domain. Since stevor
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expression is late in the erythrocytic cycle, it would be unlikely to reach the iRBC-surface
before the development of the schizont. At this late stage of intra-erythrocytic
development STEVOR could potentially be important for adhesion to RBCs, making
parasites more effective in rosetting, similar and in addition to PfEMPl function during
the trophozoite-stage. This could enable faster access of the merozoites to new RBC.
A tyrosine-based motif found conserved in all STEVOR (YWLY) and RIFIN proteins
(YLIL), raises the interesting possibility that STEVOR may be found in the merozoite
apical organelles, in addition to its presence in sporozoites, sexual and asexual
erythrocyte-stages. This location would not be unique to the STEVOR family as in
addition, the much smaller SURFIN family of proteins are expressed both on the iRBC
surface and at the apical tip of merozoites (Winter et al., 2005).
Tyrosine-based motifs of this type are known in mammalian cells and also Toxoplasma 
gondii, another intracellular Apicomplexan parasite with specialised secretory organelles, 
to direct targeting of transmembrane proteins to sub-cellular locations e.g. rhoptries 
(Hoppe et a l,  2000). A similar motif is also conserved in the C-terminus of a sub-set of 
the P. yoelii yir multigene family (Sandra Koemig personal communication).
In summary, the stevor multigene family is found consistently in the genome of all the P. 
falciparum isolates tested, and considerable diversity between isolates is observed, 
although some orthologues were found. In all isolates, except one (A4), stevor genes were 
transcribed and in any population there were multiple genes transcribed. Phylogenetic 
analysis did not reveal any STEVOR sub-groups, unlike rifins where 2 distinct sub­
groups were verified. STEVOR are also not a further sub-grouping of the RIFINs. Several 
potentially important architectural differences were found to exist between the STEVOR 
and RIFIN multigene families, including a very different cysteine distribution, predicted 
helical transmembrane percentage and hydrophobicity distribution within the hyper-
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variable loop region. Finally, the STEVOR proteins may be expressed and located on
both the iRBC surface and in merozoite apical organelles.
In conclusion, the HVR of the STEVOR gene family is highly divergent both within and 
between isolates. The question now is what is the driving force of this gene 
diversification. One reason for the loop to show no sign of conservation is an absolute 
lack of function, however studies have shown the evolutionary rate of the loop is higher 
than that of the genome overall average, this strongly suggests the second possibility; that 
the genes are under positive selective pressure. It has been clearly shown for several other 
Plasmodium genes that regions encoding exposed loops are driven to diversify by 
immune pressure (Conway et a l , 2000; Escalante et a l, 1998). Of course immune 
pressure can only be exerted upon genes that are translated, expressed in exposed 
locations and that are the target of immune responses that lead to reduced parasite fitness. 
While it has clearly been shown that isolates transcribe stevor, the number of stevors 
transcribed per parasite is unknown, as is the location and topology of the protein product.
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Chapter 4) Introduction: Generation of antibody reagents for detecting STEVOR
Proteins belonging to the P. falciparum multigene family, STEVOR, are variant proteins.
In order to study the expression of STEVOR in the iRBC, it will be necessary to have
antibody reagents that detect as many STEVOR variants as possible. Therefore the most
useful antibodies, for localisation and expression studies, will be those specific for the
conserved or semi-conserved regions of these homologous proteins. We have firstly
identified those conserved STEVOR-specific regions (see chapter 3), before generating
antibodies that detect the maximum number of STEVOR proteins.
Proteins belonging to the P. falciparum multigene family, STEVOR, share conserved 
composition. They have an N-terminal region (amino acids 1-53), which contains highly 
conserved motifs (PEXEL/VTS) and is known to have protein targeting properties (Hiller 
et al., 2004; Marti et a l , 2004). This N-terminal region is involved in directing the 
trafficking of STEVOR proteins into the iRBC cytosol and to the Maurer’s clefts 
(Przyborski et al., 2005). Adjacent to the N-terminal is a conserved/semi-conserved 
region, of approximately 130 amino acids, which is then followed by the first potential 
transmembrane domain (TM1). This region has 74 percent similarity between P. 
falciparum 3D7 stevor sequence pairs, likewise 71 percent similarity was found between 
sequence pairs within the initial signal sequence (amino acids 1-24) (Kyes et al., 2001), 
suggesting that the conservation of residues seen could be due to functional restraints 
(figure 4.1). In contrast, the level of similarity between sequence pairs in the subsequent 
approximately 70 amino acid HVR, is only 47%, which suggests that this region may be 
under strong immune pressure or non-functional. The antigenic diversity generated in this 
region may have a role in immune-evasion or other parasite-survival functions that are yet 
to be revealed.
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Figure 4.1: Schematic o f conserved features in STEVOR and RIFIN proteins showing
location o f  peptides and recombinant proteins
Peptides 1-3 and recombinant proteins are marked with red bars. N-terminal signal 
sequences are shown in grey including a canonical signal sequence (encoded by exon 1) 
and Plasmodium exported element/vacuolar transport signal (PEXEL/VTS) sites. 
Predicted transmembrane domains are shown in black (TM1/2'). Apical organelle 
targeting motifs (YIWL) are identified in the C-terminal following the TM2. Percentage 
similarity data is taken from a review from (Kyes et al., 2001).
The positions o f  all cysteines are indicated (C), Black arrows indicate those cysteines that 
are conserved in at least 75% o f proteins. The dark grey arrows indicate cysteines 
conserved in at least 50% o f proteins. The light grey arrows indicate cysteines conserved 
in less than 25% o f proteins. Numbers 1-6 show those cysteines highly conserved at a 
structurally equivalent site in both STEVORs and the majority o f RIFlNs. Proteins are 
shown to scale (lcm equals 16 amino acids). Amino acid position is based on an 
alignment o f  the complete P. falciparum 3D7 STEVOR and RIFIN repertoires 
(www.plasmodb. org).
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Interestingly, studies using recombinant RIFIN proteins that express the N-terminal (130
amino acid) region and also include a proportion of the HVR, showed anti-RIFIN
antibodies are produced in natural infections (Abdel-Latif et a l, 2002) (figure 4.1, RIFIN,
regions included in the recombinant proteins are shown for comparison, red bar).
A similar semi-conserved region including amino acids 26-182 (figure 4.1. STEVOR,
red bar) from two STEVOR genes: Pfl0_0395 and PfF0850c (www.plasmodb.org)
(Gardner et al., 2002), was selected for expression into recombinant proteins for use in
the studies described in this thesis. Pfl0_0395 and PfF0850c are transcribed during the
erythrocytic cycle of P. falciparum parasites (personal communication Colin Sutherland
(Sharp et a l, 2006)). Both genes contain all the major features of STEVOR proteins:
including N-terminal signalling motifs, 8 highly conserved cysteines (Black arrows,
including 6 shared between STEVORs and RIFINs, numbered 1-6 in figure 4.1),
predicted transmembrane domains 1 and 2 (TM1; TM2), and tyrosine-based C-terminal
apical organelle targeting motif (YIWL).
The recombinant STEVOR proteins were used for immunisation of rabbits and mice for 
the generation of antibodies, and for testing of the post-immunisation sera in ELISA 
assay. Although antibodies primarily recognise tertiary protein structures, they can also 
recognise linear amino acid sequences (structures). Previous studies on CSP have 
successfully used anti-peptide antibodies, raised against the (NANP)3 repetitive peptide 
region, which is a dominant B cell epitope (Del Giudice et a l, 1991). Peptides are easy 
and quick to synthesise, and importantly, anti-peptide antibodies have been used 
previously in Western blots and immunofluorescent assays to detect STEVOR (Kaviratne 
et a l,  2002; McRobert et a l, 2004). A genome-wide picture of the complete stevor 
multigene family is now available for different P. falciparum clones, and has been used in 
this project to assess the conservation of the peptides used for antibody generation 
(Gardner et a l, 2002), (see short red bars, peptides 1-3, shown in figure 4.1). Therefore
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for the studies described in this thesis, both anti-peptide and anti-recombinant protein
antibodies were generated for the identification of STEVOR in blood-stage parasites from
multiple laboratory strains, and Kilifi field isolates.
The objectives of this chapter were:
1) To utilise stevor sequence information and determine which peptides and 
fragments of STEVOR to use in the generation of antibody reagents.
2) To determine how many STEVORs they will represent.
3) To raise and test anti-sera to be used later in immunofluorescence studies.
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Results
4.1. Selection and design of STEVOR peptides
3 peptides from different regions of STEVOR originally described by Kaviratne et al, 
were analysed for conservation within the stevor family, re-synthesised and used to 
immunise rabbits and mice. The peptides were originally based on an alignment of six 
STEVOR sequences from www.plasmodb.org (Kaviratne et a l, 2002). With the 
completion of the P. falciparum 3D7 genome sequencing, and partial sequencing of other 
clones (Gardner et a l,  2002), it is now possible to make a more comprehensive 
assessment of the P. falciparum STEVOR family repertoire to ensure that the peptides 
were designed to highly conserved regions and therefore that antibodies would detect a 
wide repertoire of STEVOR proteins as shown in table 4.1.
Peptides 1 and 2 are in close proximity to one another on the N-terminal side of the HVR? 
whereas peptide 3 is located within the highly conserved C-terminal end of STEVOR 
(figure 4.1). These regions were proposed to be on the internal cytoplasmic side of the 
iRBC membrane and therefore unlikely to be exposed on the iRBC surface (Cheng et a l , 
1998).
It was observed that peptide 3 (IWLY) RRRKNSWKHECKKHLC included 4 amino 
acids (in brackets) that constituted part of the hydrophobic predicted transmembrane 
region (figure 4.1), which may render anti-peptide antibody recognition within the native 
STEVOR protein difficult. It is possible that this linear epitope would not be accessible to 
antibodies in its natural tertiary configuration, due to the predicted proximity to the 
membrane.
Peptide 1 is clearly the most conserved in both P. falciparum 3D7 and the Ghanaian 
isolate STEVORs (see chapter 3), whereas peptide sequences 2 and 3 were present and 
conserved in around 50% or less of STEVOR genes, and were overall less conserved in 
the Ghanaian genome than in the 3D7 genome (see table 4.1). This suggested that the
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anti-peptide 1 antibody would identify the majority of STEVORs, if expressed, whereas
anti-peptide 2 and 3 antibodies would recognize a more limited range of STEVORs.
There were no other regions sufficiently conserved to be useful as peptides.
Table 4.1) Percentage of STEVOR genes with 100% identity to the peptide 
sequences used for the generation of STEVOR-specific antibodies.
Peptide 3D 7(1) Ghanaian isolate <2>
Peptide 1 78.5% (22/28) 77.78% (21/27)
Peptide 2 42.86% (12/28) 22.22% (6/27)
Peptide 3 53.57% (12/28) 44.44% (12/27)
1) Available from www.sanger.ac.uk/Projects/P_falciparum/ via GeneDB or PlasmoDB.
2) Available from www.sanger.ac.uk/Projects/P_falciparum/ via P. falciparum Blast 
server.
4.2. Expression and purification of recombinant STEVOR proteins
STEVOR fragments (SI (containing PF100395 amino acids 28-182), and S2 (containing 
PFF0850c amino acids 26-182), see figure 4.1) were cloned into pET24a+ expression 
vector constructs as described in materials and methods chapter 2. Competent E. coli 
bacteria strain BL21 were transformed with the vectors and cultures expanded. 
Expression within the BL21 strain host resulted in the expression of insoluble proteins, 
which could be solubilised in 8M urea. Therefore, protease deficient E. coli BL21 RIL 
and Rosetta-gami cells were transformed with the vectors containing SI or S2. These 
bacterial host strains are manipulated to allow functional expression of the rare tRNA 
genes making them more suitable for the high A/T percentage of the P. falciparum 
genome, and the Rosetta-gami cells additionally have enhanced disulfide bond formation, 
to maximise solubility of the expressed proteins. Both host cell types allowed expression 
of soluble SI and S2 proteins.
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After transformation and induction with IPTG the bacterial cells were harvested and
sonicated, and the recombinant proteins were purified from the sonicated extract using a
Ni-NTA column, as described in materials and methods.
A bacterial growth time-course (from 0-5 hours) was used to determine optimal timing 
for maximal expression and minimal degradation of the STEVOR proteins (figure 4.2). 
Bacterial samples were taken hourly following induction with IPTG, insoluble (i) and 
soluble (s) protein fractions from each time point were analysed on an SDS-PAGE gel. 
Western blotting using an anti-His tag antibody revealed proteins of the expected size 
(SI: 18.49kDa /S2: 19.47kDa) in insoluble and soluble fractions following induction of 
protein expression. A small amount of SI and S2 protein was seen already in Western 
blot at 0 hours (figure 4.2 C): This was probably due to mis-regulation and leaky 
expression of the proteins.
STEVOR protein, SI and S2, were present in both the insoluble and soluble fractions, and 
an additional smaller product of approximately 9kDa was present in the soluble fraction. 
SI expression was maximal at 2-3 hours, and S2 expression was maximal at 2-4 hours, 
after which time the level of protein expression declined. A much larger polypeptide of 
around 49kDa, in the protein blots, reacted with the anti-His tag antibody. These are most 
likely due to non-specific binding of the anti-His tag antibody, or to insufficient protein 
reduction and protein dimerisation.
Equal volumes of culture were processed at each time-point. However these are only 
roughly equivalent, as the bacterial cultures were continually growing throughout the 5 
hours, therefore bacteria were at a greater density at 5 hours than at 1 hour (At 0 hours 
OD600’ 0.6).
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Figure 4.2: SDS-PAGE and Western blot analysis o f  a time course o f recombinant 
STEVOR protein expression in BL21 RIL host cells
A time-course from 0 hours to 5 hours post-induction with IPTG was followed hourly for  
both SI (A, and B), and S2 (C and D). Bacterial culture insoluble (i) and soluble (s) 
fractions were separated on 4-12% BisTris gels in MES SDS running buffer under 
reducing conditions. See Blue molecular marker was used fo r  size identification (kDa). 
Arrows mark expected molecular weight o f  recombinant proteins. A control His-tagged 
protein o f  approximately 60kDa was used as a positive control fo r  the Western blot (lanes 
marked C).
Proteins were either visualised specifically in Western blot (A, and C) by 
chemiluminescence using anti-His tag antibodies, detected via a secondary anti-mouse 
IgG HRP-conjugated secondary antibody, or stained with Coomassie blue stain (B and 
D).
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Using the optimum induction time of 2 (SI) or 3 (S2) hours, large-scale bacterial cultures
were set up. A comparison of protein production was made, between small-scale (100ml)
and large-scale cultures (2L) (figure 4.3). The large-scale cultures were successful with
proteins produced within the same timeframe. Large-scale (Is) protein induction gave
comparable yield to small-scale (ss), but with more breakdown products. For a
comparison of small-scale and large-scale cultures: (figure 4.3 (A) lanes 3 and 4 (SI), and
lanes 7 and 8 (S2) respectively). An equivalent gel stained with Coomassie blue stain
showed equal loading (figure 4.3 (B) protein quantities are low, but visible bands are
comparable). Large-scale cultures resulted in greater quantities of the 9kDa protein, and a
smaller product also appeared around 6kDa. These may be breakdown products of the SI
and S2 proteins. To minimise this degradation, protease inhibitors were subsequently
included at all stages of large-scale purification, and all purification steps were carried out
at 4°C.
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Figure 4.3: SDS-PAGE and Western blot analysis o f  a trial 2L large-scale culture o f
STEVOR SI and S2 expression
Proteins were separated on a 4-12% BisTris SDS gel in MES SDS running buffer under 
reducing conditions, before either (A) detection o f  recombinant protein’s 6-Histidine tag, 
using commercially available anti-His tag antibodies, visualised by chemoluminescence, 
via a secondary anti-mouse IgG antibody conjugated to HRP, or (B) staining o f  proteins 
with Coomassie blue stain. Lanes (1-4) BL21 R1L transformed with construct SI soluble 
fraction, lanes (5-8) BL21 RIL construct S2 soluble fraction. The arrows in A and B show 
the expected size o f  the recombinant proteins.
Lane contents: lanes 1; 5) 0 hour culture small-scale, lanes 2; 6) 0 hour culture large- 
scale, lanes 3; 7) 2 hours post-IPTG induction small-scale culture, lanes 4; 8) 2 hours 
post-IPTG induction large-scale cultures fo r  comparison. See Blue molecular marker was 
used for size identification (kDa). All strips shown are from the same gel and were 
developed at the same time.
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Small-scale purification on Ni-NTA was successful (figure 4.4 A and B), however in 
addition to the SI protein expected size, a smaller 9kDa protein which reacts with the 
anti-His tag antibody, was also purified on the column. Other larger (e.g. 45kDa) proteins 
observed to cross-react with the anti-His tag antibody were removed by the Ni-NTA 
purification process (figure 4.4 lane 4).
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Figure 4.4: SDS-PAGE and Western blot analysis o f  small-scale protein purification on 
Ni-NTA matrix
Full-length SI protein was purified on Ni-NTA matrix along with the smaller 9kDa 
protein fragment (indicated by arrows in A and B). Proteins were separated on a 4-12% 
BisTris SDS gel in MES SDS running buffer under reducing condition before either (A) 
detection o f  recombinant protein’s 6-Histidine tag, using commercially available anti-His 
tag antibodies, visualised by chemoluminescence, via a secondary anti-mouse IgG 
antibody conjugated to HRP, or (B) staining o f  proteins with Coomassie blue stain. See 
Blue molecular marker was used for size identification (kDa).
Lane contents: (1) unbound flow-through from Ni-NTA incubation from small-scale 
purification, (2) Ni-NTA beads post-incubation with Sl-bacterial culture supernatant, (3) 
wash, (4) fraction eluted o ff matrix by high imidazole concentration buffer.
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A representative protein gel and Western blot showing the results of the large-scale 
purification of SI and S2 are shown in figure 4.5. With both constructs, purification using 
the His-tag on Ni-NTA matrix was not completely successful, and a number of non-His 
tagged contaminating proteins were present in the eluted fraction (compare figure 4.5 lane 
E; A with B, or C with D). Therefore gel filtration using Fast Protein Liquid 
Chromatography (FPLC) was used to purify the recombinant proteins further.
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Figure 4.5: SDS-PAGE and Western blot analysis o f  large-scale purification o f  S1/S2 
using the His-tag, on Ni-NTA matrix
Proteins were run on a 4-12% Bis-Tris gel in MES SDS running buffer under reducing 
conditions. Proteins are visualised in A, and C, using an anti-His tag antibody, detected 
via a secondary anti-mouse IgG-HRP conjugated antibody using chemoluminescent 
substrate, and in B, and D, all proteins are stained using Coomassie blue stain. See Blue 
molecular marker was used fo r  size identification (kDa).
SI (A and B) and S2 (C and D) non-induced (0 hours) cultures, protein samples from  
wash 1 (Wl): lysis buffer, wash 2 (W2): high salt buffer, wash 3 (W3): increased 
imidazole buffer, and eluted (E) fractions post-Ni-NTA matrix column.
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4.2.1. Chromatographic purification of SI and S2 STEVOR fragments
The proteins eluted from the His-tag purification column were concentrated to a volume
of 3-5ml and purified further by size exclusion on Superdex 75 using FPLC, with PBS as
the mobile phase. Fractions corresponding to various peaks on the elution profile were
collected and analysed on an SDS-PAGE gel (figure 4.6). It was not possible to separate
the full-length SI or S2 recombinant proteins from the smaller 9kDa protein fragment
(fractions 26-41, gels A and B). However the larger (>28kDa) contaminating proteins
were removed by this method. The fractions 30-33 and 27-31 (black bar 1) containing
maximal full-length SI or S2 protein respectively, were pooled, concentrated and used to
immunise mice. The large peaks, fractions 34-40 and 32-40 (black bar 2), containing full-
length and also the smaller protein fragment, were collected and used in ELISA assays.
Mass spectrometry of this smaller SI species revealed it was approximately 9kDa, but the
exact size did not specifically correspond with a breakdown product from a full-length
recombinant STEVOR. The SI and S2 9kDa protein consistently reacted with an anti-His
tag antibody which suggests the C-terminal (His-tag) is intact. Therefore N-terminal
sequencing of the proteins would need to be carried out to determine exactly their origin.
Recombinant proteins were used immediately where possible as they both exhibited
precipitation on freezing, and therefore were stored a short time at 4°C.
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Figure 4.6: Chromatographic purification o f  SI and S2 recombinant protein, on
Superdex 75
A) Profile ofproteins from the purified SI protein after FPLC, black bars 1 (fractions 30- 
33) and 2 (fractions 34-40) were collected and pooled. B) Purified S2 protein profile 
black bars 1 (fractions 27-31) and 2 (fractions 32-40) were collected and pooled. SI 
fractions 20, 26, 29, 32, 34, 36 and S2 fractions 20, 26, 29, 32, 34, 36 41, were run on 
12% Bis-Tris gel in MES SDS running buffer under reducing conditions and stained with 
Coomassie blue. See Blue molecular marker used for size comparison (kDa).
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4.3. Verification of rabbit anti-STEVOR SI and S2 sera
Rabbits were immunised by ProSci Inc., CA, USA as described in materials and methods. 
Post-immunisation sera were tested and ELISA screening assays performed by the 
company (figure 4.7). Anti-Si serum specifically recognised insoluble recombinant 
protein SI in ELISA assays (A). Rabbit (1) anti-Sl serum showed an ELISA titre positive 
at 1: 25000, whilst rabbit (2) anti-Sl serum had antibody at a 1:14500 dilution. This is 
normalised against the rabbit pre-immunisation sera, sera were considered to contain 
specific antibody if they had an absorbance measurement of > 0.1, read at 405nm optical 
density (OD). However anti-S2 sera did not show any significant S2-specific binding (B). 
The two rabbits immunised with insoluble S2 recombinant protein did not show a clear 
antibody-specific response even at 1:1000 dilution.
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Figure 4.1: ELISA to measure levels o f  anti-STEVOR SI and S2 antibodies in sera from
immunised rabbits: SI, but not S2-specific antibodies were detected in post-immunisation
sera.
2 rabbits were immunised per recombinant protein: Post-immunisation sera were tested 
fo r the presence o f anti-Sl or S2 antibodies (solid lines): Antibodies to STEVOR SI (A), 
and S2 (B). Pre-immunisation sera from each rabbit, collected before the start o f  the 
immunisations, was included as a negative control (dotted lines). The endpoint is 
calculated relative to the pre-immunisation background and sera considered only to 
contain specific antibody at an absorbance above 0.1 (measured at OD 405 (horizontal 
dashed line on graph)). ELISAs were carried out by ProSci incorporated, CA, USA.
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4.4. Generation of mouse anti-STEVOR SI and S2 specific antibodies
BALB/c mice were immunised with soluble recombinant STEVOR SI and S2 proteins, 
as described in materials and methods. Initially, anti-Sl/S2 sera were tested in ELISAs on 
the recombinant proteins, and SI and S2-specific antibodies were detected in post­
immunisation sera, (figure 4.8). Sera from 3 mice were tested from a 1 in 5, to a 1 in 2560 
dilution, at which they still showed specific reactivity to the recombinant proteins above 
the background (pre-immunisation sera baseline). All post-immunisation sera showed a 
similar profile, relative to each other, in response to the recombinant proteins.
A control His-tagged protein of approximately 20kDa was used to test for specificity and 
the anti-His antibody component of the responses. Anti-S2 sera showed minimal response 
to this irrelevant His-tagged protein (B, open symbols, tested at the two highest sera 
concentrations); however anti-Sl sera reactivity was not as STEVOR-specific, with only 
1 serum showing specificity for SI recombinant protein (A, solid symbols), over and 
above that seen in response to His-tagged protein controls (open symbols). Control wells 
of diluents in place of sera, no peptide coat, and no secondary antibody were included and 
were negative (data not shown).
Although these anti-sera bound recombinant protein in ELISAs, they were unable to 
recognise any proteins in Western blots of SDS-PAGE gels of SI and S2 run under 
reducing or non-reducing conditions.
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Figure 4.8: ELISA to measure levels o f anti-STEVOR SI and S2 antibodies in sera from  
immunised mice.
Post-immunisation sera from 3 mice are shown A) anti-Sl recombinant protein B) anti- 
S2 recombinant protein. Sera were titrated in 2-fold serial dilutions starting at 1:5 The 
end-point is calculated relative to the pre-immunisation serum (NMS' dotted line) diluted 
identically to the immune sera, and is shown for comparison. Sera were tested on an 
approximately 20kDa His-tagged irrelevant protein control, at 1:5 and 1:10 sera 
dilutions, and the results shown as open symbols. The ELISA reader was set to take 
measurements at an optical density (OD) 405nm.
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4.4.1. ELISA assays to measure the antibody titre of mouse peptide-specific sera
The presence of antibodies to the different STEVOR peptides was determined by ELISA
as described in materials and methods, and peptide 1 and 3-specific antibodies were
detected in post-immunisation sera (figure 4.9). Post-immunisation sera (solid lines) from
4 mice immunised with peptide 1 (A), contained peptide-specific antibodies at titre 1
/10000, for mice 1/2/4, after which it indistinguishable from the pre-immunisation sera
background (dotted lines). Mouse 3 showed a 10-fold higher antibody response than the
other animals, discernible from background at a titre 1/100000.
Post-immunisation sera from 5 mice immunised with peptide 3 (B) contained peptide- 
specific antibodies with titres of approximately 1/10000, compared with the pre­
immunisation sera (dotted lines). Mouse 5 anti-sera (circle solid lines) contained 10 fold 
less detectable antibody than the other 4 mice, but its pre-immunisation sera also had the 
lowest background (circle dotted lines). Control wells of diluents in place of serum, no 
peptide coat, and no secondary antibody were included and all were negative (data not 
shown).
Post-immunisation sera containing anti-peptide 1 and 3-specific antibodies were used for 
expression and co-localisation studies. Animals immunised with peptide 2 did not show 
specific anti-peptide antibodies, following completion of the immunisation schedule, and 
therefore were not used for further analysis (data not shown).
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Figure 4.9: ELISA to measure levels o f  anti-STEVOR peptide antibodies in sera from  
immunised mice. Post-immunisation sera from A) four mice immunised with peptide 1, 
and B) five mice were immunised with peptide 3, were tested for the presence o f  anti­
peptide antibodies (solid lines). The sera were titrated using 10-fold serial dilutions 
starting at 1:100. Pre-immunisation serum from each mouse, collected before the start o f  
the immunisations, was included as a negative control (dotted lines). The endpoint is 
calculated relative to the pre-immunisation background, and sera considered positive 
only when readings were above the absorbance (OD 405nm) o f  identically diluted pre­
immunisation sera. The assay was done in duplicate wells and the average value plotted.
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4.5. Generation and verification of rabbit anti-peptide sera
Rabbits were bled and preliminary bleeds tested in ELISA assays to determine whether 
anti-peptide antibodies were present (data not shown). Seven days after the final boost 
(3rd), the host rabbits were bled out. Plasma was prepared as described in materials and 
methods, and tested in ELISA assays on the specific peptide and on an irrelevant peptide 
control (figure 4.10).
Rabbits immunised with peptide 1 (A) and peptide 3 (C) produced high titres of specific 
antibodies, (1:4000-1:400000), with anti-peptide 1 sera showing the highest titre. 
However rabbits immunised with peptide 2 had no peptide-specific antibody response. 
This was not a technical problem with immunisation, since anti-KLH antibodies were 
present, up to 1:4000000 titre (B). Indeed, the problem also occurred with peptide 2 
immunisations of mice. This peptide may not have coupled successfully to the carrier 
protein: The peptide was not hydrophobic and was very hydroscopic (Peter Fletcher, 
personal communication), but may still be a problem. Secondly this peptide may simply 
be non-immunogenic.
All anti-sera showed negative results when tested on an irrelevant-peptide control. 
Additional ELISA control wells of diluents in place of sera, no peptide coat, and no 
secondary antibody were included and in all cases negative.
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Figure 4.10: ELISA to measure levels o f  anti-STEVOR peptide 1/2/3 or anti-keyhole
limpet haemocyanin (KLH) antibodies in sera from immunised rabbits
Two rabbits were immunised with A) peptide 1 B) peptide 2 and C) peptide 3, serum was
tested for the presence o f  anti-peptide antibodies either using the correct peptide or an
irrelevant peptide control. Rabbits (anti-peptide 2) were also tested fo r  anti-KLH
antibodies (B). The sera were titrated using 10-fold serial dilutions starting at 1:40. The
end-point was calculated relative to the pre-immunisation serum from each rabbit,
collected before the start o f  the immunisations, and was included as a negative control,
diluted identically to the immune sera. The assay was done in duplicate wells and the
average value plotted.
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4.5.1. Affinity purification of rabbit anti-sera on peptide immunogen
Previous work in the lab has shown that rabbit sera used in FACS, IFA, etc tends to give
high background staining. This is possibly due to natural antibodies in sera that cross-
react on human proteins, and also due to binding of rabbit antibodies to human FcR
(Alexander etal., 1979).
To reduce the antibody binding to e.g. human antigens, affinity purification of the rabbit 
anti-peptide sera was carried out using NHS-activated sepharose ™ high performance Hi 
TRAP ™ columns covalently coupled to the STEVOR peptides (via the primary amino 
groups). Sera from 2 rabbits, one specific for peptide 1, and one for peptide 3, which 
showed the highest reactivity to peptide by ELISA, as well as a serum from 1 rabbit 
immunised with a control peptide (anti-A20/B) were purified on their respective peptides, 
lml of each rabbit serum was diluted 1:5 and passed over the respective column, washed 
and eluted in 6 elutions. For anti-peptide 1 serum, all 6 elutions contained anti-peptide 1- 
specific antibodies (tested in ELISA assays on the respective peptide and control 
irrelevant peptide), and all were pooled. Anti-peptide 3 serum-elution fractions 3-5 were 
pooled, and anti-A20/B serum-elution fractions 1-3 were pooled. The amounts of peptide- 
specific IgG recovered from lml of each serum are shown in table 4.2.
Table 4.2) Purification of peptide-specific antibodies
Anti-sera Volume of serum 
passed over 
column
Amount of 
peptide-specific 
IgG recovered
Final
concentration to 
give positive result 
in ELISA assay
Anti-peptide 1 lml 251pg 1:2560 dilution
Anti-peptide 3 lml 68 pg 1:2560 dilution
Anti-peptide A20/B lml 406 pg 1:2560 dilution
Antibodies were visualised by Coomassie blue staining on a protein gel run under 
reducing conditions to determine purity and check for degradation (figure 4.11). Antibody
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(either anti-peptide 1 or A20/B) heavy chain (approx 60kDa) and light chain (approx 
25kDa) are marked with arrows, antibodies were not fully reduced on the gel therefore 
larger bands (approx 170kDa) are also marked with an arrow. Multiple products, possibly 
due to degradation of the heavy chain are seen below 60kDa. The dialysed and 
concentrated eluted fractions were used subsequently in Western blot assays, 
immunofluorescence assays and in flow cytometry assays of gametocytes (see chapter 5).
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Figure 4.11: SDS-PAGE and Coomassie blue stained gel showing purified rabbit 
antibodies
Proteins were run on a 12% Bis-Tris gel in MES SDS running buffer under reducing 
conditions. Anti-peptide 1 and A20/B purified antibodies are reduced into heavy and light 
chains (marked with arrows). See Blue molecular marker was used for size comparison 
(kDa)
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4.6. Western blot analysis of mouse anti-peptide sera
Western blot analysis was performed to determine whether the mouse anti-STEVOR sera 
recognised proteins of the predicted 30-40kDa in P. falciparum iRBC protein extracts 
(Cheng et al., 1998). STEVOR mean molecular weight equals 36.75kDa, based on amino 
acid composition of 24 STEVOR sequences.
As described in the materials and methods, P. falciparum 3D7, DIO and A4 schizont- 
stage iRBC and uninfected RBC were hypotonically-lysed to remove all soluble non­
membrane proteins including haemoglobin, which was present in large amounts and has 
approximately the same molecular weight as STEVOR proteins (Papakrivos et a l , 2005). 
Mouse anti-peptide 1 serum detected a prominent band running above the 28kDa 
molecular marker, in the pellet membrane fraction (P) of P. falciparum 3D7 schizont 
iRBC, which was not present with the pre-immunisation sera (figure 4.12). This is close 
to the predicted 36.75kDa mean molecular weight for STEVOR. The corresponding band 
is absent from membrane-ffaction proteins (P) extracted from uninfected RBC, 
suggesting that this protein is of parasite origin and is in fact STEVOR. Other weaker 
bands are visible above and below the band of interest, but these are observed in all 
protein fractions from both infected and uninfected RBCs, and were present with mouse 
pre-and post-immunisation sera.
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Figure 4.12: SDS-PAGE and Western blot assay o f  P. falciparum 3D7 protein extracts
using mouse anti-peptide antibodies
Proteins were run on a 10% Bis-Tris gel in MES SDS running buffer under reducing 
conditions. Mouse antibodies were detected by anti-mouse IgG-HRP conjugated 
secondary antibody, and visualised using chemiluminescence. See Blue molecular marker 
was used for size comparison (kDa).
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4.7. Affinity purified rabbit anti-peptide sera tested on parasite extracts by Western
blot
No parasite-specific proteins were detected using the rabbit anti-peptide antibodies, as no 
difference was detected in binding of post- versus pre-immunisation antibodies to parasite 
extracts. The affinity purified rabbit anti-peptide antibodies had identical band patterns to 
pre-immunisation sera and anti-control peptide antibodies, due to non-specific binding to 
proteins of parasite and/or RBC origin. The majority of bands present were visible with 
secondary antibody alone, therefore a range of secondary anti-rabbit-immunoglobulin 
HRP-conjugated antibodies were tested. Problems with the secondary reagents were 
finally resolved by use of two excellent products, goat anti-rabbit Ig HRP-conjugated 
antibody, and swine (human absorbed) anti-rabbit immunoglobulin HRP-conjugated 
antibody (Dako, Denmark) (see antibody overview table 2.4, in materials and methods). 
However, following optimisation of the secondary antibodies by titration, it was still not 
possible to detect bands at the molecular weight expected for STEVOR (figure 4.13)
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Figure 4.13: SDS-PAGE and Western blots o f rabbit anti-peptide 1 or 3 affinity purified 
antibodies on P. falciparum 3D7 iRBC and uninfected RBC protein samples.
A) anti-peptide 1 affinity purified antibodies B) pre-immunisation sera C) anti-peptide 3 
affinity purified antibodies D) Secondary anti-rabbit IgG antibody only, were tested on 
iRBC and uninfected RBC protein samples split into soluble (S) and pelleted membrane 
(P) fractions. See Blue molecular marker was used for size comparison (kDa).
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4.8. Specificity of rabbit STEVOR SI protein sera tested on parasite extracts by
Western blot
The anti-SI sera with high antibody titres to the STEVOR recombinant protein, SI, were 
tested in Western blot assays using extracts of P. falciparum schizont iRBC (figure 4.14). 
Since STEVOR is an integral-membrane protein (Przyborski et al., 2005), it is expected 
that STEVORs would be detected in the membrane pellet (P) fraction following the 
sequential protein extraction as described in materials and methods (figure 2.4).
Anti-Si serum detected a protein of the expected molecular weight for STEVOR in the 
pellet-integral-membrane fraction of P. falciparum 3D7 iRBC only. A single band was 
observed at approximately 35kDa (arrow) in this pellet fraction (P) of P. falciparum 3D7 
iRBC (A), corresponding to the predicted molecular weight of STEVOR. This band was 
not present in the equivalent pellet fraction from the STEVOR P. falciparum clone A4 
which does not express STEVOR (personal communication Sue Kyes), nor in the 
uninfected RBC control, or in the 3D7 extract and the pre-immunisation rabbit serum (B). 
The Coomassie blue stained gel (C), shows equal loading of parasite material and RBC 
control proteins.
One non-specific band at 36kDa, two above and below 14kDa, and a fourth at 
approximately 3kDa are visible, these are most prominent in the soluble (S) protein 
fractions. A 14kDa band was also very obvious in the soluble fractions in the Coomassie 
blue stained gel (C); these bands were recognised by both pre- and post-immunisation 
sera. This may be due to cross-reactivity of rabbit antibodies with human normal RBC 
proteins. Preliminary Western blots using protein extraction method 1, as described in 
materials and methods, were unsuccessful and therefore the extended fractionation 
method 2 was used.
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Figure 4.14: SDS-PAGE and Western blots using rabbit- anti-Sl sera on P. falciparum
A4/3D7 iRBC and uninfected RBC protein samples.
P. falciparum 3D7 (STEVOR-positive) and A4 (STEVOR-negative) clones were 
fractionated into 3 protein populations: soluble proteins (S), carbonate-peripherally 
membrane-associated proteins (C), and pellet-integral-membrane proteins (P). An 
uninfected RBC control was treated identically. Anti-Sl rabbit serum detected STEVOR 
as an approximately 35kDa protein (A, marked by arrow). Rabbit pre-immunisation sera 
did not detect STEVOR (B). A secondary swine anti-rabbit IgG HRP-conjugated antibody 
and chemiluminescence was used to visualise the result on photographic film. An 
identical protein gel was stained with Coomassie blue stain to allow comparison o f  
protein sample loading (C).
Proteins were separated on a 12% Bis-Tris gels in MES-SDS running buffer under 
reducing conditions. See Blue molecular marker was used for protein size comparisons 
(kDa).
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Discussion
This chapter describes the development of a panel of mouse and rabbit antibody reagents 
that will allow the detection and localisation of STEVOR proteins in P. falciparum 
parasites. The STEVOR proteins are highly variable in certain regions and the peptide 
and recombinant protein sequences were therefore designed to avoid these regions, so that 
antibody reagents could be developed that recognise the maximal number of STEVORs 
possible within a wide range of parasite lines, clones or isolates.
All anti-peptide and anti-recombinant protein sera were validated by ELISA to determine 
whether their respective STEVOR antigens were recognised specifically. Positive and 
specific sera were then tested by Western blot on P. falciparum blood-stage proteins, 
which had been separated into different fractions: Soluble proteins; carbonate buffer 
soluble membrane-associated proteins, and pelleted integral-membrane proteins. This 
method enabled detection of protein of the expected size (mean: 36.75kDa) in P. 
falciparum 3D7 schizont iRBC, using both mouse anti-peptide 1 antibodies, and rabbit 
anti-recombinant SI protein antibodies in the pellet fraction, thus supporting the evidence 
of Przyborski et al that STEVOR is an integral-membrane-bound protein (Przyborski et 
a/., 2005).
The peptide regions, 1 and 3, were conserved in 45% to 80% of STEVORs, and therefore 
gave sufficient coverage of the STEVOR family to make useful reagents. The P. 
falciparum 3D7 STEVOR family was recently assessed by quantitative RT-PCR, and 
common major transcripts shown to be present in both gametocytes and their asexual 
progenitors, the two genes found to have the highest abundance compared to total stevor 
transcript abundance were PF10 0395 and PFF0850c (Sharp et al., 2006). The 
recombinant proteins SI (containing PF10 0395 amino acids 28-182) and S2 (containing 
PFF0850c amino acids 26-182) therefore will detect the major STEVOR proteins 
expressed in P. falciparum 3D7 asexual and sexual blood-stage parasites. In addition, the
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recombinant proteins cover conserved regions of the protein (including peptide regions 1
and 2) and these antibodies are therefore expected to cross-react with other STEVOR
variants.
Recombinant protein work in malaria is notoriously difficult with the majority of proteins 
insoluble in E. coli protein expression systems (Mehlin et al., 2006). In addition, 
STEVOR is a transmembrane protein, and overall is hydrophobic and highly likely to be 
insoluble: The two predicted transmembrane regions and hydrophobic HVR were 
therefore left out of the recombinant constructs. In order to improve solubility, STEVOR 
N-terminal fragments were expressed in specialist host bacterial cell lines, and soluble 
protein was obtained. This was however at a relatively low efficiency of, on average lmg 
per litre of culture despite optimisation of culture procedures. Preliminary circular 
dichroism data from the two recombinant proteins revealed alpha-helical structure (data 
not shown), this is consistent with secondary structure predictions for STEVOR (see 
chapter 3), suggesting the recombinant proteins had, in part, the expected secondary- 
structure configuration.
The recombinant protein constructs containing the STEVOR sequences do not represent 
the entire N-terminal semi-conserved domain (figure 4.1), missing both the canonical 
signal sequence at the N-terminus, and 7 amino acids prior to the first predicted 
transmembrane domain (TM1). The solubility and conformation of the recombinant 
proteins may have been improved by the inclusion of these additional 7 amino acids at the 
C-terminus of both recombinant proteins (amino acids 183-189), as this would have 
included an important, positionally conserved, cysteine (see figure 4.1; black arrow 
number 4), and incorporated a total of four conserved cysteines from within the N- 
terminal region.
198
Chapter 4______________________________________________________________Results
Limitations of peptides
Disappointingly, despite removal of “non-specific” binding antibodies, in Western blot 
assays none of the rabbit anti-peptide antibodies detected proteins of the molecular weight 
of STEVOR. There were severe background problems in the Western blot assays, with 
cross-reactivity of the anti-peptide rabbit and mouse antibodies to various soluble 
proteins, solved as described above, in addition to various cross-reactive secondary 
antibody reagents. The problem with separating the “problematic cross-reactive soluble 
proteins” away from STEVOR is that when using these sera on iRBC in other assays IF A 
etc, it is not possible to separate away these same cross-reactive proteins. Therefore 
removal of non-specific antibodies was used to try and improve the sensitivity of the 
rabbit anti-peptide sera. Rabbit anti-peptide antibodies were affinity purified successfully, 
but this was not sufficient for recognition of STEVOR proteins within parasite extracts by 
Western blotting.
The anti-peptide sera may also have been unsuccessful in Western blot assays because the 
antibodies detect linear (peptide), rather than tertiary structural epitopes, and the linear 
forms are unavailable for antibody binding in the context of the endogenous proteins. 
STEVOR is expected to have some structural complexity, predicted as a globular protein 
with approximately 60% alpha helical structure by secondary structure predictions from 
PHDsec and PHDhtm programs (see chapter 3)(Rost & Sander, 1993; Rost et al., 1995). 
The peptides were designed to highly conserved regions of STEVOR, the reason these 
regions are conserved may be that they are structurally confined and therefore hidden in 
the native protein structure.
Indeed, the converse may also be true in the case of the mouse anti-soluble recombinant 
proteins, whereby antibodies directed to tertiary structural epitopes do not then recognise 
the reduced form of the protein in the Western blot assay. Immuno-precipitations were 
carried out to determine if these antibodies would bind STEVOR protein successfully in
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the liquid phase, as opposed to in a membrane-bound state: However specific bands were
not detected by the post-immunisation sera (data not shown). It is highly likely that the
vast majority of the soluble protein produced was not in the correctly folded
configuration; therefore antibodies recognising non-native epitopes consequently do not
recognise reduced endogenous STEVOR by these methods.
Advantage of recombinant proteins
The anti- recombinant SI antibodies recognised STEVOR-sized proteins in Western blot 
assays. Optimised Western blot assays were successful with the rabbit-anti-SI 
recombinant protein sera, and STEVOR was detected as a 35kDa band in the pellet 
fraction from P. falciparum 3D7 iRBC, but not in the A4 iRBC fraction. This provides 
further evidence for the non-expression of STEVOR in the A4 parasite clone, and 
suggests that under cultured in vitro conditions the stevor multigene family is non- 
essential. This may also explain why anti-peptide 3 antibodies did not recognise 
STEVOR in Western blot assays, as low expression levels of the STEVOR multigene 
family in the cultured laboratory parasites (see chapter 5, table 5.1), in combination with 
only approximately 50% of STEVOR sequences being recognised by the anti-peptide 3 
sera (see table 4.1), may have meant STEVOR was below the detection level for these 
reagents. Indeed anti-peptide 3 antibodies would not recognise, (having two amino acid 
mismatches), the stevor gene PF10 0395 the major transcript found in P. falciparum 3D7 
blood-stage parasites (Sharp et al., 2006).
Conclusions
In conclusion, we have a number of rabbit and mouse antibody reagents, which recognise 
up to 80% of the P. falciparum 3D7 STEVOR multigene family, and approximately the 
same proportion of STEVORs from a Ghanaian field isolate. These specifically recognise
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STEVOR peptides, and recognise an integral membrane protein of similar molecular 
weight to STEVOR in the pellet fraction from P. falciparum 3D7 iRBC in Western blot 
assays. Therefore they will be useful tools for fully evaluating the expression and 
localisation of STEVOR within a range of P. falciparum clones and isolates.
Table 4.3) Summary of anti-STEVOR antibody reagents
ELISA Western
blot
Reagent Host Result Figure Result Figure
SI Rabbit + 4.7 + 4.14
S2 Rabbit - 4.7 n.d.
SI Mouse ~ 4.8 - p i 77 (data
not shown)
S2 Mouse + 4.8 - PI 77 (data
not shown)
PI Rabbit + 4.10 4.13
P2 Rabbit - n.d.
P3 Rabbit + 4.10 4.13
PI Mouse + 4.9 4.12
P2 Mouse - n.d.
P3 Mouse + 4.9 4.12
201
Chapter 5_____________________________________________________  Results
Chapter 5) Introduction: Co-localisation of STEVOR
The presence of STEVOR-proteins in several parasite life-stages has lead to the 
suggestion that STEVOR may have multiple functions. Transcription of STEVOR during 
the later-stages of the blood-stage cycle (from 22 hours post-invasion) (Kaviratne et al., 
2002; Sharp et al., 2006), following that of the r if  and var gene families (Kyes et a l, 
2000), raises the possibility that STEVOR is functionally required post-expression of 
these two families. Therefore the final destination of STEVOR will most likely be found 
at the late schizont-stage, just prior to or at, rupture and merozoite release. Interestingly, 
another smaller gene family encodes SURFINs which are found both on the surface of the 
iRBC and at the apical tip of merozoites (Winter et al., 2005). Therefore given the timing 
of STEVOR expression it potentially could also be located in merozoites. The late stages 
of the erythrocytic cycle were thus the major focus in this chapter.
STEVOR within asexual-stages
Current knowledge of STEVOR location within the iRBC is based almost entirely upon 
immunofluorescence studies with anti-peptide antibodies on fixed P. falciparum 3D7 
iRBC, which locate STEVOR in the Maurer’s clefts during trophozoite and schizont- 
stages (Kaviratne et al., 2002). STEVOR was found to co-localise with anti-PfSBPl 
antibodies, and also with anti-truncated PfEMP3 antibodies, both of which stain proteins 
located in, or exported to the Maurer’s clefts.
A second study of STEVOR export within 3D7 trophozoites transfected with GFP-fusion 
constructs, observed full length STEVOR is exported to the Maurer’s clefts where it was 
shown to co-localise with PfSBPl and PfEMPl (Przyborski et al., 2005).
The polymorphic nature of STEVOR’s HVR, together with the high copy numbers of 
homologous stevor genes in the P. falciparum genomes, suggests that STEVOR is an 
immune target. Evidence exists that multigene families including var and potentially r if
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commonly encode VS As. This suggests that the iRBC surface is a reasonable location to
expect to find STEVOR. Whether STEVORs, RIFINs, of indeed another family of two
transmembrane paralogues, PfMC-2TM, reach the iRBC surface is not known.
This iRBC surface prediction is inconsistent with evidence from studies of STEVOR and
RIFIN using transfections and GFP-tagged recombinant proteins to investigate protein
localisation and orientation, which indicate that both STEVORs and RIFINs reside in the
Maurer’s clefts in late stage iRBCs (Khattab & Klinkert, 2006; Przyborski et a l , 2005).
Selective permeabilisation experiments to determine the orientation of STEVORs within
the Maurer’s cleft, place the HVR within the Maurer’s cleft lumen (Przyborski et a l,
2005). In contrast, the longer HVR of the RIFIN protein was exposed to the iRBC cytosol
(Khattab & Klinkert, 2006). Thus the final destination and orientation of these proteins is
somewhat contradictory. What their functions are and how they are related to one another
is also unknown.
Other surface immunofluorescence techniques, such as flow cytometry allow a direct- 
examination of the surface of individual iRBCs, which means that blood containing a low 
percentage of late stages (as low as 0.05%) can be tested without prior purification and 
concentration, suitable in particular for field parasite isolates where parasitaemia may be 
low. In addition, heterogeneous samples, containing more than one serotype, can be 
identified by the relative percentage of fluorescent and non-fluorescent pigment- 
containing cells (Hommel et al., 1983). Therefore it was possible using reagents 
described in chapter 4, to examine live (unfixed) iRBCs for STEVOR surface expression.
STEVOR within gametocytes
Transcription, expression and location of STEVOR is different in gametocytes to in 
asexual-stages: 1) truncated stevor transcripts are present in gametocytes; and a missing 
second transmembrane domain could lead to a different orientation of STEVOR in the
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membrane (Przyborski et al., 2005; Sutherland, 2001). 2) STEVOR is expressed in late
stage gametocytes and is associated with the iRBC membrane, and not within Maurer’s
clefts (McRobert et al., 2004). 3) Export to the iRBC membrane is Maurer’s clefts
independent, since these structures are not present in late stage gametocytes. Maurer’s
cleft PfSBPl staining was only transiently observed in day 6 gametocytes with no
evidence of STEVOR co-localisation (McRobert et al., 2004). All these facts suggest that
STEVOR may be located in the surface membrane of gametocyte iRBC, and potentially
orientated in a different membrane-bound state, to that in the asexual-stages.
Consequently regions to which peptides 1, 2 or 3 were designed could be exposed on the
surface of unfixed gametocytes. Mediation of gametocyte sequestration has been
suggested as one possible function for STEVOR at this stage, thus if expressed on the
surface of gametocytes, STEVOR could function through conserved N-terminal
sequences encoding binding domains (Rogers et al., 2000).
Finally, a comparison of transcription of r if  and stevor gene families in P. falciparum 3D7 
and fresh isolates revealed higher transcription levels in fresh isolates compared with the 
3D7 parasite (Daily et a l,  2005). In addition a genome-wide comparison of three P. 
falciparum  laboratory clones Dd2, 3D7 and HB3, revealed transcriptional differences in 
polymorphic antigens e.g. encoding var and rifins, whilst transcription of stevor during 
the intra-erythrocytic-stage was not observed (Llinas et al., 2006). Expression of 
STEVOR has thus far only been studied in P. falciparum 3D7 and it is possible that 
prolonged culture has affected STEVOR expression. Therefore a more comprehensive 
study of STEVOR from multiple P. falciparum sources is necessary.
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Objectives
This chapter describes the investigation of:
What is the final destination of STEVOR within the iRBC
1) Is STEVOR expressed on the iRBC surface
2) Is STEVOR expressed in the apical organelles of merozoites
3) Does expression of STEVOR in the laboratory strain P. falciparum  3D7 
reflect that of other laboratory grown parasites, and, more importantly, fresh 
field isolates of P. falciparum .
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Results
5.1. Detection of STEVOR using affinity purified anti-peptide antibodies
Affinity purified rabbit anti-peptide 1 immunoglobulin (see table 4.2 and figure 4.11) was 
used to determine STEVOR expression in the P. falciparum laboratory strains 3D7, DIO, 
and a representative field isolate from Kilifi: K1657 (figure 5.1).
This anti-STEVOR antibody gave a punctate staining throughout the iRBC, present from 
the late trophozoite-stage and throughout schizont development. However, in the highly 
developed segmented schizont-stage parasites the staining pattern of STEVOR was more 
diffuse both around the parasite nuclei and throughout the iRBC cytosol, potentially 
associated with the iRBC surface membrane. The amount of STEVOR positive parasites 
differs marginally between the two lab strains (table 5.1) but the intensity and pattern are 
similar. The field isolate, K1657 (figure 5.1c) however has a much brighter, stronger 
staining most visible at late schizont-stage, and a much higher proportion of parasites are 
STEVOR expressing (table 5.1).
Maurer’s cleft staining by PfSBPl antibodies was punctate throughout the iRBC 
cytoplasm as described previously (Blisnick et al., 2000), although the majority of 
Maurer’s clefts were often found in the periphery of the iRBC cytosol during the late 
schizont-stage, compared with earlier trophozoites (figure 5.1b LT/ES compared with 
LS). This pattern and distribution of Maurer’s clefts was consistent regardless of whether 
parasites were cultured, or parasite’s origin.
In both the laboratory strains and in the K1657 field isolate, STEVOR and PfSBPl 
antibodies co-localised at late trophozoite and early schizont-stages, but at late schizont- 
stage the staining patterns of each were distinct, suggesting that the final location of 
STEVOR was not the Maurer’s cleft.
For all isolates, control stains using normal rabbit immunoglobulin or secondary antibody 
reagents alone were negative. The positive control anti-MSPl-19 (FITC) showed
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characteristic staining of the merozoite’s surface and did not co-localise with Maurer’s
cleft staining with anti-PfSBP 1.
Table 5.1) Percentage of STEVOR positive parasites
P. falciparum  clone/ 
Kilifi field isolate
%  STEVOR expressing 
schizonts
Anti-STEVOR antibody 
reagent
3D7 3% Anti-peptide 1
5% Anti-Si
DIO 7% Anti-peptide 1
7% Anti-Si
A4 0% Anti-Si
K1657 50% Anti-peptide 1
K1640 50% Anti-Si
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Figure 5.1: STEVOR immunofluorescence staining o f  mature (>24hour) blood-stage P. 
falciparum A) 3D7 B) DIO and C) representative Kilifi field  isolate (K1657) parasites 
using anti-peptide 1 antibodies.
a) An early or late-stage trophozoite (ET/LT), b) a late trophozoite-early schizont-stage 
(LT/ES), c) late schizont (LS)-stage parasite double-stained with STEVOR anti-peptide 1 
rabbit affinity-purified antibodies (green), and Maurer ’s cleft anti-PfSBPl mouse serum 
(red). Parasite nuclei are stained with DAP I  (1/ug/ml) (blue), d) Negative control anti- 
irrelevant peptide antibodies (green) e) Positive control anti-MSP 1-19 anti-sera (green) f)  
Secondary goat anti-rabbit IgG FITC conjugated antibody only (green).
Goat anti-rabbit IgG FITC conjugated antibody and goat anti-mouse IgG TRITC 
conjugated antibodies were used as secondary antibodies. Cells were viewed on a 
Deltavision fluorescence microscope under a 100X oil objective, overall magnification 
11 OX. Images shown represent the vast majority o f  iRBC viewed in 100 plus fields.
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5.2. Location of STEVOR using rabbit anti-recombinant protein SI anti-sera
Anti-Si rabbit-serum was used to determine STEVOR expression in the P. falciparum
laboratory strains 3D7 (figure 5.2A), DIO (5.2B), two representative field isolates from
Kilifi: K1640 (5.2C) and K1489 (5.2D) and one laboratory strain (A4) that does not
express STEVOR.
As described with the anti-peptide antibodies in section 5.1, the anti-Sl serum gave a 
punctate staining-pattem in late trophozoite, early and late schizonts, and again was more 
diffuse in the late schizonts (figure 5.2A-C), identical to the distribution seen with the 
affinity-purified anti-peptide 1 antibodies. Again, the staining showed a greater intensity 
on both field isolate parasites compared with that seen on 3D7 and DIO parasites. 
Co-staining using antibodies specific for PfSBPl and the anti-STEVOR SI antibodies 
showed that the STEVOR proteins co-localised with Maurer’s clefts in late trophozoite 
through to schizont-stages, and verified that the punctuate STEVOR staining was within 
the Maurer’s clefts. Localisation of STEVOR protein changed during parasite 
development, from early trophozoites through to late schizont-stages, from within the 
Maurer’s clefts to a more diffuse staining throughout the parasitophorous vacuole and 
iRBC cytosol in the late schizonts. Analysis of bright field images showed that staining of 
STEVOR was closely associated with the iRBC surface membrane (figure 5.2A and B). 
Prior to localisation within the Maurer’s clefts, STEVOR is thought to travel via the 
parasite endoplasmic reticulum, across the parasite plasma membrane, and into the lumen 
of the parasitophorous vacuole (Przyborski et al., 2005). Further evidence for this 
trafficking is provided here using anti-STEVOR SI antibodies, as STEVOR staining was 
observed around the parasite early in trophozoite development (figure 5.2C ET-stage (a 
and b)).
Mouse anti-Sl sera were also generated and tested in IFA for co-localisation with rabbit 
anti-Sl sera to verify STEVOR staining on iRBC (figure 5.2E). The characteristic
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punctuate staining is observed in P. falciparum 3D7 with both antibodies indicating the
mouse anti-sera are STEVOR-specific. Both antibodies were observed to completely
merge when overlaid.
Staining of P. falciparum A4 parasites was carried out with anti-STEVOR antibodies, as 
this clone does not transcribe or express STEVOR proteins (RT-PCR and Western blot 
assays chapter 3 figure 3.4, and chapter 4 figure 4.13). Staining of all P. falciparum A4 
schizonts with all anti-STEVOR antibodies was negative.
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Figure 5.2: STEVOR immunofluorescence staining o f  mature (>24hour) blood-stage P. 
falciparum A) 3D7, B) DIO, and two representative Kilifl field  isolates C) K1640, and D) 
K1489parasites, using anti-Sl sera. Early trophozoite (ET), late trophozoite (LT), early 
schizont (ES), or late schizont (LT) iRBC were either double-stained with STEVOR anti- 
S l rabbit serum (green), and Maurer's cleft anti-PfSBPl mouse serum (red), or only 
single-stained with STEVOR anti-Sl serum (green) and bright field  images shown.
E) IFA showing complete co-localisation o f  rabbit (green) and mouse (red) anti-Sl 
recombinant protein anti-sera, a) late trophozoite (LT) blood-stage parasite with a single 
nucleus, b) an early schizont (ES) with the beginnings o f  multiple nuclei.
Goat anti-rabbit IgG FITC conjugated antibody and goat anti-mouse IgG TRITC 
conjugated antibodies were used as secondary antibodies. Parasite nuclei are stained 
with DAPI (IfLig/ml) (blue). Cells were viewed on a Deltavision fluorescence microscope 
under a 100X oil objective, overall magnification 11 OX. Images shown represent the vast 
majority o f  iRBC viewed in 100 plus fields.
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In summary, both affinity-purified anti-peptide 1 antibodies and anti-Sl recombinant
protein anti-sera give similar staining-pattems. Importantly STEVOR is seen closely co­
localised in the Maurer’s clefts throughout late trophozoite and schizont-stages, but not in 
late schizonts of all STEVOR-expressing parasites studied. All parasites studied showed 
the same pattern and localisation of STEVOR protein-expression. However STEVOR 
expression in the Kilifi field isolates looked very different compared with the in vitro 
laboratory cultured lines. A much higher proportion of the iRBCs expressed STEVOR 
and the staining was much more intense than those of the laboratory lines.
5.3. Only a sub-population of iRBCs express STEVOR proteins
Table 5.1 summarises the percentage of schizont-stage parasites that express STEVOR. 
Not all the schizonts in each of the parasite clones tested gave positive staining with the 
anti-peptide 1 antibodies and the anti-Sl anti-serum, suggesting that only a proportion of 
iRBCs express STEVOR. In the case of two laboratory lines 3D7 and DIO, only 3-7% of 
iRBC were positively stained. The proportion of positively stained iRBC was 
substantially higher in the iRBC from field isolates (50%). This difference between 
cultured strains and field isolates was unlikely to be due to expression of different 
STEVORs as theoretically the antibody reagents were able to detect a large number of 
STEVORs from all parasites studied (see chapter 4). By contrast, all P. falciparum 
schizonts counted had Maurer’s clefts, judged by the PfSBPl antibody staining.
In order to assess whether the low percentage of P. falciparum 3D7 schizont-stage 
parasites expressing STEVOR may have been due to preparation of samples at different 
stages or times in the in vitro cycle, slides of purified schizonts undergoing transfer from 
schizont to reinvasion states were prepared and stained with anti-Sl serum. Previously, 
parasite samples although cultured to allow trophozoite and late schizont-stages to 
develop, still contained mixed parasite-stages, as the cultures were not synchronous.
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Therefore assessment of STEVOR positive schizonts was difficult due to low numbers of
schizonts per viewing field, whereas field isolate samples were synchronous as they were
not cultured beyond a single cycle after resuscitation.
However, even in the samples with purified schizont-stages, expression of STEVOR 
occurred only in a small sub-population of parasites. The percentage of STEVOR positive 
(3D7) schizonts, using anti-Sl rabbit anti-sera, was found to be 5% only in this purified 
schizont population, slightly higher than when previously assessed (compared to 3% 
using anti-peptide 1 rabbit sera).
5.4. Is STEVOR expressed on the surface of RBC infected with asexual-stages?
The peripheral staining pattern of STEVOR on late schizont-stages in P. falciparum  fixed 
iRBC suggested that STEVOR may be either associated with the iRBC membrane or is 
on the surface of the iRBC, similar to VAR and RIFINs (Baruch et al., 1995; Fernandez 
et al., 1999; Kyes et al., 1999; Smith et al., 1995; Su et al., 1995).
To test this hypothesis, both the affinity-purified anti-peptide antibodies and anti-Sl 
serum were used to stain live P. falciparum in different stages of the intra-erythrocytic 
life cycle from culture.
5.4.1. Optimisation of staining conditions for flow cytometry
The staining method for flow cytometry of live P. falciparum infected-cells was 
optimised on the in vitro culture parasite lines: P. falciparum 3D7 and A4. Parasites were 
grown to late schizont-stage, which was shown in the previous section to be the optimum 
time in the erythrocytic-stages of 3D7 development, when STEVOR expression was 
associated with the iRBC membrane.
Hoechst 33342 or Ethidium bromide were used to stain parasite iRBC and thus identify 
and determine the proportion of iRBC in the sample (figure 5.3). The excitation of
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Ethidium bromide with the argon laser (488nm) leads to peak emission at 605nm when
bound to DNA in iRBCs (Jagers, 1983; Watson, 1981), but it can also be detected by
photomultipliers with band passage filters set at 585nm (FL-2) and >650nm (FL-3) on the
FACSCalibur (Vindelol, 1978). Hoechst 33342 exclusively stains DNA: it is excited by a
UV laser (355nm) and detected in the UV range (395-415nm) (Hiller et a l, 2004). Both
methods were titrated to give parasitaemias comparable with counts on Giemsa-stained
thin blood films. However, due to health and safety restrictions it was only possible to
carry out live-cell flow cytometry on a FACSCalibur thus only Ethidium bromide was
suitable for this method.
RBCs and iRBCs were first gated on forward scatter (FCS) and side scatter (SSC), 
enabling the elimination of debris. Together with cell size (FCS) and 
granularity/complexity (SSC), both DNA fluorochromes allow the distinction of 
gametocyte-stages and other single nucleated-stages (rings, trophozoites) from 
multinucleated schizont-stage iRBC (Hiller et al., 2004). Rabbit anti-human RBC ghost 
sera (W49/W50) were then used to optimise the method for labelling molecules on the 
surface of both RBC and iRBC (figure 5.4).
Additionally, the P. falciparum laboratory clone A4 was used as a negative control for the 
expression of STEVOR (Sue Kyes personal communication): Since this clone has been 
used to study expression of VS A, and reacts well in FACS assays with Kilifi immune sera 
(Macintosh, 2006). The anti-STEVOR peptide 1 antibodies did not stain the surface of P. 
falciparum A4 iRBC, whereas both RBC and iRBC could be stained with the rabbit anti­
human RBC ghost sera (figure 5.5a).
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Figure 5.3: Schematic o f flow cytometry interpretation
Schematic depiction o f  Hoechst or Ethidium bromide defined Plasmodium -stages 
(uninfected RBC, rings, trophozoites, gametocytes and multi-nucleated schizont iRBC). A) 
iRBC stained with either Ethidium bromide or Hoechst (Upper-left quadrant). Ethidium 
bromide is acquired in FL-2 (585nm) on FACSCalibur and Hoechst 33342 in FL-4 (395- 
415nm) on the LSR. B) P. falciparum late schizont-stage iRBC positive for surface 
antigen (Upper-right quadrant) e.g. human anti-iRBC sera. C) All cells stained for 
surface antigen e.g. W49/50 anti-RBC ghost antibodies.
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Figure 5.4: iRBC surface staining for flow cytometry a) P. falciparum 3D7 iRBC and 
uninfected RBC were stained with Hoechst 33342 only (Upper-left quadrant) in FL-4 
(395-415nm) on the LSR. b) Rabbit anti-human RBC ghost antibodies showing cell- 
surface staining o f  both infected and uninfected RBC (distinguished by Hoechst 33342 
double-staining), c) Single-stain using only rabbit anti-human RBC ghost antibodies 
staining iRBC or RBC showing cell-surface staining o f  the majority o f  cells, d) Secondary 
antibody control for anti-rabbit IgG and IgM FITC conjugated antibodies, e) Histogram 
comparing anti-human RBC ghost antibody stained iRBC with unstained background.
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Figure 5.5: FACS cell-surface staining o f  A) P. falciparum A4 iRBC and B) Kilifi field  
isolate (K1640) using rabbit anti-STEVOR peptide sera.
For the analysis initially a gate was set on all iRBC using forward and side-scatter to 
eliminate debris. Parasitised cells were distinguished using Hoechst 33342 dye at 
lOpg/ml (P. falciparum K1640 parasitaemia was 13% determined by blood smear count, 
compared with 10.5% by Hoechst staining o f  cells).
Rabbit anti-peptide 1 or 2, and pre-immunisation sera were used to stain fo r  STEVOR on 
the iRBC surface. A rabbit anti-human RBC ghost antibody was used as a positive 
control. Rabbit sera were detected using a goat anti-rabbit IgG + IgM FITC-conjugated 
secondary antibody. Negative control: iRBC were stained with only an anti-rabbit IgG 
FITC conjugated antibody, no primary antibody.
Inset is an IFA staining o f  a P. falciparum 3D7 or A4 late schizont-stage iRBC using the 
same anti-STEVOR peptide 1 rabbit serum.
Cells were fixed in 1% paraformaldehyde fixation buffer before acquiring on a BD™LSR  
with CellQuest software, and analysed using Flow Jo version 6.2.1 software.
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Eight Kilifi field isolates (parasitaemias 0.88%-13%) were tested over four independent
FACS staining experiments using anti-STEVOR peptide sera. In all cases no positive
staining was observed above the rabbit pre-immunisation sera background, with either
anti-peptide 1, or anti-peptide 2 sera. A representative Kilifi field isolate (K1640) is
shown in figure 5.5b. Surface staining using a rabbit anti-human RBC ghost antibody
stained the majority of cells, whilst the secondary anti-rabbit IgG + IgM antibody control
was negative in all cases.
The STEVOR anti-Sl rabbit antibody was then used to determine whether STEVOR 
might be expressed on the surface of live (unfixed) asexual P. falciparum 3D7 (figure 
5.6a), and in three Kilifi field isolates. Neither anti-Sl serum, nor human anti-iRBC sera 
(3D7 parasites are poorly recognised by agglutinating serum from Kilifi adults (Sam 
Kinyanjui personal communication)) gave positive surface staining of the P. falciparum 
3D7 iRBCs. The slight shift observed in the histogram profiles of anti-Sl and human anti- 
iRBC is observed in all cells not only iRBCs. A representative Kilifi isolate is shown 
(K1609) in figure 5.6b, the parasitaemia is approximately 1%. Although a high proportion 
(>95%) of iRBC showed positive surface staining when using Kilifi human anti-iRBC 
sera with high agglutination properties (figure 5.6b). Anti-STEVOR SI anti-sera showed 
no staining above the background of pre-immunisation rabbit sera, secondary anti-rabbit 
IgG antibody alone, or anti-MSPli9 sera (control for leaky cells). Live IF A staining of the 
cells was also attempted, but again, despite detection of iRBC surface staining using 
Kilifi human anti-iRBC high agglutination sera, no STEVOR staining was detected on the 
surface of iRBC using this second technique (data not shown).
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Figure 5.6: FACS cell surface staining o f  A) live P. falciparum 3D7 iRBCs and B) live
Kilifi field  isolate (K1609) iRBCs using rabbit anti-STEVOR recombinant protein pre-
and post-immunisation sera to stain for STEVOR on the iRBC surface.
For the analysis initially a gate was set on live, parasitised RBC (e.g. 91.3%) using
forward and side-scatter to eliminate debris. Parasitised cells were then distinguished
using Ethidium bromide (lOpg/ml). The majority o f  parasites (e.g. K1609 -1.1%  iRBC)
were schizont multi-nucleated forms, with some single-nuclei rings, and uninfected RBC
(e.g. 98.9% RBC).
Positive control staining was carried out using either human anti-iRBC sera or rabbit 
anti-human RBC ghost sera (W49/50). Controls were performed to differentiate intact 
(anti-MSPl-19 or anti PfSBPl negative) and leaky (anti-MSP 1-19 or anti PfSBPl 
positive) iRBCs.
A histogram o f  surface staining intensity (%> ° f  Maximum) is shown: human anti-iRBC 
sera/rabbit anti-iRBC ghost serum (red positive control), rabbit anti-Sl post­
immunisation sera, rabbit pre-immunisation sera and secondary goat anti-rabbit IgG + 
IgM FITC conjugated antibody alone.
Cells were unfixed, and acquired on a FACs calibur™ with CellQuest software, and 
analysed using Flow Jo version 6.2.1 software.
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5.5. Is STEVOR on the surface of gametocytes
Since expression and localisation of STEVOR in gametocytes is thought to be different 
from that in asexual-stages (McRobert et al., 2004), it is possible that STEVOR is 
expressed on the surface of RBC infected with gametocytes. P. falciparum 3D7 
gametocytes were cultured as described in materials and methods 2.2.7., and purified on a 
five-layer Percoll gradient for analysis by flow cytometry. Gametocytes formed after 
approximately 12 days of culture. The parasites were asynchronous with all stages 
present, (figure 5.7a and b). Contaminating asexual-stages, late schizonts, multiply- 
infected cells, and uninfected cells, also remained after the percoll gradients, however can 
be excluded due to their high (or low) mean fluorescence intensity of the DNA dye 
Hoechst.
None of the anti-STEVOR antibodies (affinity purified anti-peptide or anti-Sl anti-sera) 
showed positive fluorescence staining. A representative experiment is shown in figure 
5.7.
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Figure 5.7: FACS cell surface staining o f  P. falciparum 3D7 day 14 gametocyte cultures
using rabbit anti-STEVOR sera.
Giemsa-stained gametocyte culture shown a) before and b) after purification on a Percoll 
gradient. A representative experiment with rabbit STEVOR anti-peptide sera performed 
using affinity purified antibodies and P. falciparum 3D7 iRBCs.
Affinity purified rabbit anti-peptide 1 and anti-peptide 3 sera were used to stain for  
STEVOR on the iRBC surface. Rabbit post-immunisation sera fo r  STEVOR peptides 1 
and 2 are shown. Pre-immunisation serum and affinity-purified serum to a control 
peptide (A20/B) were used as negative controls. Goat anti-rabbit IgG + IgMFITC- 
conjugated antibody alone was negative. Parasitised cells were distinguished using 
Hoechst 33342 dye at 10pg/ml. Cells were initially gated fo r  size and granularity using 
forward and side scatter. A histogram comparing the surface staining with the various 
rabbit sera is shown below.
Cells were fixed in 1% paraformaldehyde fixation buffer before acquiring on a BD™
LSR with Cell Quest software, and analysed using Flow Jo version 6.2.1 software.
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5.6. STEVOR expression in the apex of merozoites
Using both anti-Sl mouse and rabbit sera, which recognise the same recombinant 
fragment of STEVOR (figure 5.2E), Immunofluorescence assays were carried out on 
schizont-stage iRBC of the laboratory line 3D7 at a very late stage of development i.e. 
shortly before release of merozoites. At this stage individual merozoites can be seen 
(figure 5.8). Unexpectedly, the pattern of staining with the anti-STEVOR SI sera 
appeared to coincide with individual merozoites when they are both inside or outside the 
iRBC surface membrane. Anti-MSPl-19 monoclonal antibodies distinguish individual 
merozoites. Closer examination of individual merozoites stained with both anti-MSPl-19 
antibodies and anti-STEVOR SI sera, revealed STEVOR expression in the apex of each 
3D7 merozoite. Anti-Sl rabbit sera staining did not co-localise with the anti-MSPl-19 
staining of the merozoite surface, and STEVOR staining was usually (but not always) 
found in a single site at one end of each merozoite.
To define the precise location of STEVOR in the apical end of the merozoite, double 
staining with antibodies to two other proteins expressed at the apical end of the 
merozoites: apical merozoite antigen-1 (AMA-1) (Triglia et al., 2000), and rhoptry 
protein (Rhop-H2) (Holder et al., 1985). Preliminary results suggest STEVOR may be 
present at the apical end of the merozoites either in the rhoptries or the micronemes 
(figure 5.9). Staining co-localises with anti-Rhop-H2 antibody staining, which is 
restricted to the apical tip of each merozoite.
Merozoites do not have Maurer’s clefts. Previously, PfSBPl was not detected in purified 
merozoite extracts, so the only source of PfSBPl protein would come from ruptured 
membranous remains (Blisnick et al., 2000). Anti-PfSBPl antibodies were used to 
determine if Maurer’s clefts remained attached to the merozoites here (figure 5.10): As it 
was a possibility that the distinct foci of STEVOR staining observed were Maurer’s clefts 
containing STEVOR, attached by membrane remnants of the iRBC ghosts. Maurer’s
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clefts were present in the merozoite slides studied, however they were randomly
distributed and not specific to individual merozoite nuclei, by contrast, STEVOR staining
within the merozoites was unique to each merozoite apex and restricted to a single point
(figure 5.10b and c). The PfSBPl staining was also quite distinct in size with larger foci
than the apical tip STEVOR staining. Therefore despite the fact that Maurer’s cleft
proteins are present, we conclude that the STEVOR staining in the merozoites is not due
to residual Maurer’s cleft STEVOR staining.
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Figure 5.8: STEVOR immunofluorescence staining o f  P. falciparum 3D7 merozoites 
STEVOR anti-Sl sera (red) reveal staining in the apical tip o f  merozoites. M SPl-19 anti­
sera (green) stain the merozoites ’ surface. Images o f  relatively intact, segmented 
schizonts (a and b), or free merozoites (c-f) are shown.
Goat anti-rabbit IgG FITC conjugated antibody and goat anti-mouse IgG TRITC 
conjugated antibody were used as secondary antibodies. Parasite nuclei are stained with 
DAP I  (1 fig/ml) (blue). Cells were viewed on a Deltavision fluorescence microscope under 
a 100X oil objective, overall magnification I I  OX.
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DAPI Stevor Rhoptry Merge
anti-S1 PfRH1 -RVIII
Figure 5.9: STEVOR staining co-localises at the apical tip o f merozoites with rhoptry 
protein-1
P. falciparum W2mef parasite merozoites were stained with STEVOR anti-Sl rabbit sera 
(green), and an anti-rhoptry protein 1 (PfRHl-RVIII) monoclonal mouse antibody (red). 
Primary antibodies were visualised with Alexa jluor® 488 goat anti-rabbit IgG (H+L), 
and Alexa fluor® 594 goat anti-mouse IgG (H+L) conjugated secondary antibodies used 
at 1:1000 dilution (Molecular probes, Invitrogen). Parasite nuclei are stained with DAPI 
(lpg/ml) (blue).
Cells were viewed on a Zeiss confocal microscope under a lOOx oil objective. Images 
from Peter Preiser, Nanyang Technological University, Singapore.
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Figure 5.10: STEVOR foci in the merozoites are not remnants o f iRBC membrane bound 
Maurer’s clefts
a) PfSBPl staining o f Maurer's clefts (red) in a ruptured schizont showing these are not 
within each individual merozoite. b) STEVOR mouse anti-Sl staining in the apex o f 
merozoites (red) c) Merge o f anti-Sl and anti-MSPl.I9 (green) antibody staining showing 
a single focus o f STEVOR per merozoite.
Goat anti-rabbit IgG FITC conjugated antibody and goat anti-mouse IgG TRITC 
conjugated antibody were used as secondary antibodies. Parasite nuclei are stained with 
DAPI (lpg/ml) (blue). Cells were viewed on a Deltavision fluorescence microscope under 
a 100X oil objective, overall magnification 11 OX.
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Discussion
In this chapter, immunofluorescence assays using affinity-purified rabbit anti-peptide 1 
antibodies and rabbit anti-recombinant protein SI sera detected STEVOR in the Maurer’s 
clefts throughout development from early trophozoite to schizont-stages. STEVOR 
accumulates in the Maurer’s clefts from trophozoite to early-mid-schizont-stages. 
However in the late schizont (once clearly defined merozoite nuclei are visible), the 
STEVOR staining pattern became more diffuse and was present around the parasite and 
throughout the iRBC cytosol. This may reflect a proportion of STEVOR that has left the 
Maurer’s clefts and is being exported to the iRBC surface, or that STEVOR functions in 
the iRBC cytosol at this stage. Although the latter is unlikely given the expected 
transmembrane orientation of the proteins. This phenomenon appears to be highly 
specific to this very late developmental stage, which may partially explain why previous 
studies have not detected STEVOR outside of the Maurer’s clefts(Kaviratne et al., 2002; 
Przyborski et al., 2005).
The redistribution of STEVOR in the late schizont forms was studied by flow cytometry 
and in IFA studies of unfixed (live) iRBC. Despite IF A data showing STEVOR leaves the 
Maurer’s cleft, reagents against neither the conserved N- nor C-terminals detected 
STEVOR on the iRBC surface.
These data extend our knowledge of the STEVOR export pathway: STEVOR is expressed 
during trophozoite development, and is trafficked to the Maurer’s clefts in the iRBC 
cytosol. At the schizont-stage, a proportion of STEVOR leaves the cleft and is exported 
further towards the iRBC surface membrane, where the hyper-variable loop may be 
expressed on the iRBC surface.
This export pathway varies dependent on parasite culture adaptation; as in vitro cultured 
parasites did not export significant amounts of STEVOR from the Maurer’s clefts 
compared with field isolates. Additionally, STEVOR was detectable in a larger fraction of
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field isolate iRBC than on long-term cultured P. falciparum strains. This is consistent
with a very recent study of var gene transcription in in vitro adapted cultures, which
showed a significant reduction in transcription within -10 days of culture (Peters et a l ,
2007).
Our data also provide the first evidence that parasites express STEVOR in blood-stage 
merozoites. STEVOR is expressed in the apical tip of the invasive blood-stage merozoites 
released upon schizont rupture. The export of STEVOR to the apical organelles may be 
due to a highly conserved YWLY motif identified in the C-terminal of STEVOR (chapter 
3.2 and figure 5.9). The orientation of STEVOR within the merozoite-stage is unknown, 
but orientation and thus function of STEVOR in the merozoite may be different from that 
in the iRBC.
VS A are exported through the Maurer’s clefts en route to the surface of the iRBC (Craig 
& Scherf, 2001). This study agrees with two previous studies where STEVOR was found 
to be present in the Maurer’s clefts. These data are consistent with our findings that 
STEVOR is co-localised with PfSBPl in the Maurer’s clefts during trophozoite 
development. In these two studies it was proposed that the Maurer’s clefts were the final 
destination of STEVOR (Kaviratne et al., 2002; Przyborski et al., 2005). However, late 
schizont-stage parasites were not studied in detail. Thus far, STEVORs are similar to 
PfEMPl and RIFINs, in that STEVOR is also present in the Maurer’s clefts during the 
trophozoite-stage in the lifecycle. The IFA studies here show that STEVOR, like PfEMPl 
and RIFINs, then pass through the Maurer’s clefts en route to their final destination 
perhaps within the (inner) outer surface iRBC membrane.
It is possible that GFP-tagged STEVOR may not reach its final destination within the 
iRBC despite being exported to the Maurer’s clefts (Przyborski et al., 2005). Use of a 
constitutive promoter, driving expression early in the parasite’s development, may 
influence protein-protein interactions required in the final stages of STEVOR export,
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either through absence or low levels of one or more interacting proteins during the
trophozoite-stage. In support of this, a recent study where EBA-175 sub-cellular
localisation was compared when under a ring/trophozoite-specific promoter or a late
schizont-specific promoter. The ring/trophozoite-specific promoter resulted in expression
at the wrong time during development; GFP-tagged EBA-175 protein aggregated and was
mis-targeted to the parasitophorous vacuole, instead of its correct location in the
micronemes. The authors conclude this was due to the absence of the appropriate sorting
machinery and predestined organelles (Treeck et al., 2006).
It would be interesting given our data, showing relocation of STEVOR in the schizont- 
stage iRBC, to observe the distribution of N-terminally GFP-tagged STEVOR later in 
schizont parasite development. The authors did not look at schizont-stages using these 
parasites (Jude Przyborski, personal communication). Therefore to ask definitively where 
STEVOR is located a GFP-construct expressed under the control of the endogenous 
STEVOR promoter would be required. This has been synthesised, and will be used to 
answer questions of STEVOR membrane orientation and localisation throughout the 
erythrocytic cycle (Peter Preiser, personal communication).
A very recent study utilised immunogold localisation of abundantly expressed C-terminal 
tagged-STEVOR and revealed small amounts at the knobs at the iRBC membrane, in 
addition to greater amounts in the Maurer’s clefts (Lavazec et al., 2006). This same study 
also placed tags within the HVR but failed to detect this region on the iRBC surface 
membrane using the same technique. In this thesis IF A data showing STEVOR 
throughout the cytosol and associated with the iRBC surface membrane is consistent with 
the location of the STEVOR C-terminal tag in the immunogold localisation.
Only a proportion of total STEVOR protein is relocated, a significant proportion remains 
in the Maurer’s clefts, this may also be a reflection of protein transport deficiencies 
(particularly in in vitro cultured parasites) (Haeggstrom et al., 2004), or that there are sub-
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types of STEVOR that function in different parts of the iRBC. Clearly unique-STEVOR
specific anti-sera, based upon the hyper-variable loop regions, would be invaluable in
determining whether STEVOR sub-types exist. However due to low levels of STEVOR
expression, it would be a difficult study without prior knowledge of which STEVORs are
being expressed. This would require quantitative (q) RT-PCR data showing exactly which
STEVORs are expressed in the parasite population. Recent qRT-PCR data from a P.
falciparum 3D7 culture, showed PF10 0395; PFI0080w; PFF0850c; and PFD0065w to
be the main STEVOR transcripts (highest-lowest) (Sharp et a l, 2006). The anti-Sl
serum used for our study is therefore specific for the most abundant STEVOR transcript
(PF100395) in P. falciparum 3D7, but despite this STEVOR was still detected at low
levels in only a small percentage of parasites (table 5.1). In addition, Kilifi pooled human
anti-iRBC sera were not able to recognise antigens on the surface of P. falciparum 3D7
iRBC, despite recognising 100% of the Kilifi field isolate parasites tested. These data
together with IFA staining data, suggest that this laboratory line is not suitable to detect
cell-surface STEVOR.
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A comparison of cultured parasites with in vivo parasites
An extremely important observation for the application of in vitro cultured P. falciparum 
clones is the huge difference in STEVOR expression from that in the field parasite 
isolates. It is important to note also that not only was the percentage of parasites-positive 
for STEVOR higher (table 5.1), but the intensity of the staining in the field isolates was 
brighter and significantly more abundant, suggesting presence of abundant STEVOR. 
This could imply STEVOR is a non-essential protein for the basic lifecycle of the 
parasite, but in vivo, the maintenance of expression of this multigene family is necessary 
and perhaps indispensable.
In line with this hypothesis, other large multigene families such as var and r if  are also not 
vital for the parasite development in vitro. RIFIN polypeptides are present on the surface 
of fresh field isolate trophozoites and r if  gene expression is detectable by RT-PCR, 
whereas in tissue culture, RIFIN protein and RNA transcription is low or absent 
(Fernandez et al., 1999). Fernandez et al detected proteins with a molecular weight of 
39kDa in the 3D7 and F32 clones but not in R29 or Dd2 clones. This was in contrast to 
six African clinical isolates where as least two prominent RIFINs were detected in each. 
However the authors were unable to show the timescale of decline of RIFIN expression 
over time in culture, as a tracking experiment carried out over 150 generations, did not 
show a consistent decline in r if  expression. The lack of RIFIN expression in laboratory 
clones was corroborated by a second r if  study in which the rosetting clone R29 did not 
transcribe or express r if  (Kyes et a l, 1999).
Differences between the 3D7 clone (in vitro) and Senegal parasite isolates (in vivo) were 
also detected in a study comparing transcription profiles from these parasites (Daily et a l , 
2005). Here a single stevor (PFD0065w) and two rifins were included in a list of just 12 
genes found over-expressed in at least four out of five Senegal in vivo samples. While the 
majority of genes transcribed in vivo are also found in vitro, a closer look at the STEVOR
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and RIFIN multigene families revealed they had a greater number of genes transcribed in
vivo than in vitro, with some members of the families transcribed exclusively in vivo. In
contrast, the number of var gene transcripts was greater in the in vitro samples.
In addition, in vitro maintained clones including the 3D7 parasite clone, may lack fully
functional transport machinery and therefore fail to export proteins out into the iRBC
cytosol. This is supported by evidence from Haeggstrom et al, who observed that on
comparison of PfEMPl and RIFIN export in fresh clinical isolates with that in the 3D7
lineage in vitro growth-adapted clones, the 3D7 parasites did not form the large Maurer’s
cleft structures seen in the fresh isolates. Instead trafficking occurred in smaller less
efficient packets (Haeggstrom et al., 2004). This would also suggest that the sole purpose
of the iRBC surface proteins exported through the Maurer’s clefts, lies in the need to
maintain parasite survival under the extreme conditions of the host’s immune system.
SURFINs, which have a similar distribution to STEVOR, have been detected in P.
falciparum clones cultured in vitro, but again variable proportions of iRBC express
SURFINs (-25% in 3D7S8 - >90 % in FCR3S1.2) but in all cases, they co-localise with
PfEMPl in the Maurer’s clefts at the trophozoite-stage (Winter et al., 2005).
The cultured parasite clones proved a difficult model for the study of surface protein
expression, as pooled sera known to have high-agglutination properties do not detect
surface proteins on P. falciparum 3D7 iRBC (Sam Kinyanjui, personal communication).
This may suggest either significant loss of 3D7 iRBC surface proteins, potentially due to
trafficking defects after long-term in vitro culture of these clones, or, an antigenically
distinct set of surface proteins. Clearly great care has to be taken when choosing a
parasite clone for in vitro studies, and where possible fresh clinical isolates should be
assessed.
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Field isolate iRBC surface proteins were clearly recognised by the human high-
agglutination immune anti-iRBC sera (figure 5.5). These same iRBC surface proteins
were however not recognised by our STEVOR specific sera in any of the assays.
We cannot conclude that these results rule out the possibility that STEVOR is expressed
on the surface of iRBC, as we did not have reagents to the hyper-variable loop region.
The reagents used in these assays are specific for either the conserved N-terminus (amino
acids 26-180 or peptides within) or the C-terminal (21 amino acids) of the STEVOR
proteins. However, if STEVOR is trafficked to the iRBC surface, this data supports the
predictions for a surface exposed hyper-variable loop flanked by two transmembrane
domains, with conserved N- and C-termini within the iRBC cytosol. Original assessments
of STEVOR led to the prediction of a membrane spanning-structure identical to the
RIFINs in both gene structure and using probabilistic model analysis (Janssen et a l,
2004; Kyes et a l, 2001). The topology predicted for both these multigene families is
cytoplasmic N- and C-terminal domains, with a hyper-variable loop exposed on the
outside of the iRBC. Our data do not contradict this, and add further support for a two
transmembrane, theoretical protein-model.
Alternatively, it is possible that due to low levels of STEVOR, combined with a stage- 
specific surface expression, we may not have been able to detect iRBC surface-exposed 
STEVOR as the number of late schizont-stage parasites expressing STEVOR on the 
iRBC surface was too low and below the detection level of the assay. Despite the fact 
flow cytometry is a sensitive technique.
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Figure 5.11: Alternative membrane-spanning topologies for STEVOR and RIFINs
Three alternative interpretations o f  the proteins ’ structures based on detailed sequence
analysis o f multiple alignments (see results chapter 3).
A) 3 potential STEVOR orientations within the Maurer’s cleft. Two transmembrane 
domains as predicted for both STEVOR and RIFIN by Kyes et al 2001, the most likely 
orientation based on surface localisation results (Kyes et al., 2001). Single C-terminal 
transmembrane domain, possible topology for both STEVOR and RIFINs, whereby the 
missing transmembrane domain region forms the internal hydrophobic core o f  the 
protein, and therefore both the hyper variable loop and N-termini are on the same side o f  
the membrane. Finally 3 transmembrane spanning domains: possible topology for  
STEVOR only. STEVOR may have an additional third highly conserved transmembrane 
domain within the hyper variable loop, whereby the N-terminal only becomes exposed on 
the outside o f  the iRBC. B) Same 3 potential membrane-spanning topologies within the 
iRBC surface membrane.
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STEVOR was not found on the surface of gametocytes using these same antibodies to
conserved regions of STEVOR. In IF A assays of day 17 gametocytes, STEVOR staining
was described as associated with the iRBC membrane in a punctuate layer (McRobert et
al., 2004). This suggested that STEVOR is expressed on or associated with the surface of
gametocyte-stage iRBC.
Our flow cytometry data again do not preclude that the STEVOR hyper-variable loop 
may be present on the surface, as the regions to which antibodies are raised may be 
cytosolic. In addition, the laboratory strain 3D7 used for its in vitro production of 
gametocytes, has low expression of STEVOR within the asexual blood-stages, and this 
may also be the case for 3D7 gametocytes.
Recent work has shown the same main stevor variants are transcribed in both 
gametocytes and asexual parasites (Sharp et ol., 2006), consistent with the absence of 
STEVOR sub-groups (figure 3.7e). Consistent with this the N and C-termini of STEVOR 
were not detected on the surface of gametocytes analogous to the asexual-stage parasites, 
suggesting that it is unlikely that the orientation and therefore function of STEVOR 
within the gametocyte could be different to within the asexual-stage parasite.
Antigenic variation through expression of variant members of multigene families, on the 
surface of the iRBC, is important for immune evasion during the blood-stage- 
development. The parasite safe within the iRBC would not however present itself as a 
direct target to the host’s immune system without the expression of parasite-derived 
proteins on the iRBC surface. The merozoite on the other hand, is released directly into 
the milieu of the bloodstream, and is subjected to the full barrage of the host’s response. 
Until recently, there was no evidence for expression of multigene families during the P. 
falciparum merozoite-stage. The majority of merozoite surface proteins are encoded as 
single copy genes. Exceptions include the rodent malaria, P. yoelii yoelii multigene 
family (Py235), with more than 14 members encoding a 235kDa protein found in the
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rhoptries, but not found on the iRBC surface. Homologues are found in both P.
falciparum and P. vivax (Cowman & Crabb, 2006; Galinski et al., 1992; Holder &
Freeman, 1981; Kaneko et al., 2002; Rayner et a l , 2000; Rayner et a l , 2001; Stubbs et
a l, 2005; Taylor et a l, 2001; Triglia et a l, 2001a; Triglia et a l, 2005; Tsuboi et al.,
1994). In P. falciparum, 10 surface-associated interspersed genes (surf genes) encoding
SURFINs found in the merozoites are located, in the words of Winter et al, in “an
amorphous cap at the parasite apex”. In addition, the SURFINs are co-transported with
PfEMPl and RIFINs to the iRBC surface (Winter et a l, 2005).
The expression pattern of STEVOR on the merozoite is similar to the much smaller 
SURFIN protein family. Thus parasites appear to conserve the antigenic composition of 
iRBC, and merozoite attachment surfaces. Merozoites are totally exposed to immune 
factors when released from the iRBC, minimising this exposure time whilst providing 
highly variable targets for the host’s immune system may increase the chances of 
merozoite survival. Since the majority of merozoite surface proteins are single copy 
genes, these are unsuitable for antigenic variation eg. MSP-1 and AMA1 (Anders et a l, 
1993; Triglia et a l, 2000). The parasite could use polymorphism as an alternative or 
additional method to avoid immune intervention of merozoite invasion, as the invasion 
pathways involve polymorphic variants e.g. CLAG 3.1 and 3.2 or the EBA-175 (small) 
family. However, this is not a viable source of variation for antigenic variation due to the 
low copy number of these genes (Alfred Cortes, personal communication). Therefore the 
presence of STEVOR proteins, (and potentially RIFINs also), in the merozoite-stage 
would provide the merozoite with suitable proteins for antigenic variation.
The N-terminal region of STEVOR proteins can bind RBCs (Peter Preiser, personal 
communication). Briefly, work from Garcia et al also found that synthetic peptides from 
the conserved N-terminus of STEVOR bound RBCs (Garcia et a l, 2005).
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The conserved STEVOR N-terminal region could be involved in RBC binding, and
combined with the discovery of STEVOR expression in the apical tip of merozoites
suggests STEVOR may function in RBC binding and invasion by merozoite-stage
parasites, such a function has also been suggested for the P. falciparum SURFIN family
of proteins although there is no evidence to date (Winter et a l , 2005).
Conclusions
A more complicated view of STEVOR has emerged involving almost the complete blood- 
stage cycle. It has long been the accepted view that STEVOR is a relatively large 
multigene family of variant Maurer’s cleft proteins. The data presented do not contradict 
the finding that STEVOR co-localises, in trophozoite and schizont-stages, with the 
Maurer’s cleft marker PfSBPl (Kaviratne et al., 2002). However this more detailed study 
has revealed stage-specific changes in this localisation, and an additional location within 
the apex of blood-stage merozoites. A schematic view of the localisation of STEVOR 
throughout the asexual blood-stages is shown in figure 6.1.
Consistent with the function of STEVOR as an antigenic-variant protein, expression of 
STEVOR is maximal in fresh clinical isolates, and is significantly reduced in parasite 
clones that have been cultured long-term in the absence of immune factors. Finally, 
STEVOR may be a multifunctional protein, contributing to the merozoite’s extensive 
armoury, providing additional antigenically-variable immune targets, and enhanced RBC 
binding capacity.
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Final discussion
The studies presented in this thesis investigated the global repertoire and expression of 
STEVOR within a range of laboratory lines and field parasites. The stevor multigene 
family is maintained within the genomes of both laboratory and field parasite isolates at a 
constant number of around 28 copies. The data presented show that stevor is consistently 
transcribed in all P. falciparum isolates examined with the exception of one laboratory 
isolate (A4). Parasite isolates share stevors within and between isolates although there is a 
diverse repertoire worldwide.
Due to its importance as the third largest multigene family in the P. falciparum genome, 
the final cellular localisation of STEVOR proteins is of considerable interest. It has been 
accepted that STEVORs are a relatively large multigene family of variant Maurer’s cleft 
proteins (Kaviratne et al., 2002). However the detailed study presented in this thesis has 
revealed that the Maurer’s clefts do not appear to be the final or exclusive destination of 
STEVOR, and therefore the transport mechanism is more complex than initially thought. 
In addition to the co-localisation of STEVOR with the Maurer’s-cleft PfSBPl protein in 
late-stage schizonts, STEVOR localisation changes at this stage, and an additional 
location for STEVOR has been identified within the apex of blood-stage merozoites 
(figure 6.1).
Both locations may be exposed to the host immune-system, suggesting that stevor HVR 
diversity’s may be driven by immune selection, presumably in the form of an effective 
antibody response. The low level and prevalence of STEVOR expression in P. falciparum 
3D7 intra-erythrocytic parasites contrasts with that of STEVOR 3D7 merozoites, which 
includes expression in the majority of merozoites, and suggests expression of STEVOR 
during the erythrocytic cycle (in vitro) is of less importance than its function at the 
merozoite stage. A more extensive assessment of STEVOR expression in field-isolate 
merozoites still remains to be addressed.
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Consistent with the function of STEVOR as an antigenic-variant protein, the expression
of STEVOR is maximal in fresh clinical isolates and in contrast is significantly reduced in
parasite-clones that have been cultured long term in the absence of immune selection,
suggesting that STEVOR is not essential under these conditions. Location of STEVOR
beyond the Maurer’s clefts in the late-stage schizont, and in the apical tip of merozoites
raises interesting questions about STEVOR’s function at these locations. It is tempting to
speculate that STEVOR is a multi-functional protein, enhancing the RBC-binding
capacity of both iRBCs and merozoites, whilst providing antigenically variable immune
targets contributing to the extensive evasive armoury at both these stages. Additionally, it
is also possible that variation in the HVR is a parasite mechanism to facilitate adherence
to RBC in the face of the huge diversity of human RBC surface proteins. (Baum et al.,
2005).
It is also possible that STEVOR, in addition to playing a role in merozoite binding to 
RBC prior to invasion, could bind RBC from the iRBC surface -  a role consistent with 
rosetting, or even binding to endothelial cells and a shared role in cytoadhesion. The latter 
was postulated for STEVOR in the binding and sequestering of gametocytes (Rogers et 
al., 2000). There is also preliminary evidence that STEVOR N-terminal domains can bind 
RBCs, a view also shared by Garcia et al, (Garcia et al., 2005). The SURFIN multigene 
family, which shares the same localisation, has also been associated with RBC binding of 
merozoites, although there is no experimental evidence to date (Winter et a l , 2005).
The question of how STEVOR may be exported to the iRBC cytosol and surface, as well 
as to the apical organelles of the developing merozoites, is interesting given that the 
STEVOR protein structures are the same in both these cases. The various motifs already 
identified {e.g. signal sequence (Burghaus & Lingelbach, 2001; Kyes et al., 2001), 
PEXEL/VTS (Hiller et a l, 2004; Marti et al., 2004), transmembrane domain/hydrophobic 
region (Kyes et a l, 2001; Przyborski et al., 2005), (and perhaps the tyrosine-based motif
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identified here) are functional in the export of STEVOR, and possibly RIFIN. Therefore
there is no indication that these two proteins should be targeted for export to different 
locations. No sub-groups have been identified in STEVOR; however, a RIFIN sub-type, 
which contains two additional cysteines in the distinguishing insert, is more similar to the 
STEVOR proteins (which also have these two cysteines) than the other larger RIFIN sub­
group. STEVOR and the smaller RIFIN sub-group share structural similarities and 
therefore may also have a similar distribution and function at the merozoite apex.
Unlike PfEMPl, expression of STEVOR in the gametocyte life-cycle stages is not due to 
transcription and expression of a particular STEVOR sub-group as the major transcripts 
are not distinct from those in the asexual stages (Sharp et al., 2006). Additionally, in this 
thesis, no stevor sub-groups were identified through analysis of the HVR, however 
sequencing was not undertaken from merozoite RNA samples. It is still possible that 
distinct STEVORs are transcribed at the merozoite stage, different from those transcribed 
during the trophozoite and schizont stages (personal communication Peter Preiser). The 
presence of two distinct activation stages (one during the trophozoite stage and one 
during the merozoite stage) could result in expression of distinct sets of stevor (and 
potentially riflns). Therefore transcription timing could also play a role, in that earlier or 
later transcripts may be translated and directed to different locations based on a hierarchy 
of signals controlling protein export at the time. This could also be due to trafficking 
requirements and the presence or absence of transporter proteins involved in recognising 
those signals and in directing STEVOR to a particular location. One way to address this 
question would be a microarray analysis comparing the transcription of stevor and rifins 
between the merozoite and the erythrocytic cycle to identify whether these particular 
genes are upregulated at specific stages.
Another question raised from this thesis is that of the orientation of STEVOR and the 
number of transmembrane regions within the membrane. Sequence diversity data
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suggests that the HVR is consistent with regions exposed to functional immune pressure.
The profound divergence across isolates confined to the HVR would suggest that this
region is indeed exposed on the iRBC surface (and potentially the merozoite apical tip
surface). Previous protein-domain predictions, locate the HVR between two
transmembrane domains, this structure would place both the N and C-terminal domains in
the iRBC cytosol. However, in order for STEVOR to function in RBC binding the N-
terminal conserved domain would also have to be on the same side of the iRBC
membrane as the HVR -  an orientation inconsistent with a two-transmembrane
prediction.
A very recent study has provided evidence for the presence of STEVOR located at the 
iRBC surface membrane in the P. falciparum NF54 parasite (Lavazec et al., 2006). 
However, we were unable to detect STEVOR on the surface of iRBC by flow cytometry 
using antibodies to the N- and C-termini, suggesting no reaction of the parasite surface 
with these antibodies. This could have been for several reasons. Firstly, it is possible that 
the N-terminal was exposed, but that the expression levels were too low to detect, or that 
only a low percentage of iRBC were expressing endogenous STEVOR on the iRBC 
surface. Secondly, the N- and C-termini may have been concealed and therefore were not 
recognised by antibodies.
If the HVR is exposed on the surface it is unlikely to be readily detected by flow 
cytometry (or any other IF A), as antibodies to the HVR probably do not cross-react with 
other HVRs (as the sequence similarity between STEVOR sequences is low in this 
region), and it would be necessary to know the repertoire of STEVOR expressed in a 
given population of iRBC and the likely population of cells expressing a single HVR. In 
addition to detection problems, studies of this STEVOR have proved extremely 
challenging due to the low level of protein expression in infected cells and HVR variant- 
specific antibody reagents are difficult to generate due to the hydrophobic nature of the
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STEVOR protein(s). Classic techniques for the study of surface protein localisation, such
as trypsinisation of the iRBC surface proteins, are also extremely difficult given the
relative proportion of STEVOR relative to the total protein content of the iRBC sample.
Various studies (Khattab & Klinkert, 2006; Przyborski et a l, 2005) have attempted to
increase protein expression levels, for example, using expression of STEVOR conjugated
to fluorescent markers such as GFP, and under the control of strong constitutive
promoters; however the results of these are inconsistent with other predictions for protein
final iRBC surface location, and orientation within the membrane, perhaps due to adverse
effects on the timing of protein expression, and therefore export.
The predicted N-terminal (exon 1) hydrophobic signal sequence would result in the entry 
of STEVOR into the endoplasmic reticulum (ER) (Elmendorf & Haidar, 1993; Elmendorf 
& Haidar, 1994). The classical secretory pathway (assuming a functional secretory signal) 
would place the STEVOR HVR on the inside of the ER consistent with the prediction of 
Pryzborski et a l, which places the HVR inside the Maurer’s cleft lumen (Przyborski et 
a l,  2005). The HVR would be located within the lumen of secretory vesicles/Maurer’s 
clefts and finally exposed on the iRBC surface. However given the many membranes 
STEVOR would have to cross to reach the iRBC surface, it is difficult to assess the true 
final orientation of STEVOR on the iRBC surface using bioinformatics and structural 
predictions. Our Western blot data support the finding of Przyborski et al, that STEVOR 
is an integral membrane protein (Przyborski et a l,  2005).
The question of the topology of STEVOR within the Maurer’s clefts is also raised by the 
incompatible results of the STEVOR and RIFIN orientation at this location. Surprisingly, 
given the same predicted topology (Kyes et a l,  2001), two studies of labelled STEVOR 
and RIFIN proteins predict alternative orientations for the HVR of these two proteins 
within the Maurer’s cleft (Khattab & Klinkert, 2006; Przyborski et a l, 2005). The RIFIN 
HVR was exposed to the iRBC cytosol (whilst the N and C-terminals were within the
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Maurer’s cleft lumen), whereas the STEVOR study placed the HVR within the Maurer’s
cleft lumen (as expected from the classic secretory pathway).
Przyborski et al, assumed that the N-terminal of STEVOR is exposed to the iRBC cytosol 
along with the GFP-labelled C-terminal. However, since only the C-terminal end of 
STEVOR was labelled, it is not possible to conclude that the N-terminal of STEVOR is 
not within the Maurer’s cleft lumen on the same side as the HVR (as predicted by either 
the single or three-transmembrane topology). In addition, neither study used multiple 
examples from the STEVOR and RIFIN families, and therefore may benefit from analysis 
of further family members. Alternatively, is it possible for STEVOR membrane topology 
to change from a two-transmembrane protein in the iRBC stage to an alternative structure 
and membrane orientation form at another stage {i.e. the merozoite where the N-terminal 
may be exposed for assisting the binding to RBCs as well as the HVR) There is currently 
no experimental evidence to suggest this is likely.
Permeabilisation with streptolysin-o (Ansorge et al., 1997), which permeabilises specific 
membranes leaving Maurer’s cleft membranes intact, in combination with affinity 
purified antibodies against the N and C-terminals may be useful approaches to elucidate 
the orientation of STEVOR. This would enable the orientation of STEVOR within the 
Maurer’s clefts to be determined under the natural stevor promoter. However, again due 
to low level of expression, laboratory strain parasites may not be ideal for this type of 
experiment, and field-isolate samples are not always readily available.
Given our finding that STEVOR may be on the surface of merozoites, the effect of anti- 
STEVOR antibodies on merozoite invasion of RBC would be interesting to study, as it is 
possible they may prevent attachment of the merozoites. However, the correct structure 
conformation of recombinant STEVOR fragments would be key to the generation of 
antibodies able to recognise the native protein, and it is known from MSP1 studies that 
not all antibodies may be functional in this kind of study (Uthaipibull et al., 2001).
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Preliminary studies have tentatively shown that STEVOR binds RBC (Peter Preiser,
personal communication). In future studies, as well as documenting the binding ability of
the protein, it will be necessary to determine if corresponding recombinant proteins or
antibodies can competitively inhibit this RBC binding to eliminate the possibility of
general protein ‘stickiness’.
The results presented in this thesis contribute significantly to the discussion on multigene 
families and have significant implications for the investigation of associations between 
the transcription and expression of multigene families and clinical manifestations of 
parasites that have undergone in vitro culture. In the future, comparative studies between 
field isolates and laboratory strains may reveal clues as to which proteins are driven by 
host factors.
In conclusion, the potential function of STEVOR needs to be re-evaluated. The 
identification of a new location of the STEVOR (and potentially RIFIN) proteins in the 
merozoite necessitates this revision in function, from immuno-variant proteins protecting 
the Maurer’s clefts to a multifunctional protein that may enable RBC binding, whilst 
providing an additional source for antigenic variation (seemingly independent of 
PfEMPl), for both schizont iRBC and merozoite stages.
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Figure 6.1: Schematic view o f  STEVOR localisation throughout the asexual blood-stage
cycle o f  P. falciparum
STEVOR is first expressed in the trophozoite stage, where it traffics from within the 
parasite across the parasitophorous vacuole membrane and accumulates in Maurer's 
clefts within the iRBC cytosol. Once the parasite develops into a mature schizont (where 
individual merozoites become visible, and Maurer’s clefts are pushed to the periphery o f  
the iRBC), the STEVOR proteins are observed throughout the cytosol o f the iRBC. They 
are closely associated with the iRBC surface, either within the clefts, or at the iRBC 
membrane. Here the hyper-variable loop may be on the iRBC surface. On schizont 
rupture, STEVOR may remain within the Maurer’s clefts and attached to the broken iRBC 
membrane (ghosts); however, merozoites are observed to have a single focus o f STEVOR 
at their apex. At this stage, this multigene family could protect against antibodies, 
targeting important proteins necessary for the invasion o f  new RBC, and may 
additionally assist in the binding o f  merozoites to fresh RBC.
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